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Summary 
Bone grafts are the second most transplanted tissue worldwide, and are essential for 
the treatment of critical size bone defects. However, this clinical need has not been 
met by conventional means through the use of autografts, allografts and synthetic 
grafts. This PhD project was undertaken to develop an effective tissue engineered (TE) 
bone graft using bone tissue engineering (BTE) strategies, through identifying a highly 
osteogenic cellular source, a bioreactor based in vitro culture system, and functional 
reconstruction from a critical sized defect small animal model. 
 
Mesenchymal Stem Cells (MSC) have been shown to be a promising cellular source for 
BTE application and been identified from multiple origins. However, the optimal origin 
of MSC for BTE application still remains unknown. To address this question, in this 
project, various human MSC types from different ontological and anatomical origins 
were isolated, characterized and systematically compared for their potential in BTE 
application. Compared to MSC from other origins (umbilical cord, adult bone marrow 
and adipose tissue), MSC derived from human fetal bone marrow (hfMSC) had the 
lowest HLA-I expression (55% vs 95-99%), highest self-renewal capacity (1.6-2.0x, 
p<0.01) and fastest doubling time (32 vs 54-111 hours, p<0.01). Moreover, hfMSC had 
the greatest osteogenic capacity, as assessed by von Kossa staining, ALP activity 
(5.1-12.4x, p<0.01), calcium deposition (1.6-2.7x in monolayer and 1.6-5.0x in 
scaffold culture, p<0.01), micro-CT analysis (3.9-17.6x, p<0.01) and osteogenic gene 
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induction. Two months after implantation of cellular-scaffolds in immunodeficient 
mice, hfMSC seeded scaffolds resulted in the most ectopic bone formation (1.8-13.3x, 
p<0.01). This head-to-head comparison unveiled that the ontological and anatomical 
origins of MSC have a profound influence on their cellular behavior, and thus their 
performance as cellular candidature for BTE application, with hfMSC being an 
potential cellular source for BTE application.  
 
A customized bi-axial rotating bioreactor was used to generate TE bone grafts from 
hfMSC mediated polycaprolactone-tricalcium phosphate (PCL-TCP) scaffolds through 
a dynamic culture system. Compared to traditional static culture, this bioreactor 
resulted in higher cellular proliferation, achieved 2 fold more cellularity within 
scaffolds, and maintained high cellular viability. In addition, the bioreactor culture 
stimulated more robust osteogenic differentiation than the static culture; bioreactor 
cultured hfMSC scaffolds had 1.5 fold higher ALP activity, 5.5 fold more calcium 
deposition and 3.2 fold greater ectopic bone formation in immunodeficient mice. 
Bioreactor culture enabled the maintenance of cellular viability 2,000 m from the 
scaffold surface, ten fold beyond the limits of conventional diffusion (200 m).  
 
A rat critical sized femoral defect model was established for the functional evaluation 
of the hfMSC TE bone grafts. Three months after transplantation, TE bone grafts 
treatment led to the successful healing of this defect as seen on X-Ray and micro CT 
imaging. Compared to the control group transplanted with accelular scaffolds, where 
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union was not achieved, hfMSC TE bone grafts induced a two fold higher bone 
formation, a ten fold improved bone stiffness, and a two fold greater 
neo-vascularisation despite the disapperance of hfMSC shortly after transplantation. 
 
In conclusion, this project provides evidence that the use of hfMSC in conjunction with 
bi-axial bioreactor and PCL-TCP scaffolds can generate TE bone grafts which can heal 
critical sized bone defects in a rat femoral defect model. This graft has superior 
properties over the use of either other MSC types or static culture, suggesting their 
potential clinical utility in the future. 
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maturation state and their functional properties, resulting in skewing 
the immune response toward in an anti-inflammatory/tolerant 
phenotype. Alternatively, when MSCs are present an inflammatory 
microenvironment, they inhibit IFN-γ secretion from TH1 and NK 
cells and increase IL-4 secretion from TH2 cells, thereby promoting a 
TH1TH2 shift. It is likely that MSCs also mediate their 
immunomodulatory actions by direct cell-cell contact as well as by 
secreted factors. Several MSC cell-surface molecules and secreted 
molecules are depicted. CCL indicates chemokine ligand; TCR, 
T-cell receptor. (Adapted from [Aggarwal, 2005]) 
 
Figure 1-16  The Mesengenic Process diagram with horizontal or diagonal arrows 
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(dotted lines) depicting the plasticity of mesenchymal cells and the 
transdifferentiation of mature phenotypes into wholly different cell 
types. (Adapted from [Caplan, 2007]) 
 
Figure 1-17  Postulated steps in the osteogenic lineage differentiation of 
Mesenchymal stem cell (Multipotential stem cell) implying 
recognizable stages of differentiation as detectable from in vitro and 
in vivo experiments. Superimposed on this scheme are several 
well-established markers of the osteoblast and current thinking as to 
how their expression changes through differentiation stages. -, no 
detectable expression; -/+ - +++, expression ranging from detectable 
to very high,  +++, heterogeneous expression in individual cells. 
(Adapted from [Aubin, 1998]) 
 
Figure 1-18  Possible tissue pools of MSCs contributing to fracture repair. 
(Adapted from [Bielby, 2007]) 
 
Figure 1-19  Frequency of MSC in the bone marrow with ages.  
(Adapted from [Caplan, 2007]) 
 
Figure 1-20  Biomimetic approach to tissue engineering. (Top panel) Cell fate and 
tissue assembly during early development and tissue remodeling in an 
adult organism are regulated by multiple cues acting across 
different-length scales and time sequences. (Bottom panel) Tissue 
engineering attempts to mimic the cell context present in vivo by 
culturing cellular tissue engineered constructs in bioreactors 
(providing an environment and regulatory signals necessary for 
functional tissue assembly).(Adapted from [Lanza, 2007])  
 
Figure 1-21  A commercially available spinner flasks (left) 
(http://www.bestlabdeals.com); and its working mechanism (right) 
(Adapted from [Martin, 2005])  
 
Figure 1-22  The design and drawback of a perfusion bioreactor: (A) the overall 
design of the perfusion bioreactor; (B) the detailed design of the flow 
chamber; (C) the flow path in the scaffolds; (D) drawback of the 
perfusion bioreactor, a dead zone (red color) of the cellular scaffolds 
can be found after a period of perfusion culture.  
(Reproduced from [Bancroft, 2003; Singh, 2007]) 
 
Figure 1-23  Rotating wall vessel (RWV) bioreactors: (A) the original RWV 
bioreactor developed by NASA (Adapted from 
http://science.nasa.gov/newhome/br/bioreactor.htm); (B) the working 
mechanism of RWV bioreactor [Martin, 2004]; (C) the RWV 
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bioreactor developed by Synthecon Inc. with perfusion system 
(Adapted from http://www.synthecon.com) ; (D) the RWV bioreactor, 
miniPERM developed by In vitro Systems & Services (Adapted from 
http://www.ivss.de/en ) 
 
Figure 1-24  Bioreactor design and working principle: this bioreactor system is 
consisted of a culture spherical vessel (500ml), where the scaffolds 
are cultured, and a medium reservoir (500ml); spherical vessel can 
rotate in two perpendicular axes (X and Z) while vessel and reservoir 
were connected by tubings with perfusion flow circulating between 
each other (as indicated by red arrow). 
 
Figure 1-25  CFD analysis of cellular scaffolds under uni-axial rotation (left) and 
bi-axial rotating (right): bi-axial rotation can combine the rotational 
effect from both axes and achieve better fluid transport. (Adapted 
from [Singh, 2005]) 
 
Figure 2-1  Indication of the observation angle. (A) High porosity PCL-TCP 
scaffolds measuring 6mm x 6 mm x 4 mm were seeded with hfMSC 
for these experiments; (B) Scaffolds were viewed from the planar (top) 
and side profile under phase contrast light microscopy through the 
culture; (C) FDA/PI was used to stain for live and dead cells 
respectively, through confocal microscopy imaging of the planar (top) 
view, and after bisecting the scaffold into two in the middle, 
achieving a view of the scaffold’s centre (core view). 
 
Figure 2-2  Bone plate design and cortex screw. (A) Bone plate to secure the bone 
fragment; (B) Synthes cortex screw; (C) detailed drawing of the bone 
plate.  
 
Figure 2-3   Surgical procedure of rat femoral defect. 
 
Figure 3-1   Experimental design of Specific Aim #1 
 
Figure 3-2  Heterogenic morphology of hfMSC isolated. After plating the bone 
marrow aspirate, hfMSC can be seen as adherent cells while 
haemopoietic cells remain in suspension (A, x 100). hfMSC were 
heterogeneous: majority of cells were spindle shape (B, red arrow 
head, x200), while there were other cells which had multiple 
processes (C, red arrow head, x200). And those cells can proliferate 
rapidly to confluence, and resulted in more homogenous spindle 
shaped morphology (D, x40).  
 
Figure 3-3  Morphology of hfMSC, haMSC, hUCMSC and hATMSC: all MSC 
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sources demonstrated a spindle shaped morphology with haMSC and 
hATMSC being slightly larger than hfMSC and hUCMSC 
 
Figure 3-4  Immunophenotype of different MSCs by ICC. All the MSCs showed 
a similar immunophenotype except that hfMSC and hUCMSC were 
positive for Oct-4 and Nanog. 
 
Figure 3-5  Flow Cytometry analysis of different MSCs. hfMSC expressed a 
lower HLA-I level and higher Stro-1 compared with rest of MSCs 
 
Figure 3-6  Trilineage differentiation capacity of the different MSC types.  Their 
trilineage differentiation was confirmed by von Kossa staining for 
extracellular calcium (black crystals), Oil-red-O for intracytoplasmic 
vacuoles of neutral fat (red), and Safranin O for extracellular cartilage 
stains in micro-mass pellet cultures (red). 
 
Figure 3-7  Proliferation and self-renewal capacities of different MSCs. (A) 
hfMSC demonstrated the fastest proliferation, followed by hUCMSC, 
hATMSC and haMSC (p<0.01); (B) CFU-F assay: hfMSC have a 
significant higher clonogenicity than other MSCs, ** p<0.01; (C) the 
cell colonies on the petric dishes, which were stained by crystal violet; 
(D) a cell colony under microscopy (40x), with cell stained in violet. 
 
Figure 3-8  Comparison of different osteogenic protocols. Von Kossa staining 
demonstrated that both hfMSC and hATMSC showed a similar 
osteogenic differentiation under the different osteogenic 
differentiation media. 
 
Figure 3-9  Comparison of the osteogenic differentiation and mineralization in 
monolayer culture. (A) hfMSC and hUCMSC experienced much 
greater mineralization than other MSCs as shown by darker von 
Kossa staining, while in control medium no mineralization was 
detected; (B) hfMSC laid down higher level of calcium than other 
MSCs, and hUCMSC deposited comparatively more calcium than 
haMSC and hATMSC, ** p<0.01, * p<0.05; (C) hfMSC expressed 5 
fold higher ALP activity than other MSCs, ** p<0.01. 
 
Figure 3-10  Cellular adhesion, viability and proliferation comparison in three- 
dimensional scaffold culture. (A) The PCL-TCP scaffold is laid down 
in a lattice formation which is highly porous as shown in this 
scanning electron micrograph (SEM) image; (B) Cellular viability of 
MSCs within the scaffolds was demonstrated by staining with 
fluorescein di-acetate (FDA), which is taken up by live cells, and 
propidium iodide (PI) which is retained by dead cells, concurrently. 
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All four types of MSCs retained high viability over 28 days, with 
hfMSC achieving confluence within the scaffolds, and attaining a 
spindle-shaped morphology at an earlier time point than other MSCs; 
(C) This was confirmed by quantification of dsDNA content by 
Picogreen assay, showing the most rapid rise and highest amounts of 
dsDNA in the hfMSC constructs (p<0.01). 
 
Figure 3-11  Rapid proliferation of hfMSC observed under light microscope. All 
the images were taken on the same pores and the large magnification 
(x200) images of each pore were obtained and indicated by the red 
circles and arrow lines. hfMSCs were found to attach to and bridge 
cross the struts of scaffold on Day 4, then underwent rapid 
proliferation and occupied the pore space within four days. 
 
Figure 3-12  Osteogenic gene expression of different MSCs cultured in 
three-dimensional scaffolds. Quantitative analysis of key osteogenic 
genes (Alkaline phosphatase (ALP); Collagen 1A1; osteonectin; 
RunX2.) of MSCs cultured in 3D scaffolds demonstrated either 
higher and/or earlier up-regulation in hfMSC scaffold-constructs than 
the others by quantitative RT-PCR.  
 
Figure 3-13  Calcium crystalline was found under microscopy and von Kossa 
staining. Mineralization of the cellular-scaffolds after 19 days of 
osteogenic induction resulted in deposition of opaque crystals within 
the scaffolds, more obviously in the hfMSC and haMSC scaffolds 
(light microscopy 40-400x), which was confirmed through von Kossa 
staining (calcium crystals staining black). Cellular-scaffolds grown in 
normal growth medium did not result in mineralization (control). OM: 
osteogenic media, and Ctrl M: control media. 
 
Figure 3-14  SEM and EDX analysis of cellular scaffolds. Scanning electron 
microscopy (SEM) showed trabecular-like networks within the 
cellular-scaffold constructs, with nodular deposits found only on the 
hfMSC scaffolds and not others (magnification 1-5,000x); such 
nodules were shown to be calcium phosphate via EDX elemental 
analysis 
 
Figure 3-15  Quantification of mineralization of different MSCs scaffolds. (A) 
Quantification of mineral content through micro computed 
tomography(micro-CT) analysis showed a higher mineral volume in 
hfMSC than other MSCs, and in haMSC than hUCMSC and 
hATMSC (n=4, threshold=200, ** p<0.01, * p<0.05); (B) This was 
confirmed through direct measurement of calcium content within the 
scaffold ( ** p<0.01) 
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Figure 3-16  Calcium depositions by acellular scaffold controls. 
Non-physiological mineralization was detected in acellular scaffold 
controls and increase with the culture time. 
 
Figure 3-17  Osteoinductive effect of 3D PCL-TCP scaffold culture. Quantitative 
analysis of key osteogenic genes (Alkaline phosphatase (ALP); 
Collagen 1A1; osteonectin; RunX2.) using real time RT PCR showed 
that the PCL-TCP 3D scaffold can induced either higher and/or earlier 
up-regulation osteogenic gene expression in hfMSC compared to 2D 
monolayer culture. 
 
Figure 3-18  MSC scaffold implants 2 month after subcutaneous implantation. All 
the implants showed high biocompatibility with no tumorigenicity, 
good tissue integration and neo-vascularization by infiltrating blood 
vessels (arrow). 
 
Figure 3-19  Validation of IHC using human specific Lamin A/C and PI as 
counterstain. (A) Under high magnification, the nuclei of human cells, 
were stained by human specific Lamin A/C (green) and PI (red); 
while the murine cell were only stained by PI (red). (B) Negative 
controls for the IHC. Both the nil-primary antibody control and the 
acellular control groups showed the specificity of Lamin A/C 
antibody for human cells.  
 
Figure 3-20  Human: mice chimerism analysis by IHC. Analysis of implanted 
cellular scaffold constructs demonstrated high levels of cellular 
viability and chimerism (60-67%) within the interior of the scaffolds 
through staining for human nuclei (lamins A/C, green) and 
counterstaining with propidium iodide (red) for all nuclei, the dark 
voids being the scaffolds (S). 
 
Figure 3-21  In vivo ectopic bone formation of different MSCs scaffold constructs. 
(A) von Kossa staining of representative sections with H&E 
counter-staining demonstrated higher degree of mineralization (black) 
in hfMSC and haMSC cellular-scaffold constructs than other 
cellular-scaffold constructs, scale bar: 30 µm; (B) micro-CT analysis 
of ectopic bone formation through 3D quantitative bone volume 
measurement demonstrated that hfMSC cellular-scaffold constructs 
resulted in the most bone formation, followed by the haMSC, 
hUCMSC and hATMSC cellular-scaffold constructs (n=3, 
threshold=200, ** p<0.01, * p<0.05). 
 
Figure 4-1   Experimental design of Specific Aim #2 
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Figure 4-2  Cell adhesion and proliferation of hfMSC cultured in the PCL-TCP 
scaffolds. (A, E) Scaffolds which had been cultured for one week 
were transferred to either bioreactor or static culture conditions over 
28 days. Bi-axial bioreactor cultured constructs achieved confluence 
of all the available space within the scaffolds by Day 7 (B-D), with 
the appearance of extracellular crystals from Day 14 of culture (red 
arrow, J), which increased in amount by Day 28, limiting the passage 
of light through the scaffold (K, L) (the light transmission area in L 
was the pinhole area). In contrast, static cultured constructs reached 
confluence only after 28 days of culture, with evidence of 
mineralization (red arrow, P) appearing only at Day 28 (E-H &M-P). 
Scaffolds were viewed from the planar (top) and side profile under 
phase contrast light microscopy through the culture. 
 
Figure 4-3  Quantification of dsDNA content in cellular scaffolds by Picogreen 
assay. It showed that bioreactor culture supported the significantly 
higher cellular proliferation rates (*** p<0.001), with cellular 
scaffolds achieving a confluence by Day 7, and achieving a higher 
final cell content within the scaffolds at all time points. 
 
Figure 4-4  Cellular viability studies (FDA/PI staining): A) FDA/PI was used to 
stain for live and dead cells respectively, through confocal 
microscopy imaging of the planar (top) view, and after bisecting the 
scaffold into two in the middle, achieving a view of the scaffold’s 
centre (core view). B-I) Bi-axial bioreactor cultured constructs 
demonstrated confluence of the scaffold surface and interior, with 
homogenous cellular distribution at an earlier time point (B-C) than 
static cultured constructs (F-G) (D14 shown here). By Day 28, 
hfMSC in bioreactor-cultured constructs assumed osteoblast 
morphology, appearing ovoid in shape (D-E), while retaining high 
cellular viabilities in the core of the scaffolds (E). In contrast, hfMSC 
in static-cultured constructs remained spindle shaped (H), with poor 
cellular viabilities in the core of the scaffolds (I). (All images here are 
confocal z-stack images, constructed from 44 horizontal image 
sections with 300 um in depth. Mag. 100x) 
 
Figure 4-5  von Kossa staining of cellular scaffolds. Results demonstrated that 
cellular scaffolds in bioreactor culture went through more robust 
osteogenic differentiation and mineralization than static culture, as 
shown in much darker of Von kossa staining at Day 14 and 28. 
 
Figure 4-6  Scanning electron microscopy (SEM) and EDX analysis of cellular 
scaffolds. (A) SEM showed that bioreactor cultured cellular scaffolds 
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at Day 28 have high mineralization and larger amount of calcium 
crystals structure. (B) EDX analysis of the element components 
revealed the mineralized nodules found in SEM (in red circle) were 
calcium phosphate salts, consisting of P, Ca and O elements. 
 
Figure 4-7  ALP activity assay. Cellular scaffolds cultured in bi-axial bioreactor 
expressed higher level of ALP activity than those in static culture 
from day 7 (* p<0.05, ** p<0.01, *** p<0.001) 
 
Figure 4-8  Calcium content assay. Analysis of calcium deposition in the 
scaffolds revealed significantly higher calcium deposition in 
bioreactor-cultured constructs than static-cultured constructs from 
Day 14 to 28. *** p<0.001. 
 
Figure 4-9  Scaffold implant images and Chimerism analysis. (A-B) Implanted 
scaffolds from both groups integrated into the surrounding tissues 
with no evidence of tumor formation. (C-G) Immunostaining for 
human-specific Lamin A/C (green nuclei, counterstained with 
propidium iodide) showed a higher human: mouse chimerism rate in 
bioreactor-cultured versus static-cultured constructs (78.5±14.6% vs. 
57.6±8.3%, p<0.05). (E,F are the enlarged images of blue rectangle 
areas in C,D; S indicates scaffold). Scale bar 500μm, * p<0.05. 
 
Figure 4-10  Histological analysis of cellular scaffold implants. Bioreactor 
cultured scaffold showed more uncalcified and calcified bone 
formation and mineralization by Mason’s Trichrome and von Kossa 
staining (counterstained with nuclear fast red) respectively, scale bar 
100 μm.. 
 
Figure 4-11  Micro CT analysis of cellular scaffold implants.  (A) 3D images of 
implants showed that there are much more ectopic bone formed in 
cellular scaffolds under bioreactor culture than static culture, and the 
empty scaffold implants (negative ctrl); (B)  ectopic bone volume 
analysis demonstrated 3.2 fold more ectopic bone formed in 
bioreactor cultured constructs compared with static-cultured 
constructs (***p<0.001) 
 
Figure 5-1   Experimental design of Specific Aim #3. 
 
Figure 5-2  In vitro maturing of TE bone grafts. (A) FDA/PI staining showed the 
complete confluence of cellular scaffolds while high degree of 
viability was maintained (scaffolds were cut longitudely into halves 
before staining with FDA/PI); (B) after two weeks culture, cellular 
scaffolds went through robust osteogenic differentiation and 
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deposited large amount of calcium crystals (inserted picture was the 
high magnification image of red rectangle area); (C) the cellularity of 
TE bone graft increased rapidly from 0.50±0.13 million to 1.59±0.40 
millions within two weeks.  
 
Figure 5-3  X-ray examination of new bone formation. TE bone grafts can heal 
the critical sized bone defect and achieved the union of defect after 3 
months implantation (TEBG group), while control group (acellular 
scaffold) failed to heal as indicated by red arrow. 
 
Figure 5-4  Micro CT images of femoral defects. TEBG group resulted in 
successful defect union, while control group showed limited new 
bone formation, and untreated group showed no formation of new 
bone. (Threshold =200) 
 
Figure 5-5  New bone formation volume analysis. After three months, TE bone 
grafts achieved significantly more new bone volume in defects than 
scaffolds alone, while this difference was not significant on 1 month 
(ns: not significant, *p<0.05). (Threshold =200) 
 
Figure 5-6  Torsional testing of the defected bone. TE bone grafts treated femurs 
(TEBG group) have significantly higher stiffness than acellular 
scaffolds treated ones (control group), and maximum torque in TEBG 
group was 0.044±0.020 Nm, while there was no observation in 
control group because of the nonunion of the defects. (*p<0.05) 
 
Figure 5-7  Micro CT analysis of vascularization in defect area. TE bone grafts 
induced neo-vascularization in the defect area, while the scaffold 
alone resulted in limited vascular penetration into the defect area. 
(Threshold=190) 
 
Figure 5-8  Vascular volume of defect area. Vascular volume analyzed from 
micro CT showed that TEBG group achieved significantly higher 
vascular volume than control group  (* p<0.05).  
 
Figure 5-9  Histological analysis. H&E, Masson’s Trichrome and von Kossa 
staining showed that much more immature and mature bone were 
formed around the rods of the scaffolds in the TE bone grafts 
treatment group than the control group. (S: scaffold rods) 
 
Figure 5-10  Chimerism analysis of TE bone grafts after implantation. The 
immuno- histochemistry study using human specific Lamin A/C 
antibody (red) with DAPI counterstaining (blue) showed that after the 
implantation of TE grafts, the human cell in the TE grafts decrease 
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dramatically within the first two weeks and cannot be detected since 
week 4. In addition, the cellular structure around the rods of the 
scaffold became denser with time as indicated by increasing density 
of nuclei around the rods. (S: scaffold rods) 
 
Figure 6-1  SEM images of TCP coating on PCL scaffold. (A) (B) microwave 
heat treated PCL scaffolds before TCP coating; (C) (D) PCL scaffolds 
after TCP coating; (E) EDX analysis of (D). (A collaborative work 
with Dr. Han Ming Yong from IMRE) 
 
Figure 6-2 Co-culture of hfMSC and hUVEC after 7 days’ monolayer culture. 
hUVEC demonstrated some special inductive effect on hfMSC to 
promote earlier osteogenic differentiation and mineralization, and the 
effect was associated with mixing ratios of two types of cells and the 
mineralization maximized with 1:5 mixing of hUVEC: MSC.  
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Abbreviations 
 
2 D Two Dimensional or Monolayer 
3 D  Three Dimensional  
Aamp  Angio-associated migratory cell protein 
ALP  Alkaline Phosphatase 
Ang1 Angiopoietin 1  
bFGF basic Fibroblast Growth Factor   
BM Bone Marrow  
BTE Bone Tissue Engineering 
CAD  Computer Assisted Design 
cAMP  cyclic Adenosine Monophosphate 
CFD   Computational Fluid Dynamics 
CFU-F  Forming Unit – Fibroblast  
CSD  Critical Size Defects  
CT  Computed tomography  
D10 medium Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum, 50 U/mL penicillin, and 50 mg/mL streptomycin  
DMEM  Dulbecco modified Eagle medium 
dsDNA  double-stranded DNA 
EC   Endothelia Cells  
ECM  Extracellular Matrix  
EDX  Energy Dispersive X-ray  
EPC   Endothelia Progenitor Cells 
FBS  Fetal Bovine Serum 
FDA/PI   Fluorescein Diacetate/ Propidium Iodide  
FDM  Fused Deposition Modeling  
GAG  Glycosaminoglycan  
GvHD  Graft-versus-Host Disease 
HA  Hyaluronic Acid  
haMSC  human adult Bone Marrow derived MSC 
hATMSC  human adult Adipose Tissue derived MSC 
hfMSC human fetal bone marrow derived MSC 
hUCMSC  human Umbilical Cord derived MSC 
hUVEC human Umbilical Vein Endothelial Cells 
IACUC  Institutional Animal Care and Use Committee  
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ICC  Immunocytochemical Staining  
IGF  Insulin-like Growth Factor 
IHC  Immunohistochemistry  
INF-γ  Interferon γ  
ISCT  International Society for Cellular Therapy  
LPF  Low Powered Fields 
Micro-CT  Micro Computed Tomography 
MLC  Mixed Lymphocyte Cultures  
MNC  Mononuclear Cells 
MSC Mesenchymal Stem Cells  
NOD/SCID mice Non-Obese Diabetic Severe Combined Immunodeficiency mice 
Osteogenic 
medium (Dex) 
D10 medium supplemented with 10 mM β- glycerophosphate, 0.2 
mM ascorbic acid and 10-8 M Dexamethasone 
Osteogenic 
medium (Vit D) 
D10 medium supplemented with 10 mM β- glycerophosphate, 0.2 
mM ascorbic acid and 10-8 M 1,25-dihydroxyvitamin D3.  
PBS Phosphate-Buffered Saline  
PCL Poly (ε-caprolactone) 
PCLM  Phase Contrast Light Microscope 
PDGF Platelet-Derived Growth Factor 
PGF  Placental Growth Factor  
PLGA   poly (D, L lactic-co-glycolic acid)  
RANK  nuclear factor-κB 
RANKL  RANK Ligand  
RER  Rough Endoplasmic Reticula  
RP  Rapid Prototyping 
RWV bioreactor  Rotating Wall Vessel Bioreactor 
SD Rats Sprague Dawley Rats 
SEM   Scanning Electron Microscope 
SFF  Solid Freeform Fabrication  
SLA  Stereolithography  
SLS   Selective Laser Sintering 
TCP β-Tricalcium Phosphate 
TE bone graft Tissue Engineered bone graft 
TGF-β1  Transforming Growth Factor beta1  
TUHSC Tulane University Health Sciences Center  
VEGF Vascular Endothelial Growth Factor 
vWF  von-Willebrand Factor  
 
  Chapter 1 Introduction 
____________________________________________________________________________________________ 
- 24 - 
Chapter 1 Introduction 
1.1 Bone defect and treatment 
Bone is a dynamic and vascularized tissue with unique capacities to heal and remodel 
by itself without leaving a scar [Salgado, 2004]. However, if the size of a defect is too 
big and exceed human body’s healing capability, termed as a critical sized defect 
(CSD), it will fail to heal naturally and require the treatment of bone graft 
implantation to achieve defect union and healing. In fact, bone graft has become the 
second most transplanted tissue in the world just after blood, with approximately one 
million cases of bone graft transplantation occurring in United States alone annually 
[Salgado, 2004; Bongso, 2005].  
1.1.1 Current treatment and limitations 
Current available bone grafts for bone defect treatment fall into three categories: 
autografts, allografts, and synthetic grafts with a breakdown illustrated in Figure 1-1. 
Their advantages and disadvantages are compared as follows and summarized in Table 
1-1. 
 
Figure 1-1 Breakdown of the current used bone grafts: autograft, allograft and synthetic graft. 
Data derived from http://www.btec.cmu.edu/reFramed/tutorial/mainLayoutTutorial.html 
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Table 1-1 Comparison of different bone grafts 




Autografts +++ +++ - + + 
donor-site 
morbidities 
Allografts ++ ++ + +++ +++ 
disease 
transmission





+++ +++ - +++ +++  
 
Autografts are the bone grafts taken from another part of the patient’s own body, 
commonly taken in the form of trabecular bone from patient’s iliac crest. This bone 
grafting strategy has been first explored by Chutro and later Phemister in early 20th 
century [Connolly, 1991]. The use of autografts is considered as the gold standard of 
bone defect treatment for many decades because they provide osteogenic cells as well 
as essential osteoinductive factors needed for bone healing and regeneration and results 
in the best clinical outcomes. However, several shortcomings have been encountered 
with the usage of autografts, including: firstly, the limited amount of autografts that can 
be obtained; secondly, the difficulty in shaping the grafts to fill the defect; thirdly, the 
requirement for two surgeries with numerous procedures resulting in the extra cost and 
infection risk. Finally, the lengthy recovery and donor-site morbidities limit their 
clinical applications. [Banwart, 1995; Fowler, 1995; Goulet, 1997; Salgado, 2004; 
Jeffrey O, 2005] 
 
Allografts, bone grafts harvested from another donor (usually from cadavers), could be 
  Chapter 1 Introduction 
____________________________________________________________________________________________ 
- 26 - 
an alternative with enhanced flexibility of graft size and shapes. However, they 
introduce the possibility of immune rejection and of pathogen transmission from donor 
to host. Furthermore, processing techniques, such as demineralization, strip the tissue 
of osteoinductive factors necessary for stimulating bone repair, resulting in impeded 
healing times, as compared to autografts [Parikh, 2002].  
 
Synthetic grafts are made from metals or ceramics. Although they have unlimited 
source and possess no immunogenicity, they are subject to problems of fatigue, fracture, 
toxicity, and wear. Moreover, they do not remodel with time, for instance, a metal bone 
implant cannot grow with the patient and it cannot change shape in response to the 
loads placed upon the implant [Salgado, 2004].  
 
Obviously, none of these current bone grafts can fulfill the demanding clinical needs for 
ideal bone graft, which should possess the following characteristics: (1) be 
non-immunogenic and pathogen free (like autografts and synthetic grafts ); (2) have 
off-the-shelf availability in different shapes and sizes (like allografts and synthetic 
grafts), which will reduce the precious waiting time for patients and fulfill the wide 
range of clinical requirement; and (3) have the ability to stimulate fast bone healing and 
undergo remodeling, achieving a better or similar clinical outcome than or as 
autografts.  
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1.1.2 Bone Tissue Engineering (BTE) 
Bone Tissue Engineering (BTE) has been proposed in order to address this current 
clinical need. Tissue Engineering was first coined by Langer and Vacanti as “an 
interdisciplinary field of research that applies the principles of engineering and the life 
sciences towards the development of biological substitutes that restore, maintain, or 
improve tissue function”[Langer, 1993]. In terms of its applicability to bone, Bone 
Tissue Engineering (BTE) has been proposed to address the pressing clinical need for 
bone grafts by applying the principles of biology and engineering to the development of 
viable bone graft that restore and maintain the function of human bone tissues.  
 
1.2 Bone biology and fracture healing 
Before further exploitation in BTE strategy, the biology of bone physiology and 
fracture healing mechanism will be reviewed here, as they are the essential fundamental 
knowledge for BTE implementation. By learning from nature and mimicking the 
in-vivo, the development of a similar environment in vitro may hold the key to the 
generation of successful BTE grafts.  
1.2.1 Functions of bone and skeleton system:  
The human skeletal system, comprised of 206 individual bones joined by connective 
tissue, provides both biomechanical support and metabolic supply for entire body. The 
skeleton system primarily provides basic biomechanical functions to (1) maintain the 
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shape of the body; (2) protect the soft tissues of the cranial, thoracic and pelvic cavities; 
(3) provide the framework for the bone marrow; and (4) transmit the force of muscular 
contraction from one part of the body to another to produce movements. The skeleton 
system also serves as a mineral ion bank, contributing to the regulation of extracellular 
fluid composition. The skeletal system constantly renews its structural makeup, adapts 
its mass, shape, and properties to the changing mechanical environment and endures 
voluntary physical activity. [Deng, 2005] 
 
1.2.2 Anatomy of bone 
1.2.2.1 Cortical bone versus (vs.) Cancellous bone 
The bone tissues in human skeletal system can be divided into cortical bone and 
cancellous bone. Cortical bone (or compact bone) is the dense bone found in shafts of 
long bones and forming a cortex or shell around vertebral bodies and other spongy 
bones. Cortical bone is the primary tissue type of human skeletal system, contributing 
80% of the entire adult skeletal mass in humans, while its porosity is 5%-10%, and has 
a low surface-to-volume ratio of around 2.5. Its main function is to provide 
biomechanical supportive and protective properties. The Haversian systems (osteons) 
are the basic structural component of the cortical bone and the center of each osteon is a 
canal referred to as Haversian canals, which are approximately aligned to the long axis 
of the bone, which in turn are interconnected by Volkmann’s canals, which are oriented 
perpendicular to the skeletal loading axis and run horizontally from periosteal (outer) 
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surface to the endocortical surface (inner) (Figure 1-2). As such, a three dimensional 
network of canals exist throughout cortical bone, containing the circulatory blood 
vessels and nerves, as well as an extracellular fluid path, facilitating the exchanges of 
nutrition and metabolites between cortical bone and its neighboring environment. 
Cancellous bone (or trabecular bone) is found in the cuboidal bones, the flat bones, 
inner regions and ends of long bones. Cancellous bone contributes only 20% of the total 
bone mass, while has a high porosity of 75-95% and a surface-to-volume ratio of 20. Its 
main function is to provide biomechanical support and maintain the bone marrow 
compartment to fulfill the homeostatic demands. Cancellous bone is composed of a 
large number of struts and plates called trabecular, forming a sponge-like trabecular 
network (Figure 1-2). [Buckwalter, 1996; Martin, 1998; Deng, 2005] 
 
Figure 1-2 Microstructure of bone tissue. (Adapted from [Martin, 1998]) 
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1.2.2.2 Woven bone vs. Lamellar bone 
According to the matrix organization, bone tissue can be categorized into woven bone 
and lamellar bone as well. In general, woven bone is an immature bone while lamellar 
bone is a mature one. Woven bones are found during embryonic skeletal development, 
longitudinal bone growth under the growth-plate complex, early fracture healing, or in 
osteosarcoma formation. Woven bone can be formed rapidly with a randomly 
orientated and loosely bundled collagen fibers and low mineral deposition, resulting in 
a weaker mechanical strength. However, when a bone fracture occurs, a large woven 
bony callus is rapidly form, yielding a temporary functional structure to partially 
restore mechanical properties, furthermore, serving as a scaffold for secondary bone 
remodeling and gradually being replaced by lamellar bone. In contrast, lamellar bone 
has much stronger mechanical strength, due to the orderly orientated and stably 
bundled collagen fibers and high mineral deposition, but forms at a much slower pace 
compared to woven bone.  The collagen fibers with mineral crystals are laid down 
parallel to each other, forming a bone matrix sheet, called a lamella. Lamellas are laid 
down layer by layer, with the direction of collagen fibers of one layer (lamella) 
perpendicular to next layer (Figure 1-3). These forms of lamellar structure give rise to 
the special characteristics of bone tissue--birefringence, which shows the alternating 
light-dark layers under polarized light. [Buckwalter, 1996; Martin, 1998; Deng, 2005; 
Lieberman, 2005] 
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1.2.3 Composition of bone 
As a specialized form of connective tissue, bone is composed of cellular elements 
(5-10%), organic matrix (20-40%), inorganic mineral (50-70%) and lipids (3%) by 
volume (Table 1-2). [Deng, 2005] 
 
Table 1-2 Composition of bone 
Component Volume percentage 
Cellular elements (including osteoblast, osteocytes, bone lining cells 
and osteoclast) 
5-10% 
Organic matrix (including collagen, proteoglycans and non-collagenous 
proteins) 
20-40% 
Inorganic mineral (including hydroxyapatite) 50-70% 
Lipid 3% 
1.2.3.1 Cellular composition 
The major cellular compositions of bone include osteoblasts, osteocytes, bone-lining 
cells, osteoclasts, and their precursors of these specialized cells (Figure 1-4) [Downey, 
Figure 1-3 Layout of the bone lamellae. (A) Three-dimensional structure; (B) Visual effect of 
arches seen when an oblique section (as indicated by the shaded plane in A) is cut; (C) The 
arches seen in an oblique section are formed by the helicoidal lamellae. (Adapted from 
[Martin, 1998]) 
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2006]. Osteoblasts, osteocytes, and bone lining cells originate from mesenchymal 
stem cells, locating in the marrow, endosteum, periosteum, and bone canals, whereas 
osteoclasts originate from haemopoietic stem cells. 
 
Osteoblasts are involved in the entire bone formation process. They synthesize and 
secrete collagen to form unmineralized bone matrix (osteoid) and participate in 
osteoid calcification by regulating the flux of calcium and phosphate in and out of 
bone. Osteoblasts contain large quantities of rough endoplasmic reticula (RER), 
mitochondria, and Golgi apparatus. Their single nucleus is found within the center of 
the cell. Eventually, the possible fates for an active osteoblast will be (1) apoptosis, (2) 
to become osteocytes surrounded by matrix, or (3) to become relatively inactive and 
form bone lining cells. 
 
Osteocytes are the most abundant cell type in bone tissue. In mature bone about 95% 
of total bone cells are osteocytes. They are embedded in a space or lacuna within the 
Figure 1-4 The origins and locations of bone cells. 
(Adapted from [Downey, 2006]) 
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bone matrix and have long cytoplasmic processes that project through canaliculi 
within the matrix, connecting with that of other osteocytes, surface osteoblasts or 
bone lining cells via gap-junctions. In this way, the three-dimensional osteocytic 
lacuno-canalicular network with interstitial fluid is formed throughout the entire bone 
(Figure 1-4), which is believe to be the mechanical sensor in Frost’s mechanostat 
hypothesis [Buckwalter, 1996]. In particular, distortion or deformation of the bone 
matrix will compress the osteocytic lacuno-canalicular periosteocytic space, and cause 
the rapid movement of the interstitial fluid. The rapid fluid flows produce shear stresses 
on the cytoplasmic membrane of the osteocytic process, consequently, stimulating the 
osteocytes to synthesize biochemical signals, which in turn lead to the coordinated 
formation and resorption of bone.[Buckwalter, 1996; Deng, 2005] 
 
Bone lining cells, also known as “resting osteoblasts” or “surface osteocytes”, are a 
layer of elongated flat cell. They have a thin, flat nucleus with an attenuated 
cytoplasm, with extended processes to communicate with adjacent bone lining cells as 
well as osteocytes through gap junctions. They are interconnected as a cellular sheet 
that covers the quiescent bone surface. Besides function together with osteocytes as 
mechanical sensors for bone tissue, they are believed to serve as a barrier to protect 
bone surfaces from inappropriate resorption by osteoclasts or other inflammatory cells. 
In addition, this cellular sheet separates the extracellular fluid from the interstitial 
fluid, serving as an ion barrier, and may have a role in maintaining a suitable 
microenvironment for the growth of bone crystals as well as regulating the influx and 
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efflux of calcium and phosphate for mineral homeostasis. [Deng, 2005] 
 
Osteoclasts are giant, multinucleated cells, responsible for bone resorption. 
Morphologically, osteoclasts tend to be much larger than other bone cells and are 
generally located on the surface of bone. They are very mobile, moving from various 
sites and along the surface of bone. Osteoclasts have acidophilic cytoplasm containing 
less RER, more mitochondria and lysosomal types of vacuoles. Furthermore, the 
cytoplasma membrane of the active osteoclast has an infolded appearance known as a 
“ruffled border”, which enlarges the membrane surface area, permitting extensive 
exchange between the intracellular and extracellular environments.[Deng, 2005; 
Downey, 2006] 
1.2.3.2 Organic bone matrix 
Collagen is the primary component of organic bone matrix and is synthesized by 
osteoblasts, secreted, and then assembled extracellularly. Type I collagen predominates, 
but types V, VI, VIII, and XII are present in small amounts. Type I collagen give bone 
flexibility and tensile strength, and it also provides loci for nucleation of bone mineral 
crystals, which give bone rigidity and compressive strength [Martin, 1998].Trace 
amounts of type V, VI, VIII, and XII may help to regulate the diameter of collagen 
fibrils during certain stages of bone matrix formation. [Deng, 2005] 
 
Proteoglycans consist the ground substance of bone; in particular decorin and biglycan 
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are small species of proteoglycans found in bone. Although their specific roles are 
unclear, decorin is known to modulate collagen fibril assembly. Proteoglycans may also 
function to control the location or rate of mineralization in bone through their 
calcium-binding properties.  
 
Non-collagenous proteins (NCPs) make up 10% of the organic bone matrix. Their 
specific roles are unclear, but they are considered important in the calcification process, 
the fixation of hydroxyapatite crystals to the collagen, as well as the control of 
osteoblastic and osteoclastic metabolism. The most abundant NCP is osteocalcin, 
which is secreted by osteoblast and appears to be important in the mineralization of new 
bone and is a chemotactic agent for bone cells. Other abundant NCPs in bone include 
osteonectin, osteopontin and bone sialoprotein, among which only bone sialoprotein 
and osteocalcin are unique to the skeleton.  
1.2.3.3 Inorganic mineral 
The inorganic mineral of bone is essential in providing the major portion of the tensile 
yield strength and plays an implant role in ion storage. It is estimated that the mineral 
salts of bone consist 99% of the calcium, 85% of the phosphorus, and between 40% and 
60% sodium and magnesium found in the human body. The physiological functions 
related to nerve conduction and muscle contraction depend on this inorganic matrix in 
order to maintain appropriate extracellular fluid ion concentrations.[Downey, 2006] 
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Hydroxyapatite is the predominant molecule of bone mineral. It exists in the form of 
needle-, plate- or rod-shaped crystals, which are deposited into the gap region between 
collagen fibers. It provides bone matrix with mechanical rigidity and load bearing 
capacity. Hydroxyapatite is impure, containing many structural substitutions (e.g. 
carbonate, citrate, magnesium, fluoride). These impurities are governed by the 
composition of body fluids and in turn affect the solubility of the bone mineral. [Martin, 
1998; Deng, 2005] 
 
1.2.4 Bone fracture healing 
Bone fractures are relatively common, and bone fracture repairs are among the most 
commonly performed orthopedic procedures; about 6.8 million come to medical 
attention each year in the United States alone [Lieberman, 2005]. Facture can occur 
because of trauma, when the accidental loading substantially exceeds the normal range 
of loading to which bone has adapted during its growth and development. In addition, 
fractures can be caused by pathological conditions as well, such as osteoporosis and 
bone tumor.  
 
Bone fracture healing is a very remarkable process, which can lead to the completely 
regeneration of damaged bones to their original anatomy and function, without scar 
formation, unlike that found during the soft tissue healing. Moreover, bone fracture 
healing is a very complex and highly regulated process that involves the coordination of 
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a sequence of biological events. It can be divided into two major categories: secondary 
(spontaneous) bone healing and primary (direct) bone healing. Secondary bone healing 
is much more common than primary bone healing, because primary bone healing 
requires very strict rigid fixation of the fracture site, but most fractures either are 
untreated or are treated in a maner that results in some degree of motion (sling or cast 
immobilization, external or intramedullary fixation). Unlike primary bone healing, one 
of the most important steps of secondary bone healing is the formation of a callus tissue 
around the fractured area involving a complicated biological process [Lieberman, 
2005].  
 
In general, secondary bone healing can be divided into three biological phases [Cruess, 
1975; McKibbin, 1978; Marsh, 1999; Giannoudis, 2007]: the inflammatory, reparative 
and remodeling phases, as illustrated in Figure 1-5. These three phases overlap one 
another and in effect form a continuous healing process.  
 
1.2.4.1 Inflammatory phase 
This initial phase serves to immobilize the fractured bone and activate the cell types 
responsible for repair (Figure 1-5, A). Immediately following the fracture, an 
inflammatory response is elicited and helps immobilize the fracture through the 
generation of pain, resulting in reduced movement of the affected area, and the 
hydrostatic swelling for immobilizing the fracture parts [Martin, 1998]. At the injured 
  Chapter 1 Introduction 
____________________________________________________________________________________________ 
- 38 - 
site, vascular endothelial damage results in activation of complement cascade, platelet 
aggregation, and release of its α-granule contents. These various growth factors trigger 
the biological signaling cascades and recruit the polymorphonuclear leukocytes 
(PMNs), lymphocytes, platelets, blood monocytes, macrophages, neutrophils, 
osteoclasts and undifferentiated osteogenic cells to the fracture area and forming the 
hematoma [Lieberman, 2005]. Research work showed that the hematoma serves as a 
source of signaling molecules that initiate cellular events essential to fracture healing 
[Bolander, 1992; Andrew, 1994].  
 
B. Reparative Phase (Fibrocartilage 
Callus Formation) – Fibrous tissue and 
new cartilage are beginning to form and 
revascularization is taking place 
C. Reparative Phase (Bony Callus 
Formation) – Intramembranous and 
endochondral ossification is taking place to 
lay down new woven bone 
D. Remodeling Phase – Replacement of 
woven bone by lamellar bone and 
resorption of excess callus. Gradual 
modification of the fracture region leads to 
restoration of normal bone architecture. 
A. Inflammatory Phase - Vascular 
endothelial damage results in hematoma 
formation to immobilize the fracture and 
activate the cell responsible for repair. 
Figure 1-5: Schematic representation of the three stages of fracture repair. (Reproduced from 
[Lieberman, 2005]) 
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1.2.4.2 Reparative phase and mesenchymal stem cells 
The result of this phase will be the development of a reparative callus tissue in and 
around the fracture site, which will provide the fractured bone internal immobilization 
and similar rigidity to intact bone (Figure 1-5, B and C). The fibrocartilage callus is 
formed first (Figure 1-5, B); this callus tissue can be consisted of fibrous connective 
tissue, blood vessels, cartilage, woven bone and osteoid. The multipotent mesenchymal 
stem cell (MSC) in the marrow stroma and periosteum is thought to play an essential 
role during this phase [Einhorn, 1998; Martin, 1998; Caplan, 2007]. In the external area 
of the callus tissue where the blood supply is quite sufficient, the MSC will differentiate 
into the osteoblasts, which produce the woven bone through an intramembranous 
ossification (direct bone formation) [Einhorn, 1998], this external callus is often 
referred to as the hard callus [Bolander, 1992]. While in the some region, because of the 
absence of adequate vascularization, MSC will differentiate into chondroblasts, and 
synthesize the avascular basophilic cartilage matrix. This will form the soft callus, and 
eventually the cartilage will replace all fibrous tissue [Bolander, 1992]. With the 
progress of the time, the cartilage will go through calcification by the process of 
endochondral ossification, glycosaminoglycans will be degraded and calcium 
phosphate mineralization will be deposited and gradually cartilage will be transformed 
to woven bone, and eventually the callus will be composed of woven bone only, which 
is referred to bony callus (Figure 1-5, C) [Einhorn, 1998]. At this time, although the 
material in the bony callus is less rigid than original cortical bone, because bony callus 
have larger cross-sectional area than original bone cortex, the overall rigidity of the 
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bony callus can equal or exceed that of the intact bone [Martin, 1998].  
1.2.4.3 Remodeling phase 
This is the final phase in the fracture healing and begins with the replacement of woven 
bone by lamellar bone and the resorption of excess callus (Figure 1-5, D). Once bony 
callus and union of the defect has been achieved, the broken bone is approximately as 
strong as the intact bone, but often it has greater mass than the original bone and is 
therefore less mechanically efficient. Modeling and remodeling of the fracture site will 
gradually restore the original contour and internal structure of the bone, by osteoclastic 
resorption of poorly located trabeculae and formation of new bone along lines of stress 
[Martin, 1998].  
 
1.3 Bone Tissue Engineering strategies 
1.3.1 Cell based strategy vs. Growth factor based strategy 
Despite many different BTE approaches which have been proposed and explored, 
basically they can be divided into two main categories of a cell or a growth factor based 
strategy. Both approaches seek to create an optimized bone growing bed with a 
biological microenvironment suitable for bone regeneration through introducing a 
critical mass of osteogenic cells onto the scaffold matrix, and modulating intercellular 
communication and cell-matrix interactions. However, the way of introducing the cells 
is different. A growth factors-based approach focuses on the delivery of high doses of 
  Chapter 1 Introduction 
____________________________________________________________________________________________ 
- 41 - 
growth factors to recruit osteogenic cells from the local environment into the repair site. 
A cell-based approach supplies exogenous osteogenic cells while relying on the 
autologous growth factors from the repair site. [Kimelman, 2007; Lanza, 2007] 
 
Although the growth factors-based approach for BTE was shown to be an effective 
approach in small animal models, the translation from small animal models, through 
large animal models, and to humans have proved to be difficult, because the 
identification of optimal dose for human clinical therapy is hampered by the great 
variation (100 fold) from small to big animals. Another problem relates to developing 
an effective delivery and release approach, because the majority of the growth factors 
have a relatively short half-life [Hollinger, 1996; Bruder, 1999]. Furthermore, the 
growth factor based approach works indirectly by attracting and stimulating the 
proliferation and differentiation of local osteogenic stem cells to repair bone defect, 
therefore its effectiveness will be greatly compromised in the absence of sufficient 
osteogenic stem cell pool [Service, 2000]. In contrast, a cell based approach works 
independently of the presence of local osteogenic cells, and can be an attractive therapy 
for patients with a diminished pool of these osteogenic progenitors because of severe 
trauma, diabetes, a history of tobacco use, irradiation, aging, osteoporosis or other 
metabolic derangements; and it will be much more cost-effective, considering about the 
self renewal capability of cells [Bruder, 1999]. Furthermore, unlike growth factor based 
strategy, which can only delivery one or several growth factors, the delivered cells in 
cell based strategy can secrete a wide spectrum of growth factors with the concentration 
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and microgradients in the physiological doses [Rouwkema, 2008]. Thus, a cell based 
strategy has been pursued in this project. 
 
1.3.2 An effective cell based BTE strategy and essential components 
Two distinct typical cell based approaches have been proposed to use cultured 
osteogenic cells in combination with scaffold matrix to engineer bone grafts 
[Lieberman, 2005; Jeffrey O, 2005; Lanza, 2007]. The first approach is to seed cells on 
the scaffold matrix with immediate implantation of the construct. In the second 
approach, a pre-implantation in vitro culture procedure is added for cellular expansion 
and constructs pre-differentation (Figure 1-6), which has been reported to regenerate 
much more new bone and achieve better bone defect healing effect in vivo, compared to 
an immediate implantation approach [Mendes, 2002; Sikavitsas, 2003; De, 2006; 
Dudas, 2006]. This approach require that: firstly, osteogenic cells are seeded into three 
dimensional highly porous biodegradable scaffolds, fabricated in a desired shape to fit 
the bone defect; secondly, cellular scaffolds are cultured and matured in a suitable in 
vitro environment, for cellular expansion and proper pre- differentiation to obtain 
bone-like constructs with extracellular mineralized matrix and pre-differentiated cells; 
lastly, this tissue engineered graft is implanted into the defect to induce and direct the 
growth of new bone with the controlled degradation of the scaffold matrix.  
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1.3.3 Protected bone regeneration for BTE 
A “Protected Bone Regeneration” theory can be applied to explain why the BTE 
cellular scaffold constructs (i.e. the TE bone grafts) can help to heal the critical sized 
defects. According to the “Protected Bone Regeneration” theory, there are three 
prerequisites for successful bone healing: (1) adequate blood supply, (2) critical mass 
of bone forming cells, and (3) protected healing space [Holmes, 2000].  
 
Bone possess the capability to heal the small defect; when the small defect forms, 
endothelial cell will migrate to the injury site from surrounding tissue, proliferate and 
form new capillaries to extend into the injury. Benefiting from the in-growth of blood 
vessels, fluids (including the nutrient, growth factors) and cells (including the bone 
forming cells) can be delivered to defects area and defects can be healed. (Figure 1-7 
A) 
 
If the defect is a critical sized defect (CSD), the defect space, which is supposed to be 
Figure 1-6 A popular approach of bone tissue engineering.  
(Reproduced from http://www.btec.cmu.edu/reFramed/tutorial/mainLayoutTutorial.html) 
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filled with new formed bone, cannot be maintained any more, because the heavy 
mechanical loading on the area will lead to the collapse of space from surrounding 
tissue, and moreover the fibrous tissue will overgrow the formation of new bone 
tissue and occupied the area rapidly. Due to the blockage of the space, blood vessel 
cannot infiltrate in and no osteogenic cells and fluid will be delivered, hence, 
nonunion healing occurs. (Figure 1-7 B) 
 
However, this CSD can be healed by the implantation of TE bone grafts, which are 
developed by seeding osteogenic stem cells into porous scaffolds and maturing in 
bioreactors to saturate the scaffolds with osteogenic cells and mineralized 
extracellular matrix (ECM). Because of the mechanical rigidity of scaffolds, TE bone 
grafts can bear the mechanical loading and maintain the defect space. In addition, 
with properly designed macroporous structure of scaffolds, TE bone grafts will 
prevent the invasion of fibrous tissue but allow the infiltration of blood vessel. The 
saturation of osteogenic cells and highly mineralized ECM in TE bone grafts will also 
help to exclude the in-growth of fibrous tissue. Finally, the osteogenic cells inside TE 
bone grafts will not only directly involved in the new bone formation, but also release 
growth factors to stimulate the formation of blood vessels and recruit the bone 
forming cells from surrounding environment. With the formation of the new bone, 
scaffolds will gradually degrade and be eventually replaced with the new formed bone. 
In this way, the cellular scaffold constructs help to repair the critical sized defects. 
(Figure 1-7 C) 
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From the above discussion, it can be concluded that in order to develop an effective 
TE bone grafts for a successful cell based BTE therapy, the following three essential 
components should be the key to the success: (1) suitable biodegradable scaffold matrix 
which has rigid mechanical properties to protect the defect area from collapse of 
surrounding tissue, proper macroporous structure to prevent the invasion of fibrous 
tissue but allow the infiltration of blood vessels, and proper chemical properties for cell 
attachment and proliferation; (2) a critical mass of osteogenic cells, to secret the 
mineralized ECM, directly involve in the formation of new bone, and furthermore 
interact with surrounding tissue in vivo to create a biological microenvironment 
benefiting the blood vessel formation and bone regeneration; and (3) a bioreactor 
Figure 1-7 Protected bone regeneration theory of (A) healing of small defects; (B) 
nonunion healing of critical sized defect; and (C) healing of critical sized defect with TE 
bone graft (cellular scaffold). 
A. Healing of small defect 
B. Nonunion healing of critical sized defect 
C. Healing of critical sized defect with TE bone graft 
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culture system with highly controlled in vitro culture environment to maintain the high 
viability of large dimension scaffolds and mature the constructs with significant 
cellularity and mineralized ECM. In order to develop a successful cell based TE bone 
grafts for clinical applications, the requirements, characteristics and selection criteria of 
these three essential components will be discussed in detail in the following sections.  
 
1.4 Scaffolds for BTE 
1.4.1 Function of BTE scaffolds 
In human body, tissues generally consist of a matrix and one or more cell types. The 
matrix, in fact, is a natural three dimensional (3D) scaffold for cells in vivo, providing 
them with a tissue specific environment and architecture [Salgado, 2004], and also 
serving as a reservoir of water, nutrients, cytokines, and growth factors. In this sense, in 
order to regenerate the damaged bone tissue, besides their mechanical functions in 
maintenance of defect space as discussed previously, three dimensional (3 D) scaffolds 
are also required to function as a supportive matrix for cell proliferation, extracellular 
matrix deposition and consequent bone in-growth and at the same time define the 
overall shape of the tissue engineered transplant [Laurencin, 1999]. Furthermore, they 
could work as a template for the rapid vascularization of the neo-tissue [Hutmacher, 
2000]. Scaffolds should also actively contribute to the regenerative process by 
enhancing the proliferation and osteogenic differentiation of the cells grew on their 
surface through the cell-scaffold interaction [Agrawal, 2001]. [Langer, 1993; Salgado, 
  Chapter 1 Introduction 
____________________________________________________________________________________________ 
- 47 - 
2004]  
 
1.4.2 Requirement of BTE scaffolds 
It has been well accepted that an ideal scaffold for BTE should fulfill the following 
requirements as stated below: [Laurencin, 1999; Hutmacher, 2000; Liu, 2004; Williams, 
2008] 
1.4.2.1 Biocompatibility : 
Safety is prerequisite requirement for the TE scaffolds, and the scaffolds should be fully 
biocompatible. Biocompatibility refers to the ability of a biomaterial to perform its 
desired function with respect to a medical therapy, without eliciting any undesirable 
local or systemic effects in the recipient or beneficiary of that therapy, but generating 
the most appropriate beneficial cellular or tissue response in that specific situation, and 
optimizing the clinically relevant performance of that therapy [Williams, 2008]. In 
other words, the scaffolds should be non-mutagenic, non-antigenic, non-carcinogenic, 
non-toxic and non-teratogenic [Leong, 2003]. This requires that the biomaterial used 
for scaffolds fabrication should be biocompatible, and that the fabrication process 
should not affect the innate biocompatible properties of the biomaterial [Hutmacher, 
2000].  
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1.4.2.2 Porosity and pore interconnectivity: 
Scaffolds must possess an open-pore and fully interconnected geometry in a highly 
porous structure with microstructure that allows cell in-growth and reorganization in 
vitro and provides the necessary space for neo-vascularization from surrounding tissues 
in vivo. The scaffold’s porosity and degree of pore interconnectivity directly affect the 
diffusion of physiological nutrients and gases to and the removal of metabolic waste 
and by-products from the cells inside the scaffold [Vacanti, 1988; Mikos, 1993]. As a 
result, a porous microstructure with interconnected porous networks is critical in 
ensuring spatially uniform cell distribution, cell survival, proliferation and migration in 
vitro [Leong, 2003; Salgado, 2004]. 
 
1.4.2.3 Pore size 
Pore size is a very critical parameter for scaffold itself. If the pores applied are too small, 
the proliferation of the cells will occlude the pores. This will affect the cellular 
penetration, extracellular matrix deposition and furthermore the in vivo vascularization 
to the inner areas of the scaffolds. However, if the pores employed are too big, the 
mechanical properties of the scaffolds will be greatly compromised and the fibrous 
tissue can easily penetrate and invade into the defect space (please refer to Section 
1.3.3). Therefore, the proper size of the pore should be carefully selected. This 
parameter for BTE applications is generally considered to be between 300-900 μm, 
which will favor the cellular migration, extracellular matrix production and 
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neo-vascularization [Boyan, 1996; Burg, 2000; Yang, 2002; Karageorgiou, 2005].  
 
1.4.2.4 Surface area and properties 
A high surface area to volume ratio is another essential property for BTE scaffolds, in 
order to accommodate clinical significant number of cells required for effective bone 
regeneration [Leong, 2003]. Furthermore, surface properties, both topographical and 
chemical, can control and affect cellular adhesion, migration, proliferation and 
differentiation [Boyan, 1996]. A rough topographical surface property has been shown 
to be more osteoconductive [Davies, 1996; Davies, 1998; Albrektsson, 2001], as 
compared to the smooth surface, the rough surface can imprison the fibrin matrix and 
facilitate the migration of osteogenic cells to the material surface. On the other hand, 
some chemical properties of the surface may have special effects on the cellular 
migration and differentiation. For example, some ceramics materials such as 
hydroxylapatite and β-tricalcium phosphate have some specific chemical properties of 
their surfaces and are shown to be not only osteoconductive but also osteoinductive, 
which means they can recruit the stem and osteoprogenitor cells to the bone healing site 
and stimulate them to undergo the osteogenic differentiation pathway [Albrektsson, 
2001; LeGeros, 2002; Salgado, 2004].  
 
1.4.2.5 Mechanical properties and biodegradability 
As templates to guide tissue regeneration, scaffolds should have sufficient mechanical 
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strength during in vitro culturing to maintain the spaces required for cell in-growth and 
matrix elaboration [Leong, 2003]. In addition, because bone is a load bearing tissue, the 
mechanical properties of the scaffold should be high enough to maintain the defective 
space for new bone formation and preferably allow the early mobilization of the injured 
sites [Hutmacher, 2000]. Furthermore, the scaffolds should be biodegradable with a 
degradation and resorption rate to match nature tissue replacement, so that the new 
regenerated tissue will completely take place of the degraded scaffold [Langer, 1993].  
 
1.4.3 Biomaterial selection 
1.4.3.1 Single material vs. Composite material 
A wide range of biomaterials have been investigated for their capability to fabricate 
into the BTE scaffolds, including the metals, ceramics and polymers from natural or 
synthetic origins. However, all biomaterials have various advantages and 
disadvantages with no one material fulfilling all the ideal requirements for BTE 
scaffolds. Metal has been widely used for all kind of permanent orthopedic implants, 
like hip prosthesis, because of their superior mechanical properties; however, their 
non-biodegradable properties limited their use in BTE. Ceramics, such as 
hydroxylapatite or β-tricalcium phosphate, have demonstrated to be effective material 
for bone regeneration due to their osteoconduction and osteoinduction properties, but 
their brittle and poor mechanical stability make it become very difficult to fabricate 
them into complicated scaffolds structure. Natural biodegradable polymer such as 
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among others, collagen, fibrinogen, chitosan, starch, hyaluronic acid (HA), and poly 
(hydroxybutyrate), have become very attractive material for their potential bioactive 
behavior and their capability to interact with host’s tissue, however, there are the 
drawbacks of potential immunogenicity, limited source and high batch-to-batch 
variation about their material properties even with the same source origin. Finally, 
synthetic biodegradable polymers, such as poly(α-hydroxyacids), poly 
(ε-caprolactone), poly(propylene-fumarates), poly(carbonates), poly(phosphazenes), 
and poly(anhydrides), have receive a lot of attention for their biocompatibility, reduced 
variation of material properties and ease of manufacture into differing shapes, but 
usually are not bioactive enough and some of their degradation byproducts may be 
harmful to biological tissue [Liu, 2004; Salgado, 2004; Ifkovits, 2007; Malard, 2007; 
Stevens, 2008]. As a result, the concept of composite material made of two or more 
distinct material has been proposed in order to conquer the drawbacks of single material 
[Wang, 2003; Stevens, 2008]. Recently, the author’s research group proposed a 
composite material made of poly(ε-caprolactone) (PCL) and β-tricalcium phosphate 
(TCP), which incorporates the strength of PCL and TCP while neutralizes their 
individual drawbacks (Figure 1-8) [Rai, 2004; Rai, 2005]. 
1.4.3.2 Poly (ε-caprolactone) (PCL) 
Poly (ε-caprolactone) (PCL) is a semicrystalline, bioresorbable polymer belonging to 
the aliphatic polyester family. It has a low glass-transition temperature of –60˚C, a 
melting point of 60˚C and a high decomposition temperature of 350˚C with a wide 
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range of temperatures that allow extrusion. Because of its high permeability, it has been 
exploited for drug delivery material [Coombes, 2004] and has been extensively study 
for its biocompatibility and efficiency in vitro and in vivo[Hutmacher, 2001; Endres, 
2003], resulting in US Food and Drug Administration (FDA) approval of a number of 
medical and drug delivery devices. Currently, PCL is employed as a scaffold material in 
various tissue engineering applications and regarded as a soft and hard tissue 
compatible bioresorbable material [Hutmacher, 2001]. In addition, chemical hydrolysis 
as opposed to enzymatic reactions is responsible for degradation of polymeric chains in 
vivo; thus degradation does not vary from patient to patient. However, it has certain 
drawbacks. As with all synthetic polymers, PCL implants experience fibrosis and 
gradually become isolated from the surrounding bone. Consequently, they do not 
adhere to bone and this has been a critical problem in their use in bone repair [Kokubu, 
2003]. In addition, a common problem to biodegradable polyesters family is that the 
release of acidic degradation products can cause acidosis [Ciapetti, 2003]. 
1.4.3.3 β-tricalcium phosphate (TCP) 
β-tricalcium phosphate (TCP), a synthetic ceramic material, has outstanding properties 
for the BTE applications: (1) it is bioactive and can generate a carbonated 
hydroxyapatite layer on its surface that is equivalent chemically and structurally to the 
biological mineral of nature bone, known as the determining step for the biointegration 
[Kokubo, 2003]; (2) it is osteoconductive and can promote the cellular adhesion, 
function and expression leading to formation of new bone and a uniquely strong 
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bone-TCP biomaterial interface; and (3) it is osteoinductive, and capable to bind and 
concentrate endogenous bone morphogenetic proteins from circulation [LeGeros, 
2002]. However, pure TCP has its drawbacks for BTE applications; it is a brittle 
material with very poor mechanical properties, leading to the difficulty of fabricating it 
into BTE use scaffolds with different shapes to fit the bone defects. 
 
1.4.2.4 PCL-TCP composite material 
To alleviate these shortcomings, a bioactive composite material comprising of a 
biodegradable polymeric phase (PCL) and a bioactive inorganic phase (TCP) has been 
developed. This construct takes advantage of the flexibility and processability of the 
bulk PCL polymer phase, combined with TCP bioactive phase, allowing the scaffold to 
bond and integrate with bone spontaneously and possess the osteoconductive and 
osteoinductive properties. Furthermore, the acidic release from the polymer can be 
Figure 1-8 PCL-TCP composite material, incorporates the strength of PCL and TCP while 
neutralizes their individual drawbacks 
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compensated by the alkaline calcium phosphate [Blaker, 2003; Maquet, 2004]. (Figure 
1-8) 
 
1.4.4 Fabrication methods 
1.4.4.1 Criteria of fabrication methods 
A proper fabrication method should be carefully selected to process the chosen 
biomaterial into the desired 3D BTE scaffolds. The proper fabrication method should 
fulfill the following criteria: [Yang, 2001; Yang, 2002; Leong, 2003] 
 Processing conditions: The whole fabrication process should in no way adversely 
affect the material properties, namely its biocompatibility, chemical and 
mechanical properties. 
 Process accuracy and consistency: The fabrication technique should be able to 
produce BTE scaffolds with highly accuracy and consistency, regarding to their 
macrostructure, such as the size and shape, and microstructure, for instance, the 
porosity, pore size, pore distribution and interconnectivity. 
 Reproducibility: Different scaffold batches should exhibit minimal variations in 
physical forms and properties when produced from the same set of processing 
parameters and conditions.  
1.4.4.2 Conventional scaffold fabrication methods 
Conventional scaffold fabrication techniques include fiber bonding, phase separation, 
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solvent casting/particulate leaching, membrane lamination, melt molding, gas 
foaming/high pressure processing, hydrocarbon templating, freeze drying and 
combinations of these techniques (e.g., gas foaming/particulate leaching, etc.). The 
conventional fabrication techniques have their pros and cons, as illustrated on Table 
1-3.[Leong, 2003] 
 
However, some significant flaws restrict their scopes of applications in BTE scaffold 
fabrications: (1) manual-based processes with highly inconsistence: the processes are 
labor intensive and time-consuming, and highly dependent on operators’ skill, thus the 
macro- and micro-structure of the scaffolds is highly inconsistent; (2) use of toxic 
organic solvents or porogens with limited thickness of the scaffolds: most of those 
techniques involve the extensive use of toxic organic solvents or porogens, the residues 
of those solvents or porogens will be of great harm to the biological tissues, and in order 
to complete removal of those solvents or porogens, the thickness of scaffolds to be 
fabricated will be only limited to 2 mm; and (3) shape limitations: for those techniques 
needed the additional modes or containers, the shape of scaffolds fabricated will be 
heavily limited to the complexity of the design and the construction of the molds.[Burg, 
2000; Hutmacher, 2000; Yang, 2001; Yang, 2002; Leong, 2003; Yeong, 2004] 
 
Table 1-3 Conventional scaffold fabrication methods, pros and cons  
(Adapted from [Leong, 2003])  
 
Process Advantages Disadvantages 
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Fiber bonding Easy process 
High porosity 
High surface area to volume 
ratio 
High processing temperature for 
non-amorphous polymer 
Limit range of polymers 
Lack of mechanical strength 
Problems with residual solvent 




Allows incorporation of 
bioactive agents 
Highly porous structures 
Lack of control over 
micro-architecture 
Problems with residual solvent 




Highly porous structures 
Large range of pore sizes 
Independent control of 
porosity and pore size 
Crystallinity can be 
tailored 
Limited membrane thickness 
Lack of mechanical strength 




Macro shape control 
Independent control of 
porosity and pore size 
Lack of mechanical strength 
Problems with residual solvent 
Tedious and time-consuming 
Limited interconnected pores 
Melt moulding Independent control of 
porosity and pore size 
Macro shape control 






Good compressive strength 
Independent control of 
porosity and pore size 




Organic solvent free 
Allows incorporation of 
bioactive agents 
Nonporous external surface 





Organic solvent free 
Allows incorporation of 
bioactive agents 
Highly porous structures 
Large range of pore sizes 
Independent control of 
porosity and pore size 
Limited interconnected pores 
Lack of mechanical strength 
Residual porogens 
Freeze drying Highly porous structures 
High pore 
interconnectivity 




No thickness limitation 
Independent control of 
porosity and pore size 
Problems with residual solvent 
Residual porogens 
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1.4.4.3 Solid freeform fabrication techniques 
Solid freeform fabrication (SFF) techniques, also commonly known as rapid 
prototyping (RP), have recently been explored for the BTE scaffolds fabrication. They 
are computerized fabrication techniques that can rapidly produce highly complex 
three-dimensional physical objects using data generated by computer assisted design 
(CAD) systems, computer based medical imaging, digitizers and other data makers. 
The SSF techniques utilize the strategy of layered manufacturing, whereby 3D objects 
are fabricated layer by layer via the processing of solid sheet, liquid or powder material 
stocks with a typical process chain illustrated in 
Figure 1-9.[Leong, 2003; Sachlos, 2003] 
 
Compared to the conventional scaffold fabrication 
techniques discussed previously, SFF techniques 
have been shown to possess a number of significant 
advantages including: (1) customized design: they 
allows the complex scaffold designs and moreover, 
the patients specific design based on the medical 
images of patients’ defect area; (2) high accuracy, 
consistency and repeatability: the whole fabrication 
process is fully controlled by computer with minimal 
manual intervention; and (3) anisotropic scaffold microstructures: the combined use of 
CAD and SFF makes it possible to incorporate different macroscopic and microscopic 
Figure 1-9 Typical SFF process 
chain (Adapted from [Leong, 
2003]) 
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design features on different regions of the same scaffold.[Leong, 2003; Sachlos, 2003; 
Hutmacher, 2004; Tsang, 2004] 
 
There are a number of SFF techniques available for TE scaffolds fabrication; based on 
the way materials deposited, they can be categorized into three major groups (Figure 
1-10) [Hollister, 2005]. The first group (Figure 1-10 a. & b.) are laser-based systems: 
Stereolithography (SLA) (Figure 1-10 a.) utilizes a laser beam to selectively 
photopolymerize the liquid photocurable monomer contained in the vat, while the 
fabricating object was held in a moveable table which can move in x, y, z-axes and 
controlled by computer. Selective Laser Sintering (SLS) (Figure 1-10 b.) works in a 
similar way except it employs the laser beam to selectively sinter material powder into 
layers. The second group (Figure 1-10 c. & d.) are based on ink jet printing techniques: 
Three Dimensional Printing (3D Printing) (Figure 1-10 c.) eject a chemical binder 
from a jet head onto the material powders and joins adjacent powder particles into a 
layer; Wax Printing (Figure 1-10 d.) directly print the wax into a 3D supportive mold 
while casting the material into this mold. The third group (Figure 1-10 e. & f.) are 
nozzle-based techniques: Fused Deposition Modeling (FDM) (Figure 1-10 e.) employs 
the concept of melt extrusion to deposit a parallel series of material roads that forms a 
material layer; and Bioplotter or 3D Plotter (Figure 1-10 f.) extrude the potting 
material into the potting medium which will immediately solidify the material into a 
layer.[Leong, 2003; Sachlos, 2003; Hutmacher, 2004; Tsang, 2004; Yeong, 2004; 
Yeong, 2004; Hollister, 2005]  
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Figure 1-10 Schematics of SFF systems categorized into three groups based on the way 
materials deposited: (a) and (b) are laser-based systems; (c) and (d) are ink jet printing based 
systems; (e) and (f) are nozzle-based systems. (Adapted from [Hollister, 2005])  
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1.4.4.4 PCL-TCP 3D scaffold fabrication by FDM 
The whole process to fabricate the PCL-TCP scaffolds using FDM technique includes 
three steps [Hutmacher, 2001; Zein, 2002].  
 
The first step is filament fabrication. PCL pellets are physically blended with TCP 
granules in a desired ratio (e.g. 80% PCL to 20% TCP) and mixed homogenously, and 
then they are melted in a high temperature (190˚C) without the addition of any solvent. 
The melted material is cooled to 140˚C and extruded through spinnerets with a die exit 
diameter of 1.63 mm and the piston speed was set at 10 mm/min. The extrudate was 
quenched in chilled water immediately. The PCL-TCP filaments prepared in this way 
have a consistent diameter (1.70 ± 0.10 mm) to fit the drive wheels of the FDM system. 
The filaments were vacuum-dried and kept in a desiccator prior to usage. 
 
The second step is scaffold design and software preparation (Figure 1-11). The 3D 
models of scaffolds with desired size and shape can be generated by the CAD, for 
example, a patient-specific scaffold to fit the patient’s bone defect area can be created 
based on the patient’s 3D computed tomography(CT) images. The CAD models will be 
imported into the Stratasys QuickSlice software and sliced into the horizontal layers. 
And the deposition path will be created and downloaded to the FDM machine, the 3D 
Modeler RP system from Stratasys Inc. (Eden Prairie, MN). 
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The last step is the scaffold fabrication. The PCL-TCP filament prepared in the first step 
will be feed into the FDM head, melted down in the liquefier and extrude out through 
the nozzle tip and deposit on a platform layer by layer (Figure 1-12 A.). The FDM head 
can move in x-y axes while the platform can move in z-axis, and their movement is 
controlled by the computer and guided by the designed deposition path prepared in the 
second step (Figure 1-12 B.).  
Figure 1-11 Summary of the software preparation. Step 1: Import of CAD data in “.stl” 
(StereoLithography) format into QuickSlicet. Step 2: Slicing of the CAD model into horizontal 
layers and conversion into a “.slc” (SLiCe) format. Step 3: Creation of deposition path for 
each layer and conversion into a “.sml” (Stratasys Machine Language) format for downloading 
to FDM machine. Step 4: FDM fabrication process using a filament modeling material to build 
actual physical part in an additive manner layer-by-layer.(Adapted from [Zein, 2002]) 
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Scaffolds, which are fabricated with the lay-down pattern of 0/60/120°(Figure 1-13) 
[Zein, 2002], have honeycomb, fully interconnected matrix architecture and 
mechanical properties close to the cancellous bone, which can support rapid 
vascularization and maintain the defect space and the structural integrity of tissue 
engineered bone grafts in load-bearing applications [Hutmacher, 2001; Schantz, 2002]. 
In addition, use of the highly reproducible and computer-controlled FDM technique 
allows the fabrication of tissue-engineered grafts that have been designed on the basis 
of computed tomography (CT) scans of individual defect sites[Hutmacher, 2000; 
Endres, 2003]. 
Figure 1-12 A schematic diagram of the FDM extrusion and deposition process: (A) the 
working mechanism of FDM head; and (B) movement of the FDM head and the platform. 
(Adapted from [Zein, 2002]) 
A B 
  Chapter 1 Introduction 
____________________________________________________________________________________________ 
- 63 - 
 
 
1.5 Cellular source for BTE 
Cells are the central players for most biological process in human body. As another 
component in the BTE strategy, they play the most essential role and directly involved 
in the bone regeneration. The selection of cell sources will eventually determine 
whether BTE strategies can succeed or not.  
Figure 1-13: (a) Lay-down pattern of 0/60/1201 forming triangular honeycomb pores 
viewed in the –Z direction of the FDM build process. (b) Alignment of filaments in 
scaffold specimens witha 0/60/1201 lay-down pattern. In the out-of-layer (OL) orientation, 
the filaments are aligned in the XY-plane. In both inlayer-vertical (ILV) and 
in-layer-horizontal (ILH) orientations, the filaments are aligned in the XZ-plane and 
YZ-plane, respectively. (c) Cross-section viewed in the XZ plane of the FDM build 
process. Symbols are denoted as RW: road width, FG: fill gap, ST: slice thickness, LG: 
layer gap. (Adapted from [Zein, 2002])  
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1.5.1 Available cellular sources for cell based approach 
The ideal cellular source for cell based BTE approach, should include the following 
characteristics: (1) no or low immunogenicity, (2) no tumorigenicity, (3) immediate 
availability, (4) availability in pertinent quantities, (5) rapid cell proliferation rate, (6) 
predictable and consistent osteogenic potential as well as (7) controlled integration into 
the surrounding tissues [Logeart-Avramoglou, 2005]. Different cell sources have been 
exploited for BTE applications, and can fall into three categories with the respect to 
their differentiation status: fresh bone marrow, differentiated osteoblasts and 
mesenchymal stem cells [Bruder, 1999; Pioletti, 2006] (Table 1-4).  
 
Table 1-4 Comparison of different cellular source for BTE.  




marrow +++ N.A. N.A. N.A.* + 
osteoblast + + + N.A.* +++ 
MSC  ++ ++ +++ ++ ++ 
N.A.*: allogenic applications can be achieved by proper HLA matching 
1.5.1.1 Fresh bone marrow 
Fresh bone marrow (BM) has been introduced to heal the nonunion bone defect in 
1980s [Connolly, 1989; Connolly, 1991; Caplan, 2005], because they are easy to 
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harvest and contain the osteogenic progenitors, which can enhance the defect 
regeneration, and furthermore, their application involves only the relocation of 
autologous tissue and is not subject to the regulation by the Food and Drug 
Administration(FDA) [Bruder, 1999]. However, their effectiveness is highly dependent 
on the number of the osteogenic progenitors, which represent approximately 0.001% of 
the nucleated cell in the healthy bone marrow at best [Bruder, 1997] and will 
dramatically decrease as a consequence of aging or disease [Pioletti, 2006]. So this 
approach may be least applicable in those situations where it is most needed, as 
fractures tend to occur more frequently in an old age group. Moreover, the allogenic 
transplantation is rarely applicable, because bone marrow contains T lymphocytes that 
encounter and respond to host antigens in virtually all tissues in the body, which can 
lead to severe multi-system graft-versus-host syndrome [Weissman, 2000].  
1.5.1.2 Differentiated osteoblasts  
Osteoblasts are involved in the entire bone formation process via synthesizing and 
secreting collagen to form unmineralized bone matrix (osteoid) and participating in 
osteoid calcification. The use of osteoblasts for the cellular source for BTE applications 
has resulted in the enhancement in the rate and extent of bone regeneration compared 
with the use of undifferentiated bone marrow [Okumura, 1997; Bruder, 1999; 
Montjovent, 2004]. However, the autologous isolation of the osteoblasts are 
considerably more difficult and complex than fresh bone marrow or MSC, and even 
after isolation, they posses a limited capacity for proliferation, making the in vitro 
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expansion of osteoblasts to clinical significant number very difficult [Bruder, 1999; 
Montjovent, 2004; Pioletti, 2006]. 
1.5.1.3 Mesenchymal Stem Cell (MSC)  
Mesenchymal stem cells (MSC) are also known as marrow stromal cell or colony 
forming unit – fibroblast (CFU-F) or more recently named as multipotent mesenchymal 
stromal cells by International Society for Cellular Therapy (ISCT) [Horwitz, 2005]. 
They were first identified and isolated from adult bone marrow [Friedenstein, 1966; 
Friedenstein, 1968] and recently have been demonstrated to be an attractive and 
promising cell source for tissue engineering applications. From the BTE perspective, 
they have a number of advantages over other cell sources: (1) MSC can be easily 
isolated by plastic adhesion method or simple antibody selection techniques[Simmons, 
1991]; (2) the osteogenic differentiation pathway is well defined and MSC have been 
shown to generate greater amount of bone tissue than fresh bone marrow in preclinical 
studies [Kahn, 1995; Inoue, 1997; Pioletti, 2006]; (3) MSC and differentiated MSC are 
reported to be non-immunogenic and suitable for allogenic applications[Le Blanc, 
2003]; and (4) cryostorage does not affect the osteogenic potential of MSC, which 
greatly facilitates their storage [Bruder, 1997].  
 
1.5.2 MSC biology 
Since the discovery of MSC, nearly half a century’s research work unveiled many 
special biological characteristics of the MSC, and gradually they have attracted more 
  Chapter 1 Introduction 
____________________________________________________________________________________________ 
- 67 - 
and more attention for their potential use in regenerative medicine and tissue 
engineering, including BTE.  
 
MSC possess no specific cell markers to distinguish themselves from others, and are 
currently defined by their ability to (1) adhere to the plastic surface of tissue culture 
flask; (2) express D105, CD73 and CD90, with absence of CD45, CD34, CD14 or 
CD11b, CD79a or CD19 and HLA class II; and (3) differentiate into the osteoblasts, 
adipocytes and chondroblasts under standard in vitro differentiating conditions. These 
are the three minimal criteria to define MSC, proposed by a consensus group at the 
ISCT recently [Dominici, 2006].  
 
1.5.2.1 Characterization and heterogeneity 
Friedenstein and his coworkers identified an adherent, non-phagocytic, fibroblast-like 
population within bone marrow (BM) and showed their capability to regenerate bone 
both in vitro and in vivo more than four decades ago [Friedenstein, 1966; Friedenstein, 
1968; Friedenstein, 1974; Friedenstein, 1976]. MSC are rare cells, exist in a very low 
frequency in human adult BM, only accounting for 0.00001% to 0.001% of 
mononuclear cells (MNC) in BM. They are non-haemopoietic and can be separated 
from the haemopoietic fraction in bone marrow by their adherence to plastic and ability 
to grow from an initial heterogeneous population into a more homogenous 
spindle-shaped cell type. They have obtained their original nomenclature of colony 
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forming unit-fibroblast (CFU-F) because of their capacity to rapidly proliferate in vitro 
and form the colonies of fibroblast-like cells in culture. It was later demonstrated by 
different investigators that CFU-F cells had the ability to differentiate into multiple 
mesenchymal lineages such as osteoblasts, adipocytes and chondrocytes [Piersma, 
1985; Pereira, 1998]. It wasn’t until 1999 that Pittenger et al used carefully selected 
batches of fetal calf serum to demonstrate the reproducible isolation, self renewal and 
multi-lineage differentiation of MSC after plastic adherence [Pittenger, 1999]. The 
nomenclature of MSC gradually moved from CFU-F through “marrow stromal cells”, 
to “mesenchymal stem cell”, which was now more widely use and was first introduced 
by Caplan [Caplan, 1991]. More recently, another term “multipotent mesenchymal 
stromal cells” was proposed by ISCT [Horwitz, 2005].  
 
MSC have been demonstrated to contain a heterogeneous population of cells. 
Properties including colony size, proliferation rate, cellular morphology, and 
multipotency both in vitro and in vivo have been routinely observed to differ in single 
colony-derived MSC strains [Muraglia, 2000; Mauney, 2005]. Besides the plastic 
adhesion method, other techniques have been refined and developed to isolate and 
purify the MSC, include immuno-depletion techniques [Baddoo, 2003] or selection via 
STRO-1 and CD 271 antibodies [Simmons, 1991; Jones, 2008]. However, the resulting 
cultures were still heterogeneous, ranging from spindle shaped cells to broad 
stromal-like cells [Digirolamo, 1999; Colter, 2000; Colter, 2001]. This is also reflected 
in inter-culture and interspecies differences in the capacity of MSC to self-renew or 
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form CFU-F in low-density cultures [Digirolamo, 1999; Phinney, 1999; Banfi, 2000; 
Javazon, 2001].  
1.5.2.2 Immunophenotype and immunogenicity 
Although there are no markers specific for MSC, it is generally accepted that MSC 
from any source do not express haemopoietic markers such as CD14, CD34 and CD45 
and are consistently negative for the endothelial markers CD31 and von-Willebrand 
factor (vWF). They express a number of adhesion molecules such as CD44 (hyaluron), 
CD29 (β1 integrin), CD49e (α5 integrin), CD62 and a number of intracellular markers 
such as vimentin, laminin, fibronectin and surface epitopes like CD105 and CD73. 
MSC express intermediate amounts of HLA-Class I and do not express HLA Class II 
[Le Blanc, 2003; Dominici, 2006]. However, variable expression of CD90 (Thy1.1), 
CD117 (ckit), CD105, CD73 and STRO-1 may occur between cultures and species, 
underlying the heterogenous nature of MSC and the different microenvironments 
required for haemopoietic support [Haynesworth, 1992; Barry, 1999; Pittenger, 1999; 
Barry, 2001; Kobune, 2003; Rombouts, 2003; Javazon, 2004; Chan, 2006] 
 
MSC are not inherently immunogenic, making them highly attractive for allogeneic 
transplantation strategies [Caplan, 2007]. MSC are HLA Class I positive and Class II 
negative and do not express co-stimulatory molecules CD40, CD40L, CD80, or CD86 
[Klyushnenkova, 2005]. This phenotype is widely regarded as non-immunogenic and 
suggests that MSC may be effective at inducing tolerance. In the mixed lymphocyte 
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cultures (MLC) assay, MSC do not elicit a proliferation response of allogeneic 
lymphocytes [Bartholomew, 2002; Le Blanc, 2003]. After MSC has been stimulated by 
interferon γ (INF-γ) to induce the full expression of HLA Class II, they can still escape 
recognition by alloreactive T-cells [Le Blanc, 2003; Klyushnenkova, 2005]; in addition, 
after cell differentiation into along the adipogenic, chondrogenic and osteogenic 
lineages, they still remain non-immunogenic[Le Blanc, 2003](Figure 1-14). At last, 
they can escape lysis by cytotoxic T-cells and alloreactive killer inhibitory receptor 
mismatched natural killer cells [Le Blanc, 2003; Rasmusson, 2003; Gotherstrom, 2007] 
 
Furthermore, MSC showed strong immunomodulatory effect both in vitro and in vivo. 
In vitro, they exhibit immunosuppressive effects and inhibit T-cell alloreactivity. 
[Pittenger, 1999; Bartholomew, 2002; Krampera, 2003; Maitra, 2004; Beyth, 2005]. 
This suppression effect of MSC is dose dependent and not only influence T cell but also 
affect the differentiation and maturation of dendritic cells from monocytes [Aggarwal, 
2005]. In vivo, infusion of ex vivo-expanded MSC has been shown to prolong the 
Figure 1-14 MSC do not elicit a proliferative response in allogeneic lymphocytes after 
differentiation and/or IFNg exposure. Ten thousand undifferentiated MSC or MSC grown in 
differentiation media for 1 week (gray bars) or MSC subsequently exposed to IFN γ(100 
U/mL) for 48 h (white bars) were cultured with 100 000 allogeneic PBL. A mixed lymphocyte 
culture (black bar) is shown as comparison. Mean ±/ SD. (Adapted from [Le, 2003])  
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survival of allogeneic major histocompatibility mismatched skin allografts in 
immunocompetent out-bred baboons [Bartholomew, 2002]. Further evidence was 
provided by Djouad et al, who found that subcutaneously injected melanoma cells in 
allogeneic immunocompetent mice formed tumors only when co-injected with MSC, 
suggesting that the presence of MSC prevented immune rejection of the tumor cells 
[Djouad, 2003]. More recently MSC have been reported to successfully cure the 
graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell 
transplantation [Le Blanc, 2004; Ringden, 2006] 
 
The mechanism governing those effects is not yet understood. However, it is quite 
likely that the paracrine effect of MSC will play a significant role in it, for example, it 
was shown that MSC may strongly inhibit T-cell recognition and expansion via 
inhibiting TNF-α and INF-γ production and, thus, increasing IL-10 levels as illustrated 
in Figure 1-15. [Aggarwal, 2005; Beyth, 2005; Caplan, 2007] 
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1.5.2.3 Differentiation capacity and osteogenic differentiation 
Besides the most well-known trilineage differentiation into osteoblasts, adipocytes and 
chondroblasts, MSC have been shown to be capable to differentiate to muscle, marrow 
stroma, tendon/ligament, and other connective tissues (Figure 1-16) [Caplan, 1991; 
Caplan, 2005; Caplan, 2007]. Many reports have further expanded this repertoire to 
neuroectodermal lineages such as neurons [Woodbury, 2000; Zhao, 2002], hepatocyte 
[Ong, 2006; Banas, 2007; Sgodda, 2007] and endothelia cell [Oswald, 2004; Gang, 
Figure 1-15 MSCs and APC interaction. MSCs may mediate their immunomodulatory 
effects by interacting with cells from both the innate (DC, pathways 2-4; NK cell, pathway 
6) and adaptive immunity systems (T cell, pathways 1 and 5). MSC inhibition of TNF-α 
secretion and promotion of IL-10 secretion may affect DC maturation state and their 
functional properties, resulting in skewing the immune response toward in an 
anti-inflammatory/tolerant phenotype. Alternatively, when MSCs are present an 
inflammatory microenvironment, they inhibit IFN-γ secretion from TH1 and NK cells and 
increase IL-4 secretion from TH2 cells, thereby promoting a TH1TH2 shift. It is likely that 
MSCs also mediate their immunomodulatory actions by direct cell-cell contact as well as by 
secreted factors. Several MSC cell-surface molecules and secreted molecules are depicted. 
CCL indicates chemokine ligand; TCR, T-cell receptor. (Adapted from [Aggarwal, 2005]) 
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2006]. More recently, a transdifferentiation phenomenon has been observed in 
differentiated MSC: the distinctive differentiated cell, such as adipocytes or 
chondrocytes can transdifferentiate into completely different lineage phenotypes such 
as osteoblasts [Tallheden, 2003; Farrington-Rock, 2004; Caplan, 2007]. (Figure 1-16) 
 
Osteogenic differentiation pathway seems to be the defaulted pathway for MSC, and 
osteogenic differentiation potential can be retained regardless of cell passage number 
until senescence: although MSC are regarded to be a heterogeneous population of cells, 
containing the tripotent (osteogenic, adipogenic and chondrogenic), bi-potent 
(osteogenic and chondrogenic) and uni-potent (osteogenic) cells through a clonal 
analysis, nearly all the clones are able to be differentiate into osteoblast. And clones 
progressively lose their adipogenic and chondrogenic differentiation potential at 
increasing cell doublings, however the osteogenic differentiation ability was retained 
Figure 1-16 The Mesengenic Process diagram with horizontal or diagonal arrows (dotted 
lines) depicting the plasticity of mesenchymal cells and the transdifferentiation of mature 
phenotypes into wholly different cell types. (Adapted from [Caplan, 2007]) 
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till senescence [Digirolamo, 1999; Muraglia, 2000]. This characteristic indicates that 
MSC may be holding more advantages in BTE applications than other TE applications. 
 
MSC can be fully differentiated into osteoblasts, bone lining cells and osteocytes under 
the osteogenic differentiation. This is a highly regulated and multi-step process with a 
sophisticated hierarchy as illustrated in Figure 1-17. MSC as multipotential stem cells, 
possessing the tremendous self-renewal and multipotent differentiation potential, are 
located on the top on this hierarchy. Followed by immature and mature 
osteoprogenitors, which are osteogenic committed progenitor cells with limited 
self-renewal and restricted differentiation capacity, but still maintaining substantial 
proliferation capacity. Further downstream are the preosteoblasts with more limited 
proliferation capacity. Mature osteoblasts are the terminally differentiated and 
functional cells, which will finally become the bone lining cells or osteocytes. With the 
progress of the osteogenic differentiation, proliferation of the cells is decreased while 
the osteogenic differentiation is increased. This process is highly regulated by various 
cellular inducing stimuli and each differentiation stage is characterized with 
expressions or up-regulation of different marker protein, such as collagen type I, 
alkaline phosphatase (Figure 1-17). [Aubin, 1998; Aubin, 2001; Bilezikian, 2002] 
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1.5.2.4 Roles of MSC in fracture healing and bone remodeling 
Owning to their well-known osteogenic differentiation potential, bone marrow derived 
MSC have been investigated for their capability for bone fracture healing in vivo and 
many studies have been demonstrated their great effectiveness to repair the critical size 
Figure 1-17 Postulated steps in the osteogenic lineage differentiation of Mesenchymal stem cell 
(Multipotential stem cell) implying recognizable stages of differentiation as detectable from in 
vitro and in vivo experiments. Superimposed on this scheme are several well-established 
markers of the osteoblast and current thinking as to how their expression changes through 
differentiation stages. -, no detectable expression; -/+ - +++, expression ranging from detectable 
to very high,  +++, heterogeneous expression in individual cells.  
(Adapted from [Aubin, 1998]) 
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bone defect in different animal models including rodents [Bruder, 1998; Meinel, 2006], 
dogs [Bruder, 1998], goats [Kruyt, 2004], sheeps [Bensaid, 2005] and a number of 
human clinical trials [Quarto, 2001; Cancedda, 2003; Schimming, 2004] as well. More 
recently, MSC have been implicated in essential and intricate roles for the maintenance 
of skeletal integrity (fracture healing) and the regulation of normal skeletal homeostasis 
(bone remodeling) in vivo. They are closely involved in fracture healing via cellular and 
paracrinal dual effects, and can regulate the bone remodeling via the sophisticated 
influence on the opposing action of osteoblast and osteoclast [Aubin, 1998; Bielby, 
2007; Caplan, 2007].   
 
1.5.2.4.1 Direct cellular involvement in callus formation 
During facture healing, as the progenitors for osteoblast, osteocyte and bone lining cell, 
MSC are involve in the fibrocartilage/bony callus formation which span the bone defect. 
In the inflammatory phase, the initial phase of the three-phase fracture healing process  
(Section 1.2.4), different sets of molecules are released, and can be categorized into 
four groups: (1) the pro-inflammatory cytokines, (IL-1, IL-6, COX-2); (2) mitogens 
(transforming growth factor beta (TGF-β), insulin-like growth factor (IGF), fibroblast 
growth factor (FGF) and platelet derived growth factor (PDGF); (3) morphogens (bone 
morphogenetic proteins (BMPs)); and (4) the angiogenic factors (vascular endothelial 
growth factor (VEGF) and angiopoietins) [Le, 2001; Gerstenfeld, 2003; Dimitriou, 
2005; Bielby, 2007]. These molecules can help to recruit MSC and their descendant 
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progenies to the fracture area from different tissue pools (stem cell niches) including 
bone marrow, periosteum, trabecular bone and so on (Figure 1-18) [Bielby, 2007]. 
Furthermore, these molecular can stimulate and enhance the proliferation and 
differentiation of MSC and their descendant progenies to contribute to the formation of 
the cartilage/ bone callus via intramembranous ossification and endochondral 
ossification processes (Previously described in Section 1.2.4.2).  
 
1.5.2.4.2 Paracrine function 
Beside their direct cellular involvement during the fracture healing, MSC can 
contribute to the regeneration of bone fracture via paracrine effect, as well. MSC, 
themselves, can secrete a broad spectrum of bioactive macromolecules. Those 
paracrine factors are immunoregulatory and have special immunomodulatory effects as 
previously discussed (Section 2.4.3.2). Moreover, those factors may have another 
Figure 1-18 Possible tissue pools of MSCs contributing to fracture repair. 
(Adapted from [Bielby, 2007]) 
  Chapter 1 Introduction 
____________________________________________________________________________________________ 
- 78 - 
special effect —“trophic activity”, which can serve to construct regenerative 
microenvironments round the site of injured tissue to accelerate the healing process 
[Caplan, 2007].  
 
MSC’ “trophic activity” effect was first noticed when culture-expanded MSC were 
transplanted to the chemotherapy/radiation-treated animals or humans, MSC were 
found to home to and rejuvenate the damaged bone marrow stroma [Lazarus, 1995; 
Koc, 2000]. More recently, MSC have been used in animal models for heart infarct 
ischemia treatment [Shake, 2002], stroke ischemia treatment [Li, 2005], meniscus 
regeneration [Murphy, 2003], and spinal cord interruption (contusion or cuts) [Lange, 
2005; Keilhoff, 2006]. Although the detail mechanism of how MSC accelerate the 
healing of different injured tissues is still unknown, but mechanism governing all of 
these cases seems to be the same: the MSC secrete bioactive factors that inhibit scarring, 
inhibit apoptosis (narrow or contain the field of injury), stimulate angiogenesis, and 
stimulate the mitosis of tissue-intrinsic stem or progenitor cells in order to accelerate 
the healing process. [Caplan, 2005; Bielby, 2007; Caplan, 2007] 
 
1.5.2.4.3 Regulation of bone remodeling 
In addition to their role in the fracture healing, MSC are responsible for the regulation 
of bone remodeling, as well. The bone remodeling or bone homeostasis of human body 
is sophisticatedly regulated by osteoblasts and osteoclasts interaction. And the 
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opposing actions of these two cell types are coupled by the molecular interactions 
between receptor activator of nuclear factor-κB (RANK), the RANK ligand (RANKL), 
and the decoy receptor osteoprotegerin (OPG), which are the molecular products 
expressed by osteoblast but regulate the differentiation of osteoclast from their 
precursors [Horowitz, 2001; Bielby, 2007]. 
 
As the progenitor for osteoblasts, MSC clearly have an indirect role not only in 
regulating the bone homeostatic balance through their progenies –osteoblasts’ anabolic 
contribution; but also in modulating the osteoclastogenesis via osteoblasts’ expression 
of RANKL and OPG. Recent studies showed that cultured MSC, themselves, can 
express RANKL and OPG protein, as well, and moreover, the expression level of 
RANKL and OPG will be regulated by the osteogenic induction agents of MSC [Gori, 
2000; Giuliani, 2001]. And all of these indicate that MSC may directly regulate the 
bone remodeling through regulating the osteoclastogenesis by the expression of 
RANKL and OPG [Bielby, 2007]. 
 
1.5.3 Sources of MSC  
1.5.3.1 Limitation of adult BM derived MSC 
The adult bone marrow derived MSC are first identified and also are the most 
established and investigated ones. They have been extensively and intensively 
exploited as an autologous cell source for BTE applications, and have demonstrated 
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their effectiveness in the bone fracture healing from small animal, through large 
animals and to human clinical trials as previously discussed.  
 
However, several barriers currently exist, limiting its clinical applications. Firstly, adult 
BM-MSC are rare cells with a very low frequency and need a long time to proliferate 
enough cells, accounting for 0.00001% to 0.001% of mononuclear cells (MNC) in the 
adult bone marrow (BM). Furthermore, they have limited proliferative capacity, only 
undergoing an average approximately 38 ± 4 population doublings before reaching 
cellular senescence [Bruder, 1997]. As a result, in order to obtain clinically significant 
cell numbers, a large amount of bone marrow aspiration is required initially. Secondly, 
for autologous usage, MSC cannot be available off-the-shelf, and a long period of 
waiting time is required for an ex vivo expansion. The ex vivo expansion procedure will 
make the whole therapy very expensive and complicated, limiting their widely use in 
the clinical setting, especially in acute clinical setting, where cells are required at short 
period. Lastly, the frequency of MSC within bone marrow and the proliferative capacity 
decrease dramatically as a function of donor age (Figure 1-19) [Caplan, 2007]and 
systemic disease, also affect the use of fresh bone marrow for therapy [Suzuki, 2001]. 
In addition, the osteogenic differentiation ability in vitro and in vivo has also been found 
to be inversely correlated with donor age [Mueller, 2001]and reduced in several disease 
phenotypes [Rodriguez, 2000]. 
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1.5.3.2 Potential sources of MSC for BTE 
Aside from the bone marrow, MSC with osteogenic potential have been isolated from a 
diverse range of other tissue types and ontogeny:  (1) In postnatal tissue, MSC have 
been isolated from tissues as diverse as periosteum[Nakahara, 1991], trabecular bone 
[Sakaguchi, 2004], synovial membrane [De, 2001], adipose tissue [Zuk, 2001] and 
peripheral blood [Eghbali-Fatourechi, 2005]. (2) In perinatal tissues, MSC have been 
found from the umbilical cord [Sarugaser, 2005], umbilical cord blood [Bieback, 2004; 
Lee, 2004], amniotic fluid [in't Anker P, 2003; De, 2007]. (3) In the prenatal tissue, 
human fetal MSC have been isolated and characterized from first-trimester fetal blood, 
liver, and bone marrow [Campagnoli, 2001], second trimester bone marrow, spleen and 
lung [in't Anker P, 2003], fetal metanephros [Almeida-Porada, 2002], dermis [Zhao, 
2005], pancreas [Hu, 2003] and thymus [Rzhaninova, 2005]. 
 
Figure 1-19 Frequency of MSC in the bone marrow with ages. (Adapted from [Caplan, 2007])
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1.5.4 Human fetal MSC (hfMSC) as a promising cellular source for BTE 
hfMSC resemble their adult counterpart in many aspects: they demonstrate a spindle 
shape with plastic adhesion properties; self-renew without showing any altered 
phenotype; differentiate down multiple mesenchymal lineages, typically osteogenic, 
adipogenic and chondrogenic lineages; have a similar immunophenotype: negative for 
CD14, 34, 45 (non-haemopoietic), and CD31, vWF (non-endothelial); positive for 
CD29, 44, 49e (adhesion molecules) and SH2, 3, 4, Vimentin (mesenchymal markers); 
while expressing lower levels of HLA Class I expression and without expressing HLA 
Class II [Campagnoli, 2001]. Besides their common MSC characteristics, hfMSC 
demonstrated some special properties, including their great proliferation capacity and 
low immunogenicity, making them a promising cellular source for BTE applications.  
1.5.4.1 Human fetal MSC (hfMSC) vs. Human adult MSC (haMSC) 
hfMSC possess some superior properties over haMSC: (1) hfMSC can proliferate much 
faster than haMSC, with a doubling time of between 24 to 30 hours compared to around 
100 hours for haMSC [Gotherstrom, 2003; Chan, 2006]; (2) hfMSC can undergo 
considerably more population doublings before senescing than haMSC (70 vs. 38 
population doublings) [Bruder, 1997; Campagnoli, 2001]; (3) hfMSC have greater 
differentiation capacity: hfMSC have shown to be capable to differentiate to 
oligodendrocyte [Kennea, 2003], stromal cells and hematopoietic elements 
[MacKenzie, 2001]. (4) hfMSC have some different immunologic properties from 
haMSC (as illustrated in Table 1-5): hfMSC express lower HLA Class I than haMSC 
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and there is no cytosolic HLA Class II in hfMSC, while intracellular deposits of HLA 
Class II is found in haMSC; to induce the expression of surface HLA Class II antigens 
by IFN-γ, a longer time, 7 full days, was required for hfMSC compared to 2 days for 
adult MSC [Gotherstrom, 2003; Le Blanc, 2003]. These immunological differences 
suggest that they may have a lower immunogenicity than haMSC. Taken together, 
these advantages indicate hfMSC may be a better cellular candidate than haMSC in the 
BTE applications. 
Table 1-5 Immunologic properties of fetal and adult MSC  
(Reproduced from [Gotherstrom, 2003; Le Blanc, 2003]) 
 
Immunologic properties Fetal MSC Adult MSC 
HLA Class I expression 0- (+ +)* + + + 
Intracellular deposits of 
HLA Class II 
0 + + + 
HLA Class II + + (7 days) + + + (2 days) 
 
1.5.4.2 Clinical use of fetal tissue for cellular therapy 
In reality, many human fetal cell types (including hfMSC) have been explored for their 
therapeutic applications in the clinic already: fresh fetal neuroblasts have been used to 
treat neuronal affections such as Huntington’s [Rosser, 2003] or Parkinson’s disease 
[Clarkson, 2001]; human fetal liver cells have been reported to be able to treat severe 
immunodeficiencies, haematological disorders and inborn errors of metabolism 
[Touraine, 1993]; and recently, a tissue engineered skin construct using the human fetal 
skin cells has been used in clinical trials [Hohlfeld, 2005; Pioletti, 2006].  Moreover, 
 “+” means positive, and “0” means no expression. *: no expression or lower expression.
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hfMSC have been exploited for intrauterine gene or cell therapy [Chan, 2005], and the 
first successful clinical applications of hfMSC has been reported by Le Blanc et al. to 
cure human fetus with severe osteogenesis imperfecta through intrauterine cell therapy 
[Le Blanc, 2005].  
 
1.5.4.3 hfMSC as the off-the-shelf cellular source for BTE 
In summary, compared with other available cellular sources, hfMSC may be an ideal 
off-the-shelf cellular source for BTE for a number of reasons. (Table 1-6). Firstly, they 
are less immunogenic than human adult MSC (as previously described in Section 
1.5.4.1) [Gotherstrom, 2003; Le, 2003]. Secondly, fetal tissues have a lower risk of 
viral and bacterial contamination compared to adult tissues as the fetus resides in an 
immunoprivileged environment within the uterus. Thirdly, a theoretically unlimited 
number of cells can be derived from one hfMSC donor. With a proliferation capacity of 
more than 70 population doublings, theoretically one single cell isolated at Passage 0 
can be proliferated to 1.2x 1021 (270) cells at Passage 70, compared with the total cell 
number in human body is only 5.0-7.5 x1013 [Britannica, 2007]. “Single-cell banks” 
can be established with cells derived from a single cell colony, whose biological 
properties are well understood and variation is greatly minimized; moreover, all the 
cells can be frozen down and made available off-the-shelf, eliminating the precious 
waiting time for patients. Fourthly, the social and ethical conundrum faced with cells 
derived from embryonic stem cells are less of a problem with the use of fetal stem cells, 
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with several applications already being reported (previously described in Section 
1.5.4.3). In addition, because of their tremendous proliferation potential, only a small 
amount of fetal tissue samples may fulfill a large clinical need. 
 
Table 1-6 Comparison of hfMSC with other cellular source for BTE.  




marrow +++ N.A. N.A. N.A.* + 
osteoblast + + + N.A.* +++ 
MSC from 
adult BM ++ ++ +++ ++ ++ 
MSC from 
fetal BM ++ +++ +++ +++ ??? 
N.A.*: allogenic applications can be achieved by proper HLA matching 
 
1.6 Bioreactors for BTE 
1.6.1 Function of bioreactors 
Bioreactors are generally defined as devices in which biological and/or biochemical 
processes develop under closely monitored and tightly controlled environmental and 
operating conditions (e.g. pH, temperature, pressure, nutrient supply and waste 
removal). They have been widely used in industrial fermentation processing, 
wastewater treatment, food processing and production of pharmaceuticals and 
recombinant proteins (e.g. antibodies, growth factors, vaccines and antibiotics), 
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because of their high degree of reproducibility, control, automation, and suitability for 
large-scale applications. [Martin, 2004] 
 
Recently in tissue engineering field, bioreactors have been utilized to mimic the native 
in vivo environment and provide cellular tissue engineered constructs with 
physiologically relevant stimuli that facilitate and orchestrate the conversion of a 
“collection of cells” into a specific tissue phenotype, to achieve the ultimate goal of 
tissue engineering— “Learning from nature” (Figure 1-20) [Lanza, 2007]. Specifically, 
they can have following functions: (1) they can increase the mass transport to mitigate 
the diffusion limitation of 3D scaffolds, providing adequate nutrient, oxygen and 
regulatory molecules to the cells while removing metabolites and CO2 away; (2) they 
can provide proper physiological stimuli, especially the mechanical cues to trigger the 
mechanotransduction signaling pathway for the differentiation of cellular constructs; 
and (3) they can provide an innovative approach to perform the efficient and 
homogenous cellular seeding in the complex 3D scaffolds. [Martin, 2004; Bilodeau, 
2006; Chen, 2006] 
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1.6.1.1 Increase of mass transport 
Compared to the 2D monolayer cultures, the in vitro culture of large 3D tissue 
engineering (TE) constructs impose more stringent requirements for efficient mass 
transfer to and from the cells for the nutrient and oxygen need and metabolic waste 
elimination. In vivo, cells in large bulk tissue can beneficiate from the proximity of 
blood capillaries for their mass-transfer requirements; in most tissues, cells are usually 
no more than 100 µm from these capillaries. The small diameter of capillaries (between 
6 and 8 µm) ensures a residence time of blood long enough in tissues to permit the 
Figure 1-20 Biomimetic approach to tissue engineering. (Top panel) Cell fate and tissue 
assembly during early development and tissue remodeling in an adult organism are regulated 
by multiple cues acting across different-length scales and time sequences. (Bottom panel) 
Tissue engineering attempts to mimic the cell context present in vivo by culturing cellular 
tissue engineered constructs in bioreactors (providing an environment and regulatory signals 
necessary for functional tissue assembly).(Adapted from [Lanza, 2007])  
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radial diffusion of chemical species [Martin, 2005]. However, during in vitro culture, 
due to the lack of this micro-vasculature system, the conventional static culture system 
normally can only support 3D tissues engineering constructs that are less than several 
hundred microns in their thickness. For example, Ishaug et al. reported that when rat 
MSC cultured under static condition for 56 days in the 3D porous poly (D, L 
lactic-co-glycolic acid) (PLGA) disk-shaped scaffolds with a diameter of 7 mm and a 
thickness of 1.9 mm, the cell proliferation and mineralized tissue formation were 
restricted in a zone 120–250 μm from the scaffold surface, with only a small number of 
cells residing in the center of the polymer scaffold [Ishaug, 1997]. Martin I et al. 
reported that glycosaminoglycan (GAG) deposition by chondrocytes cultured on 
poly(glycolic acid) meshes was poorly found in the central part of the constructs, which 
is 400μm away from the outer surface [Martin, 1999]. And Sutherland R M et al. found 
that even with the help of spinner flask the cellular spheroids larger than 1 mm in 
diameter generally contain a hypoxic, necrotic center, surrounded by a rim of viable 
cells [Sutherland, 1986]. 
 
The mass transfer in the culturing 3D TE constructs can be divided into two phases: 
external mass transfer, the transfer of nutrients, oxygen, metabolites and CO2 
between culture medium and the surfaces of 3D constructs; and internal mass transfer, 
the transfer inside the constructs between the surfaces and the single cells within the 
scaffold [Martin, 2004; Lanza, 2007]. In conventional static culture, both internal and 
external mass transfers are only dependent on the passive diffusion along concentration 
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gradients, which has been shown to be critically inadequate during the 3D construct 
culture. For example the diffusional penetration depth of oxygen has been shown to be 
in the range of 100–200 µm [Martin, 2004; Muschler, 2004]. While in the bioreactors 
culture with the dynamic flow of the culture medium, the external mass transfers 
depend primarily on the convection and internal mass transfers are driven on the 
combination of diffusion and convection, leading to the elimination of the 
concentration boundary layer around the 3D constructs surface and great improvement 
of the overall mass transfer [Lanza, 2007]. With the greatly improved mass transfer, the 
bioreactors can support larger 3D TE constructs of clinical relevant sizes. In addition, 
the 3D tissue constructs under bioreactor cultures have a homogenous distribution of 
cells and ECM without the formation of the necrotic center zone, which can be 
explained by the facts that the cells in the inner regions of 3D constructs can survive, 
proliferate and function properly due to the sufficient nutrients and oxygen with timely 
removal of metabolic wastes. Furthermore, the timely removal of metabolic wastes can 
create better uniformity of local pH value and improve the quality of ECM, such as 
better mineralization in BTE application, because the acidic environment created by 
accumulation of metabolites was reported to be harmful to the formation of ECM 
[Bilodeau, 2006]. 
1.6.1.2 Mechanical stimulus 
It is well established that mechanical stimulation, which are known to be important 
modulators of cell physiology, can increase the biosynthetic activity of cells in 3D TE 
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constructs and, thus, improve or accelerate tissue regeneration in vitro [Butler, 2000]. 
This is especially applicable for BTE, because bone is a mechanosensitive tissue, which 
require mechanical stimulation for performing its remodeling and fractures healing 
[Lanyon, 1984; Lanyon, 1984; Goodship, 1998].  
 
As previously discussed (Section 1.2.3.1), the bone cells and osteocytic 
lacuno-canalicular 3D network with interstitial fluid flowing between them together, 
are considered as the most likely candidates for mechanical sensors in Frost’s 
mechanostat hypothesis. Any external mechanical force applied on the bone will cause 
the distortion / deformation of bone matrix, leading to the compression of the 
lacuno-canalicular periosteocytic space, which in turn expedite the movement of the 
interstitial fluid. In this way, the external mechanical force will be cascaded and finally 
applied on the bone cells in the form of interstitial fluid shear stress [Buckwalter, 1996; 
Deng, 2005]. Bone-derived cells (including the osteoblasts, osteoprogenitor cells and 
MSC) possess this sensitivity to the mechanical stimulation in born in vivo or in vitro 
conditions, in the form of hydrostatic pressure [Stanford, 1995], stretching 
[Neidlinger-Wilke, 1994], bending [Kaspar, 2000; Kaspar, 2002], and most especially 
the fluid shear stress [Billotte, 1999; Ignatius, 2005].  
 
Fluid shear stress or fluid dynamic stress, induced by the fluid flowing in the bioreactor 
across the construct surface and into the porous space, is believed to be the most 
important mechanical stimulus in activating the mechaninotransduction signaling for 
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bone cells [Chen, 2006]. Shear stress has been shown to be capable to upregulate 
production of cyclic adenosine monophosphate (cAMP) [Reich, 1990], prostaglandin 
[Reich, 1997], transforming growth factor beta1 (TGF-β1) [Sakai, 1998], and nitric 
oxide [Johnson, 1996]. Moreover, it has been implicated that shear stress is the 
mechanism for stimulating bone tissue remodeling [Hillsley, 1994; Goldstein, 2001]. In 
support of this, there have been numerous reports implicating the shear stresses 
generated by bioreactors as a positive mechanical stimulation for osteogenic 
differentiation of MSC [Gomes, 2003; Sikavitsas, 2003; Holtorf, 2005; Datta, 2006].  
 
1.6.1.3 Cell seeding 
Cell seeding of scaffolds, that is the dissemination of isolated cells within a scaffold, is 
the first step in establishing a 3D culture, and may play a crucial role in determining the 
progression of tissue formation [Vunjak-Novakovic, 1998]. Thus, a cell seeding 
procedure that disseminates a high density of cells efficiently and homogenously may 
have a positive effect on the tissue regeneration and their clinical application scope.: 
firstly, scaffolds initially seeded with at high cellular densities has been associated with 
improved tissue formation [Freed, 1997; Carrier, 1999; Holy, 2000]; secondly, the 
initial homogenous cell seeding could be the foundation for later uniform tissue 
generation; and lastly in the clinical autologous application scenario, with the limited 
biopsy size and/or the extent of cell expansion, a seeding procedure with high 
efficiency is required in order to achieve high seeding density with the full utilizaiton of 
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every available cells isolated from the patients. [Martin, 2004] 
 
Currently, the static loading of cells onto the scaffolds is the most commonly used 
seeding methods. However, this method is operator-dependent and highly variable with 
poor reproducibility which is not suitable for future scale-up manufacturing of the TE 
products.  Furthermore, there had been a number of studies reporting the low seeding 
efficiencies and non-uniform cell distributions within scaffolds with static seeding 
[Kim, 1998; Holy, 2000; Bruinink, 2001; Li, 2001]. More recently, bioreactors have 
been exploited for the dynamic seeding cells to scaffolds. Dynamic seeding through the 
use of bioreactors has demonstrated improved seeding density, efficiency and 
uniformity compared to static approaches. Wendt et al. developed a bioreactor for 
automated cell seeding of three-dimensional scaffolds by continuous perfusion of a cell 
suspension through the scaffold pores in oscillating directions, resulting in higher 
seeding efficiencies and more uniform cell distributions compared with either static 
seeding or with the stirred-flask bioreactor [Wendt, 2003]. Zhao et al. developed a 
modular designed perfusion bioreactor and incorporated the dynamic depth filtration 
seeding operation to perfuse the cell suspension perpendicularly through the porous 
scaffolds, with higher seeding efficiency, seeding density and more uniform tissue 
development being achieved [Zhao, 2005]. Similar results using the other dynamic 
seeding methods have been reported by others as well [Li, 2001; Torigoe, 2007]. 
Moreover, dynamic seeding procedure can be automated and can be highly 
reproducible, being independent of operators’ experience and skill, making it easy for 
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future scale up manufacturing TE products. Dynamic seeding systems can also be 
readily integrated with bioreactors for subsequent culture of the TE constructs, which 
can not only simplify and streamline the engineering process, but also reduce the 
production cost and the safety risk associate with the handling and transferring of 
constructs between seeding and culturing [Martin, 2004].  
 
1.6.2 Types of bioreactors 
Numerous types of bioreactors have been developed for different TE applications. 
There is no single type of bioreactor can fulfill all requirements of the different TE 
applications, because the cultures of different types of tissues may require distinct fluid 
flow characteristics. According to the research interest of this project, only those 
bioreactors demonstrated their suitability for BTE applications have been reviewed 
here.  
1.6.2.1 Spinner flasks 
Spinner flasks or known stirrer-tank reactors as are probably the simplest of bioreactors 
designs. Scaffolds are attached to the needles hanging from the lid of spinner flasks, 
and convective forces are generated by a magnetic stirrer bar, allowing the continuous 
mixing of oxygen and nutrients within the culture medium and reducing the boundary 
layer at the construct surface (Figure 1-21) [Martin, 2005]. Their effectiveness for BTE 
applications has been demonstrated in numerous studies, with improved fluid flow 
leading to the enhanced cell proliferation, distribution and osteogenic differentiation, 
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when compared to the static culture [Meinel, 2004; Kim, 2007; Mygind, 2007; Song, 
2008; Stiehler, 2008]. However, spinner flasks have their limitations: because of the 
strong medium stirring, harmful turbulent flow can be generated and associated with 
high shear stress, which become a threat for new formed ECM and cells [Chen, 2006]. 
One study showed that although the cell proliferation rate and osteogenic 
differentiation were improved by spinner flasks, the cell and ECM distribution is not 
homogenous [Sikavitsas, 2002]. 
 
1.6.2.2 Perfusion bioreactors 
Perfusion bioreactors use pumps to perfuse culture medium continuously through the 
pores of the scaffolds which are usually held in the chambers, columns or cartridges 
(Figure 1-22 A, B). The path for medium is confined so that the medium flow path is 
through the scaffold, rather than around the edges (Figure 1.6-3 C), which can enhance 
the mass transfer not only at the periphery but also within its internal pores [Bancroft, 
Figure 1-21 A commercially available spinner flasks (left) (http://www.bestlabdeals.com); and 
its working mechanism (right) (Adapted from [Martin, 2005])  
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2003]. This type of bioreactor has been extensively utilized and investigated by the 
Mikos AG’s group for BTE applications and showed to be capable to enhance the 
proliferation, osteogenic differentiation and mineralization, and in vivo bone formation 
of MSC mediated scaffold constructs [Goldstein, 2001; Bancroft, 2002; Gomes, 2003; 
Sikavitsas, 2003; Sikavitsas, 2003; van, 2003; Holtorf, 2005; Sikavitsas, 2005; Datta, 
2006; Gomes, 2006; Holtorf, 2006]. Furthermore, their group also reported that the 
shear stress generated by the perfusion bioreactor alone can trigger osteogenic 
differentiation in rat MSC in the absence of dexamethasone, a common chemical 
stimulus for osteogenic differentiation [Holtorf, 2005]. However, one significant 
drawback of the perfusion bioreactors is that: cells frequently only grow within the 
middle and rear zone of scaffold along the perfusion flow, because cells in the front 
zone of scaffolds facing the oncoming flow tend to be “wash-out” due to the strong 
fluidic forces; as illustrated in Figure 1-22 D [Singh, 2007]. 
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1.6.2.3 Rotating wall vessel bioreactors 
Rotating wall vessel (RWV) bioreactors, which were first developed by the NASA’s 
Johnson Space Center (Figure 1-23 A), can provide a dynamic culture environment to 
the constructs with low shear stresses and high mass transfer rates. The vessel walls are 
rotated at a rate that enables the drag force (Fd), centrifugal force (Fc) and net 
gravitational force (Fg) on the construct to be balanced; the construct thus remains in a 
state of free-fall through the culture medium (Figure 1-23 B) [Unsworth, 1998; Martin, 
2004; Martin, 2005]. This NASA RWV bioreactor has been commercialized by 
Figure1-22 The design and drawback of a perfusion bioreactor: (A) the overall design of the 
perfusion bioreactor; (B) the detailed design of the flow chamber; (C) the flow path in the 
scaffolds; (D) drawback of the perfusion bioreactor, a dead zone (red color) of the cellular 
scaffolds can be found after a period of perfusion culture.  




Dead Zone of the cells 
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Synthecon Inc. (Figure 1-23 C). A similar RWV bioreactor, known as miniPERM, has 
been developed and commercialized by In vitro Systems & Services (Figure 1-23 D).  
 
Although it is quite well known that the microgravity will lead to the bone loss; many 
studies showed this RWV bioreactor have great potential use for BTE, owing to their 
superiority in maintaining the high mass transfer while avoid excessive shear stress, 
resulting in increased the proliferation and osteogenic differentiation and 
mineralization of the bone TE constructs [Granet, 1998; Qiu, 1999; Marolt, 2006; Song, 
2007]. However, RWV bioreactors are beset with several disadvantages: (1) the 
microgravity environment in the RWV bioreactor may become a  threat for the 
osteoblast proliferation and further differentiation [Rucci, 2002; Ontiveros, 2003; 
Figure 1-23 Rotating wall vessel (RWV) bioreactors: (A) the original RWV bioreactor 
developed by NASA (Adapted from http://science.nasa.gov/newhome/br/bioreactor.htm); (B) 
the working mechanism of RWV bioreactor [Martin, 2004] ; (C) the RWV bioreactor 
developed by Synthecon Inc. with perfusion system (Adapted from 
http://www.synthecon.com); (D) the RWV bioreactor, miniPERM developed by In vitro 
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Mukundakrishnan, 2004; Ontiveros, 2004]; (2) because of the single axial rotation, the 
cell growth and ECM distribution were found to be non-homogenous [Goldstein, 2001; 
Sikavitsas, 2002; Chen, 2006]; and (3) during the free floating culture, collision 
between the scaffolds and the wall of bioreactor can occur frequently, especially with 
the culture of large scaffolds, which is confounding factor that induces cell damage and 
disrupts cell attachment and matrix deposition on the scaffolds [Goldstein, 2001; 
Sikavitsas, 2002; Yu, 2004; Chen, 2006]. 
 
1.6.3 Bi-axial rotating bioreactor 
In the light of the drawbacks of the RWV bioreactor, the author’s research group 
developed a novel bi-axial rotating bioreactor system, which can rotate in two 
perpendicular axes at the same time [Singh, 2005; Hutmacher, 2008]. This bioreactor 
design incorporates several features which may mitigate the disadvantages associated 
with RWV bioreactor, and may have good potential in BTE applications.  
1.6.3.1 Design of the bi-axial rotating bioreactor 
This bi-axial rotating bioreactor system consists of a spherical culture vessel (500ml), 
where the cellular scaffold constructs are anchored to the lip of bioreactor by pins, and a 
medium reservoir (500ml), which allows continuous replenishment of medium, and the 
real time monitoring and control of oxygen, pH, and temperature. The spherical vessel 
can rotate in two perpendicular axes (X and Z) with individually adjustable axial 
rotation speed settings. The spherical vessel and reservoir are connected by tubing to 
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form a perfusion system with medium flow circulating between each other (as indicated 
by red arrow) (Figure 1-24). A compact design is utilized to allow the placement of the 
entire bioreactor setup within a cell culture incubator, thereby eliminating the need for 
additional temperature controls, while the spherical vessel incorporates and features a 
membrane that allows for gaseous transfer and the medium reservoir is connected to air 
with a filter.  
 
 
1.6.3.2 Performance of the bi-axial rotating bioreactor 
Compared with the previous three types of bioreactors, especially the RWV bioreactors, 
this novel bioreactor may have following advantages:  
 
 
Figure 1-24 Bioreactor design and working principle: this bioreactor system is consisted of a 
culture spherical vessel (500ml), where the scaffolds are cultured, and a medium reservoir 
(500ml); spherical vessel can rotate in two perpendicular axes (X and Z) while vessel and 
reservoir were connected by tubings with perfusion flow circulating between each other (as 
indicated by red arrow). 
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1.6.3.2.1 Enhanced shear stress with the integration with perfusion system 
The incorporated perfusion system allows the flow circulation between the vessel and 
reservoir and may result in a better fluid flow and stronger shear stress; this overcome 
the problem of “dead zone” using pure perfusion bioreactor, as stated in Section 1.6.2.2. 
In addition, this may solve the problem of “insufficient shear stress for good osteogenic 
differentiation” by using pure RWV bioreactors [Bilodeau, 2006].  
1.6.3.2.2 Homogenous fluid flow by bi-axial rotating 
Bi-axial rotating feature has been designed to replace the uni-axial rotating, which may 
lead to the non-homogenous distribution of cells and ECM, and previous computational 
fluid dynamics (CFD) analysis demonstrated that bi-axial rotation of the vessel 
combined effects of the rotational velocity “vectors” of both axes and results in 
increased fluid velocity within the constructs, and improved fluid transport through the 
scaffolds compared to uni-axial rotation (velocity “vectors” were represented by arrows 
and colored according to their velocity magnitude (m/s) in Figure 1-25) [Singh, 2005].  
 
Figure1-25 CFD analysis of cellular scaffolds under uni-axial rotation (left) and bi-axial rotating 
(right): bi-axial rotation can combine the rotational effect from both axes and achieve better fluid 
transport. (Adapted from [Singh, 2005]) 
Velocity vectors colored by velocity magnitude (m/s); FLUNT 5.5 (3d, segregated, lam) 
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1.6.3.2.3 Free from microgravity and collision by anchoring the constructs 
In this bioreactor, cellular scaffolds are secured to bioreactor by pins during the rotating, 
instead of using free floating culture, utilized by majority of the RWV bioreactors. This 
can not only avoid the use of microgravity microenvironment, which may have the 
negative effects on the osteoblast proliferation and further differentiation [Rucci, 2002; 
Ontiveros, 2003; Mukundakrishnan, 2004; Ontiveros, 2004], but also avoid the risk of 
collision among scaffolds and between scaffolds and walls. Although Yu et al. reported 
that using a novel scaffold comprising poly (lactide-co-glycolide) of different densities 
(lighter-than-water and heavier-than -water) will reduce wall collision in the rotating 
bioreactor, the dimension of scaffolds he used was relatively small [Yu, 2004]. 
Sikavitsas et al. reported that when large scaffolds were used, the collision became 
difficult to avoid [Sikavitsas, 2002]. Using the scaffold-secured culture will allow more 
flexibility in scaffolds’ size and material compared with scaffold-free-suspension 
culture. Although a pin hole will be left on scaffolds after removal from the bioreactor, 
this should be easily sealed by surrounding tissue after the in vivo implantation.  
 
1.6.3.2.4 Increased cellular proliferation compared with commercial systems 
In a preliminary study, the bi-axial rotating bioreactor was compared with two 
commercially available bioreactors (spinner flask and miniPERM) and the uni-axial 
rotation culture of this bioreactor regarding their effect on the cellular proliferation of  
human fetal osteoblasts (ATCC CRL-11372) seeded scaffold constructs. Four different 
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rotation speeds (3, 5, 10 and 15 rpm) have been investigated for each group with a 
culture period of 7 days, and the result showed that when rotated at a speed of 5 rpm for 
both axes, this bioreactor achieved significantly higher cellular proliferations than 
when used at other rotation speed (3, 5 and 15 rpm), and other types of bioreactors 
(spinner flask, miniPERM and uni-axial rotation of the same bioreactor). (Unpublished 
data) 
 
1.7 Proposed Research Objectives, Hypotheses and Specific Aims 
Based on the previous literature review, with the rapid population aging, the clinical 
need for bone grafts is expanding dramatically; however, this increasing need cannot be 
fulfilled by current available bone grafts (autografts, allografts and synthetic grafts), 
due to their own drawbacks. Therefore, there is urgent need for TE bone grafts, which 
can not only be made available in different shapes and sizes like allografts and synthetic 
grafts, but also retain the ability to stimulate the fast bone healing and undergo 
remodeling like autografts. The success of BTE strategy is mainly determined by the 
selection of three essential components: a suitable scaffold for cell growth and defect 
morphology maintenance, a suitable cellular source with highly proliferative and 
osteogenic potential, as well as a proper in vitro culture system for cultivation and 
maturation of cellular scaffold constructs. 
 
PCL-TCP 3D scaffold manufactured by FDM techniques have demonstrated its 
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potential use in BTE application [Rai, 2004; Rai, 2007]. The utilization of PCL-TCP 
composite material makes full use of TCP’s bioactivity and PCL’s advantages in slow 
biodegradation, high biocompatibility and great processability; furthermore, the 
composite material overcomes acidosis problem of PCL and processing difficulty of 
TCP. On the other hand, FDM technique endows the PCL-TCP scaffold with favorable 
characteristics for BTE application, including the interconnected porous structure, rigid 
mechanical strength, high reproducibility and customizability. Therefore, this advanced 
PCL-TCP scaffold was selected in this project for the generation of TE bone grafts. 
 
MSC have been shown to be a promising cell source for BTE application, because of 
their easy isolation, well defined osteogenesis, low immunogenicity and suitability for 
cryopreservation. However, the clinical application of haMSC (derived from adult bone 
marrow) was hampered with the critical problems, such as low frequency in bone 
marrow and fast decreasing proliferative and osteogenic capacities with ages. Hence, 
great efforts have been made to explore new MSC sources, resulting in continuous 
identification of MSC from a diverse range of tissue types and ontogenies. Among 
these newly identified MSC, the higher proliferative capacity and lower 
immunogenicity of hfMSC compared with haMSC makes it an attractive cellular 
source for BTE. However, there are still a few open questions, including:  
 
1. How is the osteogenic differentiation potential of hfMSC, compared with their 
more established and investigated adult counterpart, haMSC, and other potential 
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sources such as MSC derived from umbilical cord and adipose tissue? 
2. Can hfMSC form bone and contribute towards healing of fractures in vivo, as 
what is demonstrated for haMSC? 
 
Bioreactors have been demonstrated their effectiveness for the cultivation and 
maturation of TE bone grafts, which usually possess large dimensions and high cellular 
density. Bioreactors can increase mass transport to mitigate the diffusion limitation 
within large scaffolds, provide mechanical stimuli to trigger mechanotransduction 
signaling pathways for cellular differentiation, and offer efficient and homogenous 
cellular seeding within the complex 3D scaffolds [Martin, 2004; Bilodeau, 2006; Chen, 
2006]. A novel bi-axial rotating bioreactor system has been developed, with the 
capability to rotate simultaneously in two perpendicular axes and meanwhile circulate 
the medium between the culture vessel and medium reservoir using an integrative 
perfusion system [Singh, 2005; Hutmacher, 2008]. The in silico CFD analysis showed 
the bi-axial rotation of this bioreactor can improve mass transportation significantly 
within scaffolds compared to the uni-axial rotation of conventional RWV bioreactors 
[Singh, 2005]. Thus, it is hypothesized that this bi-axial rotating bioreactor may have a 
great potential for BTE application, and studies were carried out in this project to 
investigate this bioreactor as an in vitro culture system for the cultivation and 
maturation of TE bone grafts.  
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1.7.1 Research Objectives 
The objective of this project is to generate effective TE bone grafts, based upon the 




The hypotheses of this project are: 
(1) Human fetal bone marrow derived mesenchymal stem cell (hfMSC) are a highly 
proliferative and osteogenic cellular source for BTE application; 
(2) The use of bi-axial rotating bioreactor for in vitro maturation of a TE bone graft will 
result in improved cellular proliferation, osteogenic differentiation and 
mineralization, and maintain cellular viability beyond the limits of conventional 
mass transfer.   
(3) Bioreactor matured hfMSC PCL-TCP scaffold constructs can successfully heal a 
critical sized defect in a rat femoral defect model.   
 
1.7.3 Specific Aims 
The specific aims of this project are as follows: 
Specific Aim #1: Compare the performance of hfMSC with MSCs from other 
sources as a cellular source for BTE application.  
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Specific Aim #2: Investigate the capacity of the bi-axial rotating bioreactor to 
improve cellular proliferation, osteogenic differentiation and mineralization in 3D 
scaffold constructs. 
 
Specific Aim #3: Evaluate the treatment effectiveness of bioreactor matured TE 
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Chapter 2 Materials and Methods 
2.1 MSC isolation 
2.1.1 Samples and Ethics  
All human tissue collection for research purposes in this project was approved by the 
Domain Specific Review Board of National University Hospital (Appendix I) 
Singapore, in compliance with international guidelines regarding the use of fetal tissue 
for research [Polkinghorne, 1989]. In all cases, patients gave separate written consent 
for the use of the collected tissue.  
 
For the first specific aim study, to compare the capacities of different MSC for BTE 
applications, five human fetal samples (hfMSC), three human umbilical cord samples 
(hUCMSC), three human adult bone marrow samples (haMSC) and three human adult 
adipose samples (hATMSC) were utilized in this study. For the second specific aim 
study, two fetal samples were utilized (Donor #1 and #3) to investigate the effect of 
bi-axial rotating bioreactor. For the third specific aim study, hfMSC of Donor #1 was 
used to study its capacity to heal a critical sized bone defect in a rat model. (Table 2-1) 
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Table 2-1 Samples used in this Project 
A. hfMSC sample group C. haMSC sample group 
Source Donor Age (weeks +days) Source Donor Age (years)
fetal bone marrow 1 10+6 adult bone marrow   1 19 
 2 11+1  2 22 
 3 14+2  3 35 
 4 17+0    
  5 18+3       
B. hUCMSC sample group D. hATMSC sample group 
Source Donor   Source Donor Age (years)
umbilical cord 1  Term Pregnancy adult adipose tissue 1 20 
 2  Term Pregnancy  2 48 
  3  Term Pregnancy   3 56 
Note: 
All the samples were utilized in the first specific aim study.  
hfMSC of Donor #1 and 3 were utilized in the second specific aim study. 
hfMSC of Donor #1 was utilized in the third specific aim study. 
(Fetal gestational age was determined by ultrasonic crown-rump or femur length measurements.) 
 
2.1.2 Human fetal MSC (hfMSC)   
Human fetal bone marrow derived hfMSC isolated as previously described [Chan, 
2005]. Fetal humeri and femurs were collected after clinically-indicated termination of 
pregnancy, and single-cell suspensions of fetal bone marrow were prepared by flushing 
the bone marrow cells out of the humeri and femurs using a syringe and 22-gauge 
needle into Dulbecco modified Eagle medium(DMEM)-Glutamax (GIBCO, USA) 
supplemented with 10% fetal bovine serum (FBS), 50 U/mL penicillin, and 50 mg/mL 
streptomycin (GIBCO, USA), which is referred to as D10 medium, and passed through 
the cell strainer(70µm, BD Falcon, USA ). Then single cell suspension medium was 
plated on the petri dishes (NUNC, USA) in the D10 medium. To prevent the 
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contamination, 5% Gentamicin (v/v) was added into the medium during the initial 
phase and replaced 24 h later with medium containing 1% Gentamicin. Normal D10 
was used for subsequent culture. Medium was changed every 2-3 days and non 
adherent cells were removed. When cells grew to sub-confluence, they were 
trypsinized and replated at low density. 
 
2.1.3 Human umbilical cord MSC (hUCMSC)  
The umbilical cord of a term delivery was internally washed with phosphate-buffered 
saline (PBS, 137 mM NaCl, 2.7 mM KCI, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4), 
then filled with 1% collagenase in PBS; the extremities were clamped and incubated for 
20 minutes at 37°C. The collagenase solution with the detached cells was harvested, 
and the vein was washed twice again to gather the rest of the cells. After centrifugation 
at 400 g, the pellet was resuspended in D10 and plated in the petri dishes; medium was 
changed every 2-3 days and non adherent cells were removed. When cells grew to 
sub-confluence, they were trypsinized and replated at low density. [Sarugaser, 2005] 
 
2.1.4 Human adipocytes derived MSC (hATMSC)  
The adipose tissue was washed at least three times with 2 volumes of PBS to remove 
blood. The tissue was then digested with one volume of collagenase type I (1 g/liter of 
PBS with 1% BSA) for 60 min at 37oC with intermittent shaking. The floating 
adipocytes were separated from the stromal-vascular fraction by centrifugal force 
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(300g) for 5 min. The preadipocytes in the stromal-vascular fraction were plated in the 
petri dishes (NUNC, USA) in D10 medium. Medium was changed every 2-3 days and 
non adherent cells were removed. When cells grew to sub-confluence, they were 
trypsinized and replated at low density. [Gronthos, 2001] 
 
2.1.5 Human adult bone marrow MSC (haMSC)  
Human adult MSC samples used in this study were provided by the Tulane University 
Health Sciences Center, USA. Tulane’s MSC have been used by numerous research 
groups and can be used as standards in the comparative study. haMSC were cultured in 
the same D10 media and subcultured using trypsin when reach sub-confluence.  
 
2.2 Characterization of MSC 
2.2.1 Immunophenotype 
MSC samples were screened by immunocytochemistry (all DAKO, Denmark unless 
otherwise stated) and flow cytometry. ICC were used to screen for CD14, CD34, CD45 , 
CD31, von Willebrand factor(vWF) (Abcam, USA), CD105 (SH2) , CD73 (SH3, SH4) 
(Abcam, USA), Vimentin, Laminin, CD29 (Chemicon, USA), CD44 (BD, USA), CD 
106, CD 90 (Chemicon, USA), Oct-4 (Abcam, USA) and Nanog (Abcam, USA) while 
flow cytometry was used to search for HLA I, HLA II and Stro-1 (Chemicon, USA).    
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2.2.1.1 Immunocytochemistry 
MSC were cultured in the cover slides until sub-confluence and fixed in ice cold 
fixation solution (1:1 mix of Methanol and Acetone) at room temperature (RT) for 
15min. Then MSC were blocked in the blocking reagent (PBS supplemented with 5% 
Bovine Serum Album, 2%Goat Serum and 0.3%Triton-X) at RT for 1 hour followed by 
overnight incubation of primary antibodies (100X dilution in blocking reagent) as listed 
above. After 3 x PBS wash to remove the primary antibodies, the slides were incubated 
with secondary antibodies for 1 hour at RT, counterstained with PI for 5 mins,  
mounted in mounting media (DAKO, Denmark) and viewed under a confocal laser 
microscope (Olympus, FV300 Fluoview, Japan).  
 
2.2.1.2 Flow cytometry 
When reach sub-confluence, MSC were trypsinized, spinned down and re-suspended in 
block solution (PBS supplemented with 20% Goat Serum, 0.5% Bovine Serum Album, 
2mM EDTA). Cell suspension solution were incubated with primary antibodies for 20 
mins, washed with PBS 3 x, followed by secondary antibodies incubation for 20 mins 
and fixed by 4% Neutral Buffer Formaldehyde (NBF) for 15 min before running 
through the flow cytometry (DAKO, Denmark). 
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2.2.2 Multilineage differentiation 
2.2.2.1 Osteogenic differentiation 
To induce osteogenic differentiation, MSC were plated at 2 x 104/cm2 and cultured in 
osteogenic differentiation medium (D10 medium supplemented with 10 mM β- 
glycerophosphate, 10-8 M Dexamethasone and 0.2 mM Ascorbic Acid) for up to 20 
days, with change of medium three times per week. Evidence for extracellular 
accumulation of calcium was assayed by von Kossa staining.  
2.2.2.2 Adipogenic differentiation 
To induce adipogenic differentiation, MSC were plated at 2 x 104/cm2 and cultured in 
adipogenic differentiation medium (D10 medium supplemented with 5 µg / ml Insulin, 
10-6 M Dexamethasone and 0.6 x 10-4 M Indomethacin ) for up to 5 weeks with change 
of medium three times per week. The existence of lipid vacuoles was confirmed by 
Oil-Red staining. 
2.2.2.3 Chondrogenic differentiation 
To induce chondrogenic differentiation, MSC were pelleted and cultured in 
chondrogenic differentiation medium (DMEM medium supplemented with 0.1 µM 
Dexamethasone, 0.17 mM ascorbic acid, 1.0 mM Sodium Pyruvate, 0.35 mM L-Proline, 
1% ITSS, 1.25 mg/ml BSA, 5.33 µg/ml Linoleic acid and 0.01 µg/ml TGF-beta) for up 
to 28 days with change of medium three times per week. The spheroid cell masses were 
fixed, embedded and microtome cut before Safranin O Staining. [Campagnoli, 2001] 
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2.3 Comparison of various MSC in monolayer culture 
2.3.1 Growth kinetics and CFU-F assay 
The growth kinetics of MSC was assessed by plating in triplicates at 104 cells /cm2 in 
D10 medium (n=3). Cells were trypsinized every three days and their numbers 
enumerated using a hemocytometer, and population doubling times calculated. 
 
The CFU-F of MSC were assessed by low density plating of MSC at 4 cells/cm2 in 
100mm dishes (200 cells per dish, n=3) in D10 for 14 days, cells were stained with 3% 
Crystal Violet in 100% methanol, then the number of colonies that are 2 mm or larger in 
diameter, was counted. 
 
2.3.2 Osteogenic differentiation and mineralization assays 
In order to compare the different osteogenic potentials of various types of MSC in 
monolayer culture, MSC were plated at 2 x 104 /cm2 on 12-well plates (n=3) and 
cultured in osteogenic differentiation medium (as above) for up to 28 days, with change 
of medium three times per week. von Kossa staining, calcium deposition assay and 
alkaline phosphatase (ALP) activity assay were used to evaluate the osteogenic 
differentiation and mineralization.  
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2.3.2.1 Dexamethasone vs. 1,25-dihydroxyvitamin D3 based osteogenic protocols 
Although the most standard protocol to induce osteogenic differentiation of MSC have 
been widely used, which is the normal culture D10 medium supplemented with 
-glycerophosphate, ascorbic acid and dexamethasone, it was reported that the use of 
1,25-dihydroxyvitamin D3 induced more robust osteogenic differentiation and 
mineralization in hATMSC than the use of dexamethasone [Malladi, 2006; Zhou, 2006]. 
As such, a comparison of these two protocols was preferred in order to determine the 
optimal differentiation protocol to use. The standard osteogenic medium (Dex) is the 
D10 medium supplemented with 10 mM β- glycerophosphate, 0.2 mM ascorbic acid 
and 10-8 M Dexamethasone; while the reported osteogenic medium (Vit D) is D10 
medium supplemented with 10 mM β- glycerophosphate, 0.2 mM ascorbic acid and 
10-8 M 1,25-dihydroxyvitamin D3. hfMSC and hATMSC were utilized for this 
comparative study, they were plated on petri dishes with a density of 2 x 104 /cm2 and 
cultured in two different osteogenic media respectively for 28 days and the osteogenic 
differentiation degree of MSC was examined by von Kossa staining.  
2.3.2.2 von Kossa staining 
After 28 days culture, one well of the 12-well plates from each sample was selected, 
gently rinsed 2 x with PBS then fixed with 10% formalin for 1 hour, followed by 2 x 
wash with dH2O. Finally were stained with freshly made 2% Silver nitrate in dH2O 
(w/v) for 10 minutes in the dark and expose with bright light for 30 mins. 
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2.3.2.3 Calcium deposition assay 
Three wells from each sample were gently rinsed 2 x with PBS, then were added with 
0.4ml 0.5 N acetic acid overnight to dissolve the calcium and calcium content was 
determined by a colorimetric assay using calcium assay kit (BioAssay Systems, USA) 
and measured spectrophotometrically at 612 nm according to manufacturer’s 
instruction. 
2.3.2.4 ALP activity assay 
Three wells from each sample were gently rinsed 2 x with PBS, then were added with 
0.4ml enzymatic cocktail (consisting of 0.1% collagenase A(Roche) with 0.1% trysin 
mixed in PBS) and incubated at 37 ˚ C for 2 hrs to fully dissolve the extracellular matrix. 
After three cycles of freeze and thaw, the cell lysate solution was tested for ALP activity 
using SensoLyte™ pNPP Alkaline Phosphatase Assay Kit (AnaSpec USA) following 
the manufacturer’s instruction. The ALP activity values were normalized to the total 




2.4 Comparison of various MSC in PCL-TCP 3D scaffold culture 
2.4.1 Scaffold manufacture and surface treatment 
PCL-TCP 3D scaffolds were manufactured by Osteopore International (Singapore) 
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under clean room conditions following ISO13485. A lay-down pattern of 0/60/120˚ 
was utilized to give a honey-comb-like pattern of triangular pores with a porosity of 
70% and average pore size of 0.523 mm. After manufacture, the specimens were cut 
with a biopsy punch into smaller cylinders with dimensions of 4 mm in height and 5 
mm in diameter. The scaffolds were surface treated in 5M-NaOH for 3 hrs to enhance 
their hydrophilicity. After rinsing 3 x with PBS, they were sterilized in 70 % ethanol for 
24 hrs. This was followed by rinsing twice in PBS with centrifugation at 1000 rpm for 
10 min. The scaffolds were then transferred for 24 hrs into an incubator at 37˚C for 
drying.  
 
2.4.2 Cell seeding, culture and osteogenic induction 
MSC (Passage 4) were trypsinized, spun down, number countered, re-suspended in the 
fibrin glue (Tisseel kit, Immuno, Austria) and seeded onto the top of the scaffolds (1.6 
x105 cells per scaffold). After cell seeding, 2 ml of fresh D10 medium is added to each 
well and cells were incubated in a humidified atmosphere at 37˚C and 5 % CO2 for 
overnight, then medium was replaced by osteogenic medium (as mentioned above) on 
the second day, then the cellular scaffolds were cultured in the osteogenic medium for 4 
weeks with medium changes 3 times per week; empty scaffolds were seeded with fibrin 
glue and cultured under the same condition for 4 weeks as the control to exclude the 
influence of inherent TCP and non-physiological calcium deposition.  
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2.4.3 Cellular adhesion, viability and proliferation assay 
The morphology of the cell in 3D culture, cellular adhesion and extracellular matrix 
(ECM) production were examined daily by Phase Contrast Light Microscope (PCLM) 
for a month. 
 
The qualitative analysis of cell viability is performed via fluorescein diacetate/ 
propidium iodide (FDA/PI) staining in triplicates, where FDA stains viable cells green, 
and PI stains necrotic and secondary apoptotic cells red. The scaffolds/cells constructs 
were first incubated with 2 µg/ml FDA for 20 min at 37˚C. The samples were then 
rinsed 3 x in PBS, placed for 10 min in a 100 µg/ml PI solution, rinsed again in PBS 
once and viewed under a confocal laser microscope (Olympus, FV300 Fluoview, 
Japan). 
 
The total cell number in the 3D cellular scaffold on Day 1, 4, 7, 14, 28 (n = 3, separate 
scaffolds from those used for FDA/PI) were estimated by quantifying the DNA content 
of each scaffold using a PicoGreen DNA Quantification Kit (Molecular Probes). The 
total DNA was extracted from each cellular scaffold by incubating the cellular scaffolds 
in 0.4ml enzymatic cocktail at 37 ˚C for 2 hrs, with vortex every 30 mins then followed 
by three cycles of freeze and thaw. The solutions were diluted 12 x for the PicoGreen 
DNA assay and the assay were carried out by following the manufacturer’s instruction. 
The proliferation of the MSC inside 3D scaffold was interpreted by the change of 
dsDNA amount. 
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2.4.4 Osteogenic differentiation and mineralization assays 
2.4.4.1 Osteogenic gene expression 
Cellular-scaffold constructs were collected on Day 1, 7, 14, 21, 28 for RNA extraction 
and conversion to cDNA as previously described [Chan, 2006]. Real time Taqman 
RT-PCR was utilized to examine the expression of following osteogenic genes: 
Collagen1 A1, Osteonectin, RunX2 and Alkaline phosphatase (ALP) (Table 2-2). PCR 
reactions were performed in triplicates, in 25 μl: 5μl of cDNA, 12.5μl of TaqMan 
Universal PCR Master Mix (Applied Biosystems, USA), and 7.5μl of the primers 
working solution. Thermal cycle conditions were 50 ˚C for 2 min, 95 ˚C 10 min, then 50 
cycles at 95 ˚C 15 s, and 60 ˚C for 1 min. Amplifications were monitored with the ABI 
Prism 7000 (Applied Biosystems, USA). Results were normalized against the house 
keeping gene GAPDH, and relative gene expression analyzed with the 2-ddCt method. 
 
Table 2-2: Design of Primers and Probes 
 
gene Primers: Forward(F), Reverse(R) and Probe(P). 5’-3’ 
F:  AGGACAAGAGGCATGTCTGGTT 
R:  CCCTGGCCGCCATACTC COL1A1 
P:  CGAGAGCATGACCGATGGATTCCAGTT 
F:  ATTTGATGATGGTGCAGAGGAA 
R:  GGTGGTTCTGGCAGGGATTT Osteonectin 
P:   CCGAAGAGGAGGTGGTGGCGG 
F:   AGTAGGTGTCCCGCCTCAGA 
R:  CCTTGTGGATTAAAAGGACTTGGT RunX2 
P:  CCCACGGCCCTCCCTGAACTCT 
F:  CAGGCTGGAGATGGACAAGTTC ALP 
R:  GGACCTGGGCATTGGTGTT  
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P:  CCTTCGTGGCCCTCTCCAAGACG 
F:  CCACCCATGGCAAATTCC  
R:  GGATTTCCATTGATGACAAGCTT GAPDH 
P:  TGGCACCGTCAAGGCTGAGAACG 
2.4.4.2 von Kossa staining 
The cellular scaffolds of Day 28 were collected and fixed in 4% NBF overnight before 
the Von Koss staining (as described in Section 2.3.2.1) to investigate the mineralization. 
2.4.4.3 Micro Computed Tomography (Micro-CT) 
Micro-CT was performed with the 1076 SkyScan machine (SkyScan, Belgium). 
Cellular-scaffold constructs (n=3 from each group) were fixed in 2.5% gluteraldehyde, 
and placed in the sample holder for scanning through 180˚ with a rotation step of 1˚ at a 
spatial resolution of 35μm. An averaging of 5 and a 1mm aluminum filter were used 
during scanning. Scan files were reconstructed at a step size of 1 using a modified 
Feldkamp algorithm as provided by Skyscan. Reconstructed data were loaded into 3D 
modeling software, VGStudioMax (Volume Graphics GmbH, Germany) to stack the 
two-dimensional image into a 3D model for quantitative histomorphometric analysis. 
The threshold used was 200. Control acellular scaffolds which has been cultured in 
osteogenic media over the same period of time was imaged, and the amount of 
mineralization (0.0650.023 mm3) was subtracted from the measurements made in the 
test groups. During scanning the new bone formation in vivo, acellular scaffold 
implants was utilized as negative controls for the subtraction as well.  
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2.4.4.4 Scanning Electron Microscope (SEM) and Energy Dispersive X-ray (EDX)  
Fixed scaffolds (n=3 from each group) were then dehydrated in a graded ethanol series, 
air-dried and gold sputtered with SCD 005 gold sputter machine (Bal-Tec, 
Liechtenstein) for 70 s at 30 mA under high vacuum. The samples were viewed with a 
JSM-6700 SEM with EDX accessory (JEOL, USA) operating at 10 kV under high 
vacuum mode. The elemental composition of the nodules inside the samples was 
analyzed by EDX. 
2.4.4.5 Calcium deposition assay 
Cellular scaffolds (n=3 from each group) at day 7,14,21,28 were collected for calcium 
deposition assay. They were soaked into 0.4ml 0.5 N acetic acid overnight to dissolve 
the calcium and calcium content was determined as described in Section 2.3.2.2. 
 
2.5 Comparison of various MSC in NOD/SCID mice model 
2.5.1 Animal model selection and ethics approval 
In order to investigate and compare their capacities to form bone in vivo, a mice 
subcutaneous ectopic bone formation model has been utilized, which is a relatively 
simple and effective animal model for the preliminary study of in vivo performance of 
stem cells [Weinand, 2007]. Male NOD/SCID mice were acquired through Charles 
Rivers, Australia, and all procedures were approved by the Institutional Animal Care 
and Use Committee (IACUC) at National University of Singapore (Appendix II). 
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2.5.2 Surgery 
MSC were seeded onto PCL-TCP scaffolds and pre-differentiated in osteogenic 
differentiation medium for 2 weeks before implantation. For the surgery, after inducing 
general anesthesia, a midline longitudinal skin incision was made on the dorsal surface 
of each mouse and six subcutaneous pockets were created, into which the MSC 
cellular-scaffold constructs were inserted. The skin was closed with interrupted 6-O 
vicryl sutures. After two months, animals were euthanized, and the implants retrieved 
for histological and micro-CT analysis in triplicates. 
 
2.5.3 Histological study and chimerism analysis  
Cellular-scaffold constructs (n=3) from each group were embedded in OCT medium 
(Tissue-Tek, USA), and sectioned at 30µm thickness with a Cryostat (CM 3050S, Leica, 
Germany). Sections were stained with von Kossa and counterstained with Hematoxylin 
and Eosin (H&E) to visualize tissue morphology and evidence of new bone formation. 
 
Lamin A/C immunostaining was used to investigate chimerism of human cells in 
murine tissue as previously described [Chan, 2006; Chan, 2007]. Sections from each 
sample were blocked with blocking reagent (PBS supplemented with 5% Bovine 
Serum Album, 2%Goat Serum and 0.3%Triton-X) for 2 hours, and left to react with 
monoclonal mouse anti-human Lamin A/C antibody (1:100, Vectorlabs, UK) overnight; 
sections were then incubated with goat anti-mouse secondary antibodies (1:100 
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Alexaflour 488, Invitrogen, UK) for 1 hour, and counterstained with Propidium Iodide 
(PI). Images were visualized through confocal microscopy as above. The number of 
human and murine cells within scaffolds (n=3) was enumerated manually on six low 
powered fields (LPF) to calculate the rate of chimerism of human cells. A total of 1,189 
cells were counted (range 133 to 254 per LPF, mean 115) were counted for each 
specimen. 
 
2.5.4 Micro CT analysis of ectopic bone formation  
Besides the traditional histological study, micro CT has been utilized to analysis the 
ectopic bone formation as well. Three cellular scaffold constructs from each group 
were scanned and analyzed under micro CT as described in Section 2.4.3.3. A threshold 
of 200 was applied to distinguish the ectopic bone from the soft tissue.  
 
2.6 Comparison of bi-axial rotating bioreactor culture with static culture 
2.6.1 Pre-culture of hfMSC in PCL-TCP scaffolds 
The same type of PCL-TCP 3D bioactive scaffolds (70% porosity, 0/60/120˚ pattern) 
with a dimension of 6 x 6 x 4 mm were used in this study. Scaffolds were surface treated 
with 5M NaOH for 3 hrs to enhance their hydrophilicity. After rinsing 3 X with PBS, 
they were sterilized in 70 % ethanol for 24 hrs, and rinsed twice in PBS, and then 
transferred into an incubator at 37˚C for 24 h for drying.  
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hfMSC (Passage 3) were seeded onto the porous scaffolds by adding 50 μl of cell 
suspension media with 5 x105 cells to each scaffold (5 x 104 /μl) in a dropwise manner, 
placed in 24-well culture plates, and incubated for 3 hours in an incubator. Thereafter, 
an additional 2 ml of D10 medium was slowly added to each well and hfMSC cellular 
scaffolds were incubated in a humidified atmosphere at 37˚C and 5 % CO2 for 1 week 
with D10 medium changes 3 times a week to allow for cell attachment to scaffolds.  
 
2.6.2 Bioreactor culture vs. static culture 
After one week of static culture, scaffolds were randomly divided into two groups: (A) 
a bioreactor group where 45 scaffolds were transferred to the bi-axial rotating 
bioreactor loaded with a total of 500 ml of osteogenic inductive medium which fills the 
vessel and the reservoir. This medium was changed once a week for a total of four 
weeks, with 11.1 ml of medium per scaffold per week; and (B) the static culture group 
where another 45 scaffolds were transferred to new 24-well plates with 3.5 ml of 
osteogenic inductive medium per well which was changed three times a week for four 
weeks, with 10.5 ml of medium made available to each scaffold per week. No major 
change of pH occurred during the cultures to suggest the depletion of nutrients from 
either group. 
 
As previously described in Section 1.6.3, this bi-axial rotating bioreactor system 
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consists of a spherical vessel for culture (volume-500ml), where the cellular scaffold 
constructs are anchored to the lip of bioreactor by pins, and a medium reservoir (500ml), 
which allows the continuously replenishing medium and the real time monitoring and 
control of oxygen, pH, and temperature. The spherical vessel and reservoir are 
connected by tubings to form a perfusion system with medium flow circulating 
between each other (as indicated in red arrow) (Figure 1-24). The entire bioreactor was 
placed in an incubator with humidified atmosphere at 37˚C and 5 % CO2. Gaseous 
exchange was enabled through a special membrane incorporated into the spherical 
vessel. The spherical vessel was programmed to rotate in two perpendicular axes (X 
and Z), with both axial rotation set to 5 rpm. This setting achieves a perfusion flow rate 
of 3.8 ml/min (Figure 1-24), allowing a complete change of medium every 132 mins. A 
rotational speed of 5 rpm was chosen as it resulted in the greatest cellular proliferation 
in preliminary experiments investigating rotational speeds between 3 through 15 rpm. 
 
2.6.3 Cellular adhesion, viability and proliferation assays 
The morphology of the cell in 3D culture, cellular adhesion and extracellular matrix 
(ECM) production were examined daily by Phase Contrast Light Microscope (PCLM) 
over 28 days. Scaffolds were examined in two perpendicular panels, in planar (top) and 
side view points (Figure 2-1 B). 
 
The qualitative analysis of cell viability in 3D was performed via fluorescein diacetate/ 
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propidium iodide (FDA/PI) staining as described in Section 2.4.4.3. Before the FDA/PI 
staining, scaffolds were bissected in half to expose the centre of the scaffold to achieve 
a core view of the scaffold (Figure 2-1 C), and viewed under a confocal laser 
microscope (Olympus, FV300 Fluoview, Japan). Cellular scaffolds were examined in 
both planar view and core view on day 14 and 28 (Figure 2-1 C).  
 
The total cell number in the 3D cellular scaffold on day 0 (day of transfer to the 
bioreactor or static culture conditions) 14, 28 (n = 3) were estimated by quantifying the 
dsDNA content of each scaffold using a PicoGreen dsDNA Quantification Kit 
(Molecular Probes, USA) as described in Section 2.4.4.3. The proliferation of the 
hfMSC inside 3D scaffold was interpreted by the changes of dsDNA amount. 
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2.6.4 Osteogenic differentiation and mineralization assays 
To study the influence of bi-axial rotating bioreactor on osteogenic differentiation and 
mineralization of cellular scaffolds, a serial of osteogenic assays were carried out 
including the ALP activity assay, von Kossa staining, Calcium deposition assay, SEM 
and EDX assay.  
 
ALP activity assay: The intracellular ALP activities of hfMSC cellular scaffolds under 
two culture conditions were compared on day 0, 7, 14, 28 (n=3, triplicates) as described 
in Section 2.3.2.3. 
Figure 2-1 Indication of the observation angle. (A) High porosity PCL-TCP scaffolds 
measuring 6mm x 6 mm x 4 mm were seeded with hfMSC for these experiments; (B) 
Scaffolds were viewed from the planar (top) and side profile under phase contrast light 
microscopy through the culture; (C) FDA/PI was used to stain for live and dead cells 
respectively, through confocal microscopy imaging of the planar (top) view, and after 
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von Kossa staining: hfMSC cellular scaffolds on day 14 and 28 were stained with von 
Kossa staining as described in Section 2.3.2.1. 
 
Calcium deposition assay: the calcium content of the hfMSC cellular scaffolds on day 
7, 14 and 28 (n=3) were assayed as described in Section 2.3.2.2. And control cell-free 
empty scaffolds cultured as above (n=3) were used as a negative control to offset the 
elution of calcium from the tri-calcium phosphate component in the scaffold (27.5±4.3 
at day 7; 29.7±5.1 at day 14; 38.8±6.4 at day 28 µg/ acellular scaffold). 
 
SEM and EDX analysis: After micro CT scanning, the same 3 scaffolds were 
dehydrated, gold sputtered, viewed under the SEM and element component of 
crystal-like structure inside the samples was analyzed by EDX as previously described 
in Section 2.4.4.4. 
2.6.5 Comparison in NOD/SCID mice model 
2.6.5.1 Surgery 
The same NOD/SCID mice model was utilized in this study to investigate the influence 
of bioreactor culture on the in vivo performance of hfMSC cellular scaffolds. hfMSC 
were seeded onto PCL-TCP scaffolds pre-cultured in D10 medium for 1 week and 
pre-differentiated in osteogenic differentiation medium under either bioreactor culture 
or static culture condition for 2 weeks before implantation. The subcutaneous 
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implantation of the cellular scaffold constructs were carried out following the same 
surgical procedures as described in Section 2.5.1. After three months, animals were 
euthanized, and the implants retrieved for histological and micro-CT analysis. 
2.6.5.2 Histological study and chimerism analysis  
Cellular-scaffold constructs (n=3) from each group were embedded in OCT medium 
(Tissue-Tek, USA), and sectioned at 10µm thickness and laid onto poly-L-lysine slides. 
Sections were stained with Masson Trichrome and von Kossa (counterstained with 
nuclear fast red) to ascertain evidence of bone formation and mineralization 
respectively.  
 
Human-specific lamins A/C immunostaining was used to investigate chimerism of 
human cells in murine tissue following the same protocol as described in Section 2.5.3. 
The number of human and murine cells within scaffolds (n=3) was enumerated 
manually on six low powered fields (LPF) to calculate the rate of chimerism of human 
cells. A mean of 217 cells were counted for each LPF (range 157-313) of each 
specimen.  
2.6.5.3 Micro CT analysis of ectopic bone formation 
Micro CT has been utilized to analysis the ectopic bone formation. Three cellular 
scaffold constructs from each group were scanned and analyzed under micro CT as 
described in Section 2.4.3.3. Cellular scaffolds were imaged together with transplanted 
acellular scaffolds, untranslanted empty scaffold and bone tissue. The threshold value 
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between untransplanted empty scaffold and known bone tissue was used for delinating 
ectopic bone from the scaffolds through visual and histograph analysis, and a value of 
195 was chosen. Three acellular scaffold implants were utilized as negative controls to 
cancel out the influence of the TCP component within the scaffold on mineralization.  
 
2.7 Healing the critical size defects in a rat model 
2.7.1 Animal model selection and ethics approval 
Rat critical size femoral defect model was selected to investigate the defect healing 
capacities of bioreactor matured hfMSC PCL-TCP scaffold constructs. The femur is 
one of the main weight loading bones and femoral defect model can give us large 
amount of information about the bone healing process under such loading situation, 
which cannot be provided by craniofacial defects model or ectopic bone formation 
model. Rats are an appropriate and cost effective model in this femoral defect study. 
Although they are quadrupedal unlike human, they maintain upright postures during 
feeding and grooming, as a result, they have a similar anatomic structure of femur and 
postural loading on the femur[Jeffrey O, 2005]. Critical size defects (CSD) was defined 
by Schmitz and Hollinger as “the smallest size intraosseous wound that will not heal 
spontaneously during the lifetime of the animal.”[Schmitz, 1986] The critical size 
defect exceeds the body’s ability to regenerate adequate amounts of bone; instead, the 
defect site is filled with fibrous connective tissue. CSD make an excellent model to test 
the new bone grafts [Hollinger, 1990]. In this study, a critical size segmental defect of 
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s7 mm was created on the right femur of each rat. 
 
Male Sprague Dawley (SD) Rats were acquired through NUS' Laboratory Animals 
Centre and all procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) at National University of Singapore (Appendix II). 
 
2.7.2 Preparation of the tissue engineered bone grafts 
The same type of PCL-TCP 3D bioactive scaffolds (70% porosity, 0/60/120˚ pattern) 
were manufactured for this study. After manufacture, the scaffolds specimens were cut 
with a biopsy punch into smaller cylinders with dimensions of 8 mm in height and 5 
mm in diameter, which can be press-fit to the defect. Scaffolds were surface treated 
with 5M NaOH for 3 hrs to enhance their hydrophilicity. hfMSC (Passage 3) were 
seeded onto the porous scaffolds on a basis of 5 x105 cells per each scaffold using a 
fibrin free method as previously described in Section 2.6.1. The hfMSC/PCL-TCP 
cellular constructs were pre-differentiated and matured in osteogenic induction medium 
under bi-axial rotating bioreactor culture for two weeks before being surgically 
implanted into the rat femoral defects.  
 
2.7.3 Bone plate design 
An external fixation bone plate was designed and custom made to secure the bone 
fragments before bone healing (Figure 2-2 A, C). Bone plates were made of 
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biocompatible and radiolucent plastics (Delrin) so that they did not affect the new bone 
regeneration and the X-ray and micro CT examination. Four stainless steel self-tapping 
cortex screws (diameter 1.5mm, length 8 mm, Synthes, Switzerland) were applied to 
secure the bone plate to femur (Figure 2-2 B).  
 
 
2.7.4 Immunosuppression and animal surgery 
Adult, male SD rats weighing 400-500 g were used in the study. To prevent the 
potential immunorejection of human cells based TE bone grafts, Cyclosporin A 
(Novartis, Switzerland) was injected into all the SD rats on a dosage of 10mg per Kg 
body weight per day from one week before the surgery until the end of experiment.  
 
Figure 2-2 Bone plate design and cortex screw. (A) Bone plate to secure the bone fragment; 
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All surgical procedures were performed under general anesthesia and aseptic 
conditions. After anesthetizing the rat, a longitudinal incision over the proximal hind 
limb was applied to expose the femur (Figure 2-3 A), then femur was stabilized with an 
external fixation bone plate (Figure 2-3 B) and 7 mm segmental defect was created 
with a miniature oscillating saw (Figure 2-3 C). Finally, the scaffolds or cellular 
constructs were pressed fit into the defects (Figure 2-3 D).  
 
2.7.5 X-ray examination 
Radiographic system (General Electric, USA) was used for the 2 D X-ray images of the 
femoral defects immediately after the surgery and at week 4, 8 and 12 X-ray under 
general anesthesia. 
Figure 2-3 Surgical procedure of rat femoral defect. 
A B 
C D 
  Chapter 2 Materials and Methods 
____________________________________________________________________________________________ 
- 133 - 
 
2.7.6 Micro CT analysis 
SkyScan 1076 in vivo micro CT machine (SkyScan, Belgium) was used to do the live 
scanning of rat femoral defects (n=3 from Group I and II) under general anesthesia 
immediately after surgery and at week 4 and 12. The detailed operation procedure and 
parameters were described in Section 2.4.4.3. A threshold of 200 was utilized for new 
bone visualization and bone volume calculation.  
 
2.7.7 Vascularization assay 
New vascular ingrowth into the bone graft implant is regarded as the one of the most 
critical step in the bone regeneration. With the addition of a perfused contrast agent, 
micro-CT analysis can be used to quantify vascular ingrowth into defect area [Duvall, 
2004; Rai, 2007]. A correlation between the bone regeneration and vascular ingrowth 
will then be established. 
2.7.7.1 Perfusion of micro CT contrast agent 
A radiopaque silicone rubber compound containing lead chromate (Microfil MV-122, 
Flow Tech, USA) was used to visualize the new vascular ingrowth under the micro CT 
[Duvall, 2004; Rai, 2007]. At week 4, rats (n=3 from Group I and II) were perfused via 
left ventricles under the under general anesthesia, firstly flushed with heparinized 
normal saline and subsequently the vasculature was injected with Microfil. The 
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Microfil was allowed to polymerize for 2 hours before the hind limbs being removed 
and stored in formalin for 2 weeks.  
2.7.7.2 Decalcification of hind limbs 
In order to remove the influence of bone tissue on the vascular network under the micro 
CT, decalcification of hind limbs were performed. The fixed femurs were decalcified in 
30 % buffered formic acid at room temperature. At the end of each day, the solution was 
chemically tested for the presence of calcium using the ammonium oxalate (5 %) 
precipitation assay. Once fully decalcified, the femurs were rinsed and transferred to 
formalin before micro-CT imaging. 
2.7.7.3 Micro CT scanning 
Hindlimb vasculature were investigated by a micro-CT system (1076, SkyScan, 
Belgium). A spatial resolution of 35μm, an averaging of 4 and a 1mm aluminum filter 
was used during the scanning. For the details, please refer to Section 2.4.4.3.  A 
threshold of 190 was utilized to visualize and calculate the vascular volume at the 
defect area. A volume of 550 mm3 (a cylinder volume with diameter of 10mm and 
height of 7mm) in the defect region was selected as the region of interest during the 
vascular volume calculation.  
 
2.7.8 Torsional testing 
A torsional test was utilized for evaluation of the biomechanical properties of the new 
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bone. At week 12, femurs were removed from the sacrificed rats (n=3 from Group I and 
II, n=2 from Group III as a negative control, n=3 from intact legs as positive control) for 
the testing. After the bone plates and screws were carefully removed from the femurs, 
femur ends were potting into the dental cement (Meliodent, Heraeus Kulzer, USA) 
according to manufacturer’s instruction. Then femurs were mounted into the torsional 
testing machine (Mini-Bionix 858, MTS, USA) and tested to failure in torsion. The 
rotation rate used was 3 degrees per second and data were collected at 100 Hz. The 
angular displacement and torque was recorded till failure. Maximum torque and 
angular displacement at failure were recorded, and the curve of torque against angular 
displacement was plotted. The stiffness was calculated as the slope of the linear portion 
of the torque-angular displacement curve.  
 
2.7.9 Histology  
At week 12, one representative femur from each group (Group I and II) was collected 
for histological study as previously described [Rai, 2007]. They were fixed in 10% 
neutral buffered formalin for 2 weeks and dehydration through a graded series of ethyl 
alcohols and clearing with xylene substitute. Specimens were infiltrated by a graded 
series of methyl methacrylate solutions (ACROS Organics, USA) and embedded in  a 
catalyzed mixture of Osteo-Bed resin solution containing 2.5 g of benzoyl peroxide per 
100 ml for 2 weeks. After polymerization, specimens were placed in a freezer for 24 h. 
Specimens were trimmed of excess plastic and longitudinally sectioned (5 mm thick) 
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using a microtome (Microm HM355S, Richard Allan Scientific, USA). Sections from 
each specimen were then stained with Hematoxylin and Eosin, Masson’s Trichrome, 
and von Kossa to detect general tissue morphology, woven and mature bone structure 
respectively.  
 
2.7.10 Immunohistochemistry assay 
Femurs with implantation of hfMSC/PCL-TCP constructs at day 4, week 2, 4 and 8 
were retrieved for immunohistochemistry assay to investigate of the chimerism of 
human cell in rat tissue. They were embedded in OCT medium (Tissue-Tek, USA), and 
sectioned at 8 µm thickness with a Cryostat (CM 3050S, Leica, Germany).with the aid 
of CryoJane Tape-Transfer system (Instrumedics, USA). Six representative sections 
from each sample were immunostained with human-specific Lamins A/C antibody and 
counterstained with DAPI as previously described in Section 2.5.3. Secondary antibody 
with red fluorescence was applied to avoid the strong auto-fluorescence of bone tissue 
in green channel. The number of human and murine cells within scaffolds (n=3) was 
enumerated manually on six low powered fields (LPF) to calculate the rate of 
chimerism of human cells. A mean of 315 cells were counted for each LPF (range 
189-473) of each specimen.  
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Chapter 3 Identification of the Optimal MSC 
Source – hfMSC vs. other MSC 
3.1 Introduction 
Mesenchymal Stem Cells (MSC) are rare cells which can be readily isolated from the 
bone marrow (BM) and expanded through multiple passages while retaining their 
multipotent differentiation capacity [Pittenger, 1999]. They are therefore an attractive 
cellular source for tissue engineering applications [Le Blanc, 2005; Porada, 2006; 
Pountos, 2007]. Under permissive stimulation, MSC undergo osteogenic differentiation 
through a well defined pathway [Frank, 2002; Qi, 2003], acquiring osteoblastic 
markers and secreting extra-cellular matrix and calcium crystals [Bruder, 1997; 
Pittenger, 1999]. MSC have been shown to be non-immunogenic in both in vitro [Di, 
2002; Krampera, 2003; Tse, 2003] and in vivo transplantation paradigms [Horwitz, 
2002; Koc, 2002], suggesting their utility for both autologous and allogeneic BTE 
applications [Mauney, 2005; Niemeyer, 2006; Caplan, 2007]. Investigations into its use 
in various animal models have validate its efficacy [Bensaid, 2005; Meinel, 2006; Shao, 
2006]. However, its clinical utilization has been encumbered by the low frequencies at 
which MSC exist in the BM, especially in the older age groups where fractures and 
non-union are more common. In addition, adult BM derived MSC have generally high 
cellular senescence, limited proliferation capacity [Bruder, 1997; Phinney, 1999], and 
osteogenic potential [D'Ippolito G 1999; Mueller, 2001; Mendes, 2002].  
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More recently, other sources of MSC with osteogenic potential have been identified 
from a diverse number of tissue types and ontogeny, including adipose tissue [Zuk, 
2001] and perinatal tissues such as the umbilical cord [Sarugaser, 2005], umbilical cord 
blood [Bieback, 2004; Lee, 2004], amniotic fluid [in't Anker, P 2003; De, 2007], and 
fetal blood, bone marrow and liver [Campagnoli, 2001; Chan, 2005; Chan, 2006; Chan, 
2007]. While investigations into their basic biology, immunogenicity and osteogenic 
potential have been reported, they have not been systematically compared against each 
other for BTE applications. Hence, it is not presently clear how these novel MSC 
sources compare with their adult BM MSC counterparts for osteogenic differentiation 
and tissue engineering, and what will be the best cellular source for BTE applications.  
 
In order to address these questions, a systematic head-to-head comparison of four types 
of MSC from four different ontological and anatomical origins: human fetal bone 
marrow (hfMSC), human umbilical cord (hUCMSC), human adult adipose tissue 
(hATMSC) and human adult bone marrow (haMSC) was conducted. Result showed 
that while all MSC had comparable immunophenotype, only hfMSC and hUCMSC 
were positive for the embryonic pluripotency markers Oct-4 and Nanog. hfMSC 
expressed the lowest HLA-I (55% vs 95-99%), the highest Stro-1 levels (51% vs 
10-27%) and had the greatest CFU-F capacity (1.6-2.0x, p<0.01) and fastest doubling 
time (32 vs 54-111 hrs, p<0.01). hfMSC had the greatest osteogenic capacity, as 
assessed by von-Kossa staining, ALP activity (5.1-12.4x, p<0.01), calcium deposition 
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(1.6-2.7x in monolayer and 1.6-5.0x in scaffold culture, p<0.01), calcium visualized on 
micro-CT (3.9-17.6x, p<0.01) and scanning electron-microscopy, and osteogenic gene 
induction. Two months after implantation of cellular-scaffolds in immunodeficient 
mice, hfMSC resulted in the most robust mineralization (1.8-13.3x, p<0.01). The 
ontological and anatomical origins of MSC have profound influences on the 
proliferative and osteogenic capacity of MSC. hfMSC had the most proliferative and 
osteogenic capacity of MSC sources, as well as being the least  immunogenic, 
suggesting they are superior candidates for BTE applications. 
 
3.2 Experimental design 
After isolation, four types of MSC, hfMSC, hUCMSC, hATMSC and haMSC, were 
fully characterized of their immunophenotype and multilineage differentiation 
capacities. The head to head comparison was carried out three levels (Figure 3-1): in 
vitro monolayer culture, they were compared for their proliferation and osteogenic 
potential; in vitro 3D scaffold culture, they were compared for cellular proliferation, 
viability and osteogenic differentiation capacities; and in vivo, their cellular scaffolds 
were implanted into NOD/SCID mice for 2 months and compared for the human: 
murine chimerism rate and ectopic bone formation capacities.  
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3.3 Isolation and characterization of hfMSC and other MSC 
3.3.1 MSC isolation 
hfMSC: Twenty-one hfMSC samples (n=21) have been isolated from first trimester 
and second trimester of fetal bone marrow using the plastic adhesion method. After 
bone marrow of fetal tissue was flushed out and plated on the petri dishes in the cell 
culture medium overnight, hfMSC can be seen as adherent cells (indicated by red arrow 
head, Figure 3-2) while haemopoietic cells (indicated by black arrow head, Figure 3-2) 
remained in suspension, which were removed by the change of medium (Figure 3-2 A). 
hfMSC consisted of heterogeneous cellular populations, which were predominantly 
spindle shaped (Figure 3-2 B), with a few which had multiple processes (Figure 3-2 C). 
hfMSC can proliferate rapidly to confluence over 3-4 days, assuming a more 
homogenous spindle shaped morphology at subconfluence(Figure 3-2 D).   
Figure 3-1 Experimental design of Specific Aim #1 
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Other MSC: MSC isolated from human umbilical cord (hUCMSC) (n=3) and human 
adult adipose tissue (hATMSC) (n=3) demonstrated a similar pattern as hfMSC, with 
the adhered hUCMSC and hATMSC being heterogeneous initially, but gradually more 
homogenous with culture expansion. Human adult MSC samples (haMSC) used in this 
study were obtained from the Tulane University Health Sciences Center chosen as these 
well characterized cell types have been used widely by other investigators, allowing a 
standard point for comparison between different groups.  
Figure 3-2 Heterogenic morphology of hfMSC isolated. After plating the bone marrow 
aspirate, hfMSC can be seen as adherent cells while haemopoietic cells remain in suspension 
(A, x 100). hfMSC were heterogeneous: majority of cells were spindle shape (B, red arrow 
head, x200), while there were other cells which had multiple processes (C, red arrow head, 
x200). And those cells can proliferate rapidly to confluence, and resulted in more 
homogenous spindle shaped morphology (D, x40).  
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At the passage three, hfMSC, haMSC, hUCMSC and hATMSC showed a homogenous 
population with a similar spindle-shaped morphology, with haMSC and hATMSC  





The immunophenotype of hfMSC, haMSC, hUCMSC and hATMSC were screened and 
compared by both immunocytochemical staining (ICC) and flow cytometry (Table 
3-1).  
 
Figure 3-3 Morphology of hfMSC, haMSC, hUCMSC and hATMSC: all MSC sources 
demonstrated a spindle shaped morphology with haMSC and hATMSC being slightly larger 
than hfMSC and hUCMSC 
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 ICC revealed a consistent MSC immunophenotype for all four types of MSC, which 
was negative for haemopoietic (CD14, CD34, CD45) and endothelial markers (CD31, 
and vWF), and positive for mesenchymal markers (CD105 (SH2), CD73 (SH3, SH4)), 
intracellular markers (Vimentin and Laminin) and cell adhesion molecules (CD29, 
CD44, CD 106, CD 90) (Figure 3-4). However, a sub-population of hfMSC 
Figure 3-4 Immunophenotype of different MSC by ICC. All the MSC showed a similar 
immunophenotype except that hfMSC and hUCMSC were positive for Oct-4 and Nanog. 
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(37.1±3.4% and 24.3±3.9% respectively) and hUCMSC (32.5±3.5% and 20.4±2.9% 
respectively) expressed the embryonic stem cell markers Oct-4 and Nanog, both of 
which were absent in haMSC and hATMSC (Figure 3-4). 
 
Flow Cytometry showed that all the MSC expressed a variable amount of HLA-I and 
do not express HLA-II. hfMSC had a lower expression level of HLA-I (55.0%) 
compared to the other MSC types (95.5-99.1%, Figure 3-5). hfMSC had a higher 
expression level of Stro-1 (51.2%) compared with other MSC (10.4-27.2%), which is 
well known osteogenic progenitor cell marker. All the ICC and Flow Cytometry results 




Figure 3-5 Flow Cytometry analysis of different MSC. hfMSC expressed a lower HLA-I 
level and higher Stro-1 compared with rest of MSC 
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Table 3-1 Summary of immunophenotype of different MSC. 
  hfMSC hUCMSC haMSC hATMSC 
CD 73 + + + + 
MSC marker 
CD 105 + + + + 
CD 29 + + + + 
CD 44 + + + + 
CD 90 + + + + 
Adhesion 
molecules 
CD 106 + + + + 
Vimentin + + + + Intracellular 
markers Laminin + + + + 
CD 14 - - - - 
CD 34 - - - - 
Haemopoietic 
markers 
CD 45 - - - - 
CD 31 - - - - Endothelial 
markers vWF - - - - 
Oct-4 27.1%+ 24.3%+ - - Stemness 
markers Nanog 32.5%+ 20.4%+ - - 
HLA-I 55.1%+ 95.5%+ 99.1%+ 96.2%+ 
HLA 
HLA-II 0.1%+ 0.7%+ 0.9%+ 0.6%+ 
Osteo-progenitor 
marker 
Stro-1 51.2%+ 27.2%+ 10.4%+ 12.3% 
 
3.3.2.2 Multilineage differentiation 
All MSC sources differentiated into osteogenic, adipogenic and chondrogenic lineages 
under permissive conditions. Exposure to osteogenic inductive medium resulted in 
secretion of extracellular calcium crystals, identified on von Kossa staining, indicating 
osteogenic differentiation (Figure 3-6). When cultured in adipogenic inductive 
medium, intra-cytoplasmic lipid vacuoles were observed from day 14, confirmed by 
oil-red staining (Figure 3-6). After 30 days of cell pellet culture in chondrogenic 
inductive medium, chondrogenic differentiation was observed, with hfMSC developing 
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the largest cell pellet, followed by haMSC, while both hUCMSC and hATMSC 
displayed less Safranin O staining (Figure 3-6). 
 
3.4 Comparison of MSC in monolayer culture 
Four types of MSC, hfMSC, hUCMSC, haMSC and hATMSC, were compared in  
amonolayer culture environment (petri dishes) regarding their proliferation, 
self-renewal and osteogenic differentiation capacities.  
 
3.4.1 Proliferation and self-renewal 
In two-dimensional (2D) monolayer cultures, hfMSC proliferated the fastest 
(population doubling time 32.3±2.5 hours, n=3), followed by hUCMSC (54.7±4.3 
Figure 3-6 Trilineage differentiation capacity of the different MSC types.  Their 
trilineage differentiation was confirmed by von Kossa staining for extracellular calcium (black 
crystals), Oil-red-O for intracytoplasmic vacuoles of neutral fat (red), and Safranin O for 
extracellular cartilage stains in micro-mass pellet cultures (red). 
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hours, n=3), hATMSC (70.4±3.6 hours, n=3), with the slowest being haMSC 
(116.6±22.4 hours, n=3), resulting in a significant difference in the number of 
population doublings achieved over the 18 day culture period (p<0.01, Figure 3-7 A).  
 
In addition, hfMSC had higher CFU-F forming ability as a matter of clonogenicity and 
self renewal, with 75.1± 5.0% of cells forming colonies, compared to haMSC 
Figure 3-7 Proliferation and self-renewal capacities of different MSC. (A) hfMSC 
demonstrated the fastest proliferation, followed by hUCMSC, hATMSC and haMSC (p<0.01); 
(B) CFU-F assay: hfMSC have a significant higher clonogenicity than other MSC, ** p<0.01; 
(C) the cell colonies on the petri dishes, which were stained by crystal violet; (D) a cell colony 




n=3 p<0.01 n=3 
 
n=3 
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(39.6±4.6%), hUCMSC (47.5±7.5%) and hATMSC (37.5±5.6%) (p<0.01, Figure 3-7 
B to D).  
 
3.4.2 Osteogenic differentiation and mineralization 
3.4.2.1 Dexamethasone vs. 1,25-dihydroxyvitamin D3 based osteogenic protocols 
Although the most standard protocol to induce osteogenic differentiation of MSC have 
been widely used, which is the normal culture D10 medium supplemented with 
-glycerophosphate, ascorbic acid and dexamethasone, it was reported that the use of 
1,25-dihydroxyvitamin D3 induced more robust osteogenic differentiation and 
mineralization in hATMSC than the use of dexamethasone [Malladi, 2006; Zhou, 2006]. 
As such, a comparison of these two protocols was preferred in order to determine the 
optimal differentiation protocol to use.   
 
After 28 days monolayer culture under different osteogenic media, both hfMSC and 
hATMSC demonstrated the osteogenic differentiation and mineralization under two 
osteogenic media, with a similar efficacy for mineralization as seen by the von Kossa 
staining (Figure 3-8). Therefore, a standard osteogenic medium, D10 medium 
supplemented with 10 mM β- glycerophosphate, 0.2 mM ascorbic acid and 10-8 M 
Dexamethasone, was utilized for subsequent experiments across all MSC sources 
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3.4.2.2 Comparison among different MSC 
When exposed to osteogenic medium over 28 days, hfMSC underwent more robust 
osteogenic differentiation, generating more extra-cellular mineralization than other 
MSC types as shown by intenser von Kossa staining, this was followed by hUCMSC, 
haMSC and lastly hATMSC (Figure 3-9 A). This was confirmed with direct 
quantification of calcium deposition, showing that hfMSC had a 1.6 to 2.7 fold increase 
over other MSC (Figure 3-9 B, p<0.01), while hUCMSC showed a 1.5 and 1.7 fold 
higher calcium deposition than haMSC and hATMSC respectively. 
Figure 3-8 Comparison of different osteogenic protocols. von Kossa staining demonstrated 
that both hfMSC and hATMSC showed a similar osteogenic differentiation under the different 
osteogenic differentiation media. 
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This was further confirmed by the ALP activity, an important biomarker for osteogenic 
differentiation of MSC, with hfMSC demonstrating a 5.1 to 12.4 fold increase in ALK 
activity over other MSC types (Figure 3-9 C, p<0.01), while no significant differences 
were found between the other three MSC. Overall, the order of preferential osteogenic 
differentiation was hfMSC, followed by hUCMSC, haMSC and finally hATMSC. 
Figure 3-9 Comparison of the osteogenic differentiation and mineralization in monolayer 
culture. (A) hfMSC and hUCMSC experienced much greater mineralization than other MSC 
as shown by darker von Kossa staining, while in control medium no mineralization was 
detected; (B) hfMSC laid down higher level of calcium than other MSC, and hUCMSC 
deposited comparatively more calcium than haMSC and hATMSC, ** p<0.01, * p<0.05; (C) 
hfMSC expressed 5 fold higher ALP activity than other MSC, ** p<0.01. 
A. von Kossa staining  
C. ALP activity assay B. Calcium content assay 
n=3 n=3 
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Figure 3-10 Cellular adhesion, viability and proliferation comparison in three- dimensional 
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porous as shown in this scanning electron micrograph (SEM) image; (B) Cellular viability of MSC 
within the scaffolds was demonstrated by staining with fluorescein di-acetate (FDA), which is 
taken up by live cells, and propidium iodide (PI) which is retained by dead cells, concurrently. All 
four types of MSC retained high viability over 28 days, with hfMSC achieving confluence within 
the scaffolds, and attaining a spindle-shaped morphology at an earlier time point than other MSC; 
(C) This was confirmed by quantification of dsDNA content by Picogreen assay, showing the most 
rapid rise and highest amounts of dsDNA in the hfMSC constructs (p<0.01). 
 
3.5 Comparison of MSC in 3D scaffold culture 
Next, the various MSC were loaded onto high porosity 3D PCL-TCP scaffolds 
(cylinder shape, 5mm in diameter and 4 mm in height, as shown in Figure 3-10 A) and 
cultured up to 28 days to test their proliferative and osteogenic capacities in a three 
dimensional culture paradigm. Furthermore, the osteogenic induction effect of the 3D 
PCL-TCP scaffolds has been studied and demonstrated as well.  
3.5.1 Cellular viability and proliferation 
FDA/PI staining was utilized to study the cellular viability in the 3D cellular scaffold 
constructs, in which the FDA stained only the cytoplasm of the viable cells (green) 
while PI stained non viable cell nuclei (red). The FDA/PI staining of the 
cellular-scaffold constructs demonstrated high cellular viability over 28 days in culture 
in all four MSC constructs with majority of the cells being viable (green) (Figure 3-10 
B). After loading with fibrin glue, all four MSC types remained spherical during the 
initial period, due to their confinement within the fibrin gel. Over the next 7 to 14 days, 
they assumed spindle shape morphology reminiscent of that seen in monolayer cultures, 
with hfMSC achieving that at an earlier time point at Day 7, compared to Day 14 for the 
other MSC types (Figure 3-10 B), demonstrating a more dynamic cellular 
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performance.  
 
During the proliferation within the scaffolds, hfMSC were found to attach to and bridge 
across the struts of scaffolds first, then underwent rapid proliferation and reached 
confluence within the scaffold, taking up all available spaces by Day 7 (Figure 3-10 B 
and Figure 11), while other MSC types achieved confluence only at the end of the 28 
day experimental period (Figure 3-10 B).  
 
Figure 3-11 Rapid proliferation of hfMSC observed under light microscope. All the 
images were taken on the same pores and the large magnification (x200) images of each pore 
were obtained and indicated by the red circles and arrow lines. hfMSC were found to attach to 
and bridge cross the struts of scaffold on Day 4, then underwent rapid proliferation and 
occupied the pore space within four days.
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This was confirmed by analysis of cell numbers with a double-stranded DNA (dsDNA) 
quantification method via Picogreen assay, showing a sharp increase during the first 
week of culture in hfMSC, undergoing a four-fold further increase between day 4 and 7 
(Figure 3-10 C). Thereafter, levels plateaued in hfMSC constructs, in line with the 
FDA/PI results. In contrast, in other MSC scaffolds, there was a small drop in dsDNA 
quantity from Day 1 to 4, followed by a slow increase of dsDNA amount which finally 
plateaued on day 28. hfMSC consistently showed a higher dsDNA percentage than 
hUCMSC and haMSC from Day 4 and hATMSC from Day 7 to Day 28 (p<0.001); 
hATMSC dsDNA were higher than haMSC and hUCMSC from Day 7 to Day 28 
(p<0.001), and hUCMSC dsDNA were higher than haMSC from Day 21 onwards 
(p<0.05) (Figure 3-10 C). 
 
3.5.2 Osteogenic differentiation and mineralization 
3.5.2.1 Osteogenic gene expression  
Real time RT PCR has been utilized to investigate the events during osteogenic 
differentiation of MSC within 3D PCL-TCP scaffolds. Four key genes were chosen and 
they are RunX2, ALP, Collagen I A1 and Osteonectin, which were well known 
osteogenic genes involved in different phases of osteogenic differentiation of MSC. 
When cultured in 3D PCL-TCP scaffolds, all four osteogenic genes were upregulated 
earlier (ALP) or more robustly (RunX2, Collagen I A1 and Osteonectin) in hfMSC 
scaffolds compared to other MSC scaffolds. haMSC demonstrated earlier expression of 
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3.5.2.2 Osteogenic assays 
Using serial light microscopy, extracellular crystalline deposits were seen appearing 
within the scaffolds , which was most abundant in the hfMSC scaffolds, followed by the 
haMSC, hUCMSC and hATMSC scaffolds when exposed to osteogenic induction 
medium (Day 19 analysis, Figure 3-13). In contrast, no crystalline deposits were 
Figure 3-12 Osteogenic gene expression of different MSC cultured in three-dimensional 
scaffolds. Quantitative analysis of key osteogenic genes (Alkaline phosphatase (ALP); 
Collagen 1A1; osteonectin; RunX2.) of MSC cultured in 3D scaffolds demonstrated either 
higher and/or earlier up-regulation in hfMSC scaffold-constructs than the others by 
quantitative RT-PCR.  
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observed in MSC scaffolds cultured in control growth medium (D10) (Figure 3-13). 
The nature of these calcium crystals was confirmed through von Kossa staining, 
demonstrating the darkest staining in hfMSC followed by the haMSC, hUCMSC and 
hATMSC scaffolds respectively (Figure 3-13). 
 
 
High magnification analysis of dehydrated scaffolds by SEM demonstrated a trabecular 
bone-like structure in all, with hfMSC scaffolds having the most extensive trabecular 
network of extracellular matrix (ECM), followed by haMSC, and the other two 
scaffolds. There were a large number of nodules seen within the ECM of hfMSC but not 
other MSC scaffolds, which were confirmed as calcium phosphate nodules through 
Figure 3-13 Calcium crystalline was found under microscopy and von Kossa staining. 
Mineralization of the cellular-scaffolds after 19 days of osteogenic induction resulted in 
deposition of opaque crystals within the scaffolds, more obviously in the hfMSC and haMSC 
scaffolds (light microscopy 40-400x), which was confirmed through von Kossa staining 
(calcium crystals staining black). Cellular-scaffolds grown in normal growth medium did not 
result in mineralization (control). OM: osteogenic media, and Ctrl M: control media. 
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EDX analysis (Figure 3-14).  
 
 
Next, microCT was used to quantify the mineralization within the scaffolds, allowing 
assessment of the entire volume of the construct. hfMSC scaffolds showed a 3.9 to 17.6 
fold higher mineral content than the other scaffolds (p<0.01), while haMSC 
demonstrated 4.1 and 4.5 fold higher mineral content than hUCMSC and hATMSC 
respectively (p<0.05) (Figure 3-15 A). This finding was confirmed by direct 
measurement of the calcium content within scaffolds through dissolution of the 
minerals, and quantification of calcium ions. From Day 14 of culture on, hfMSC 
Figure 3-14 SEM and EDX analysis of cellular scaffolds. Scanning electron microscopy 
(SEM) showed trabecular-like networks within the cellular-scaffold constructs, with nodular 
deposits found only on the hfMSC scaffolds and not others (magnification 1-5,000x); such 
nodules were shown to be calcium phosphate via EDX elemental analysis 
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scaffolds had a calcium content 1.6 to 5.0 fold higher than other constructs (p<0.01), 
with haMSC demonstrating 2.8 and 3.2 fold higher calcium content than hUCMSC and 
hATMSC respectively (p<0.01, Figure 3-15 B). 
 
Figure 3-15 Quantification of mineralization of different MSC scaffolds. (A) 
Quantification of mineral content through micro computed tomography(micro-CT) analysis 
showed a higher mineral volume in hfMSC than other MSCs, and in haMSC than hUCMSC 
and hATMSC (n=4, threshold=200, ** p<0.01, * p<0.05); (B) This was confirmed through 
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During the quantifying the mineralization of cellular scaffold using micro CT and 
calcium deposition assay, the influence of non-physiological deposition of calcium 
phosphate from the osteogenic medium and TCP element of the scaffolds has been 
taken into consideration as well. The acellular scaffolds cultured in the same osteogenic 
medium for 28 days were used as the negative control for subtracting the 
non-physiological calcium phosphate deposition. The non-physiological 
mineralization were detected with a value of 0.0650.023 mm3 under the micro CT 
analysis after 28 days culture (Figure 3-15 A); and calcium content deposited within 
the acellular constructs cultured for 7 through 28 days in osteogenic media were 
23.5±3.7; 27.8±3.1; 35.9±7.8; 36.7±5.4 g/scaffold at Day 7, 14, 21 and 28 
respectively (Figure 3-16). These values were substracted from the total calcium 
values in Figure 3-15 B. 
 
Figure 3-16 Calcium depositions by acellular scaffold controls. Non-physiological 
















Time in culture (Days) 
n=3 
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3.5.3 Osteoinductive effect of 3D PCL-TCP scaffolds culture  
The influence of culture condition on the hfMSC was compared between 3D PCL-TCP 
scaffolds and traditional monolayer (2D) culture. Real Time RT PCR was utilized to 
analyze the osteogenic gene expression. It was found that the four key osteogenic genes 
(ALP; Collagen 1A1; osteonectin; RunX2.) in the hfMSC were up-regulated earlier 
and/or more robust in 3D PCL-TCP scaffold culture when compared to the 2D culture 
(Figure 3-17). This demonstrated the osteoinductive effect of the 3D PCL-TCP 
scaffolds and its advantages over the traditional 2D culture.  
 
Figure 3-17 Osteoinductive effect of 3D PCL-TCP scaffold culture. Quantitative analysis 
of key osteogenic genes (Alkaline phosphatase (ALP); Collagen 1A1; osteonectin; RunX2.) 
using real time RT PCR showed that the PCL-TCP 3D scaffold can induced either higher 
and/or earlier up-regulation osteogenic gene expression in hfMSC compared to 2D monolayer 
culture. 
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3.6 Xenotransplantation of MSC scaffolds in NOD/SCID mice model 
In order to test the in vivo ectopic bone formation potential of the different cellular 
scaffolds, a well characterized subcutaneous xenogenic implantation model was used. 
The various MSC cellular constructs were cultured for two weeks in vitro as osteogenic 
pre-induction before implantation, before subcutaneous implantation into the back of 
immunodeficient NOD/SCID mice. MSC scaffold constructs were removed after 2 
months for the analysis regarding the chimerism rate of human cells in murine tissue 
and the ectopic bone formation. 
 
3.6.1 Chimerism of human cells in murine tissue 
All MSC scaffold implants demonstrated a high biocompatibility, with no 
tumorigenicity and good tissue integration.  Neo-vascularization of the grafts was 
observed as blood vessels infiltrating the scaffolds (Figure 3-18).  
 
 
Figure 3-18 MSC scaffold implants 2 month after subcutaneous implantation. All the 
implants showed high biocompatibility by showing no tumorigenicity and no fibrous 
encapsulation, good tissue integration and neo-vascularization by infiltrating blood vessels 
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Immunohistochemistry (IHC) was used to study the chimerism of human cells in the 
murine tissues. Human specific antibody, Lamin A/C, stained the nucleus of human 
cells with green fluorescence, all nuclei were counter-stained by the PI in red 
Figure 3-19 Validation of IHC using human specific Lamin A/C and PI as counterstain. 
(A) Under high magnification, the nuclei of human cells, were stained by human specific 
Lamin A/C (green) and PI (red); while the murine cell were only stained by PI (red). (B) 
Negative controls for the IHC. Both the nil-primary antibody control and the acellular 
control groups showed the specificity of Lamin A/C antibody for human cells.  
A 
B 
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fluorescence (Figure 3-19 A). This method is validated by the high specificity of the 
antibody Lamin A/C to human cells, as in the acellular scaffolds implants control and 
the nil-primary antibody control, green fluorescence did not stain any nuclei (Figure 
3-19 B).  
 
Using this IHC method, viable human cells were detected with high degree of 
chimerism (60 to 67%) in all MSC constructs two months after implantation, with 
murine cells infiltrating the scaffolds accounting for a third of the cellular population 
within the internal spaces of the scaffolds (Figure 3-30). There were no difference 
chimerism rates between groups.  
 
Figure 3-20 Human: mice chimerism analysis by IHC. Analysis of implanted cellular 
scaffold constructs demonstrated high levels of cellular viability and chimerism (60-67%) 
within the interior of the scaffolds through staining for human nuclei (lamins A/C, green) 
and counterstaining with propidium iodide (red) for all nuclei, the dark voids being the 
scaffolds (S). 
n=3 
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3.6.2 Ectopic bone formation 
The ectopic bone formation within MSC scaffold constructs was evaluated using both 
traditional von Kossa histological staining and micro-CT analysis. von Kossa 
demonstrated that hfMSC scaffolds resulted in the largest mineralization area, followed 
by haMSC, hUCMSC and hATMSC scaffolds (Figure 3-21 A, with H&E counter 
Figure 3-21 In vivo ectopic bone formation of different MSCs scaffold constructs. (A) 
von Kossa staining of representative sections with H&E counter-staining demonstrated higher 
degree of mineralization (black) in hfMSC and haMSC cellular-scaffold constructs than other 
cellular-scaffold constructs, scale bar: 30 µm; (B) micro-CT analysis of ectopic bone 
formation through 3D quantitative bone volume measurement demonstrated that hfMSC 
cellular-scaffold constructs resulted in the most bone formation, followed by the haMSC, 
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stain). This is further confirmed by micro-CT evaluation, which showed that hfMSC 
scaffolds generated the highest bone volume (16.6±3.0 mm3, p<0.01), followed by 
haMSC scaffolds (9.1 ±1.1 mm3, p<0.05), while hUCMSC and hATMSC scaffolds 
generated the lowest new bone volume (2.9±1.0 and 1.3±0.1 mm3 respectively). 
(Figure 3-21 B) 
 
3.7 Discussion 
The identification of various MSC types from different ontological and anatomical sites 
has raised the question as to the optimal cellular source for BTE applications, which 
becomes the motivation for this first part of study in this Project. In this part of work, 
four well-characterized MSC types from different tissue origins were systematically 
compared for their potential in BTE applications using a battery of stringent tests in the 
same setting. The key finding was that hfMSC is a superior cellular candidate not only 
due to their primitiveness and expression of embryonic stem cell markers, lower HLA I 
expression, and higher proliferative capacities, but in particular because of their 
osteogenic potential both in vitro and in vivo for ectopic bone formation when 
compared to hUCMSC, haMSC and hATMSC.  
 
The detailed characterization of the cells used in this study was the prerequisite 
investigation for the following studies. The three MSC types (except haMSC) here 
were subjected to identical isolation and culture conditions in the same laboratory, to 
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better control for the inherent differences that characterize samples processed in 
different laboratories, while the well characterized haMSC were obtained from the 
Tulane University Health Sciences Center as a comparative reference. They were fully 
characterized in excess of criteria of being MSC laid down by the International Society 
for Cellular Therapy (ISCT) [Dominici, 2006], being fibroblastic in morphology, 
demonstrating clonogenicity, expressing various mesenchymal markers and adhesion 
molecules, lacking in haemopoietic and endothelial markers, and being capable of 
tri-lineage differentiation under permissive conditions.  
 
A Vit D based inductive medium was compared to the standard Dex based protocol 
using hATMSC and hfMSC, which demonstrated no difference in these experiments,. 
This was contrary to previous reports by Malladi et al. and Zhou et al. [Malladi, 2006; 
Zhou, 2006]. It was noticed that the most of the data on the use of VitD were derived 
from animal adipose MSC such as murine, which may have different differentiation 
cues to those found in humans [Bellows, 1994; Atmani, 2003; Malladi, 2006; Zhuang, 
2007]. In addition the nature of the cell types involved is not clear in many of these 
publications, which were not characterized extensively according to ISCT’s criteria 
[Zhou, 2006]. As such, a standardized Dex based differentiation protocol, with batch 
tested reagents, serum and media was utilized throughout the following study, allowing 
comparison among groups in a controlled fashion. 
 
The osteogenic potential of these MSC types was investigated both in standard 
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monolayer cultures, and after loading onto an advanced generation bioactive scaffold 
suitable for clinical applications, and results corroborated through multiple 
proliferation assays (cell enumeration, CFU-F capacity, FDA/PI confocal imaging, 
dsDNA quantification), osteogenic induction (real time RT PCR of key osteogenic 
genes and ALP activity) and extracellular matrix deposition (von Kossa staining, 
quantitative calcium content, micro-CT quantification and SEM / EDX analysis).  
 
Only hfMSC and hUCMSC expressed the pluripotency markers, Oct-4 and Nanog, 
which are essential factors for the maintenance of pluripotency and proliferative 
capacity of embryonic stem cells [Loh, 2006], reflecting their primitiveness. This may 
in part explain their higher proliferative potential and CFU capacity compared to other 
sources, which confers advantages for their rapid expansion and consequent 
downstream applications. In addition to the first trimester derived hfMSC [Guillot, 
2007], it was now demonstrated that similar pluripotency markers were expressed in 
the second trimester BM derived hfMSC, as well. Oct-4 and Nanog positive MSC from 
human umbilical cord veins were identified by Kermani et al.[Kermani, 2008], 
suggesting that these markers are an ontological rather than an anatomical feature. In 
this study, these markers were not found in adult MSC types, although Pochampally 
and co workers showed that these pluripotency markers can be induced in haMSC after 
a period of selection under serum deprivation [Pochampally, 2004].  
 
hfMSC expressed the lowest level of HLA I expression, which for allogeneic 
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applications should render them immunologically advantageous over the other MSC 
types. Further advantages include their lack of intracellular HLA class II and slower 
upregulation in response to stimulation by -interferon compared to haMSC,  as 
previously reported by Gotherstrom et al [Gotherstrom, 2003; Gotherstrom, 2004; 
Gotherstrom, 2007]. Already allogeneic hfMSC transplantation in a clinical case of 
osteogenesis imperfecta (OI) resulted in chimerism of up to 7% in the bone, with 
possible clinical benefit [Le Blanc, 2005], while intrauterine xeno-transplantation in a 
murine model of OI resulted in similar chimerism rates, and amelioration of the 
phenotype without evidence of immune rejection [Guillot, 2008], suggesting their 
utility for skeletal based cellular therapeutic applications. 
 
Stro-1, which is a marker most commonly associated with the osteogenic progenitor 
fraction found within MSC cultures [Simmons, 1991; Gronthos, 1994] has the highest 
expression in hfMSC. This may in part explain their observed superior osteogenicity in 
monolayer and 3D scaffold cultures, and in vivo ectopic bone formation over the other 
MSC types. 
 
The observations that ontogeny is an important determinant for proliferative and 
osteogenic capacity mirror Kim et al’s findings of diminishing capacity from fetal 
through neonatal, infant and juvenile BM-derived Rhesus macaque MSC, although 
they did not examine adult BM [Kim, 2008]. More recently, Guillot et al demonstrated 
that first trimester hfMSC sources had higher expression of osteogenic genes both 
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basally, and during osteogenic induction compared to haMSC in both in vitro and in 
vivo paradigms [Guillot, 2008]. Comparison of hUCMSC and haMSC by Baksh et al 
concurs with the findings in this experiment that hUCMSC have a higher proliferative 
and osteogenic differentiation capacity than haMSC in 2D cultures [Baksh, 2007], 
which suggest that ontogeny may play a bigger role than the anatomical origins of MSC. 
Conversely, in 3D scaffold culture both in vitro and in vivo, haMSC produced higher 
proliferation rates and more robust osteogenic differentiation. While the reason for this 
disparity between two and there-dimensional behavior for proliferation and osteogenic 
differentiation in haMSC and hUCMSC is unknown, it is speculated that haMSC may 
respond differently to cues of 3D culture, which may be associated with the adoption of 
a more native morphology, and multi-dimensional cell-cell signaling processes 
[Cukierman, 2001; Abbott, 2003; Grayson, 2006].  
 
It was also found that the anatomical origin of cultured expanded MSC influences its 
osteogenic potential, with BM derived hfMSC and haMSC performing better than 
MSC derived from the umbilical cord and adipose tissues. This is in agreement with Im 
et al and Liu et al’s findings that hATMSC have higher adipogenic but less osteogenic 
and chondrogenic potential than haMSC [Im, 2005; Liu, 2007], which has a role in 
producing bone and cartilage tissues in the bone marrow. Gene expression studies 
support this anatomical relationship to the osteogenic potential of each MSC source, 
with Panepucci et al demonstrating haMSC being more committed to osteogenesis, 
while hUCMSC is more committed to angiogenesis in keeping with their anatomical 
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site of origin [Panepucci, 2004]. Finally, in line with this, Guillot et al demonstrated 
higher osteogenic gene expression in first trimester fetal BM derived hfMSC over fetal 
blood and fetal liver hfMSC [Guillot, 2008]. 
 
Analysis of a panel of genes, which are known to be upregulated in early (Osteonectin 
and RunX2), intermediate (Alkaline Phosphatase) and late (Collagen IAI) stages of 
osteogenesis, demonstrated that hfMSC scaffolds undergo earlier and more robust 
upregulation, mirroring their phenotypic performance in mineralization. 
 
Scaffolds offers a three dimensional framework in which a temporary matrix for 
cellular proliferation, differentiation, deposition of extracellular matrix and allow the 
development of neovasculature to occur [Salgado, 2004; Rai, 2007]. The bioactive 
PCL-TCP scaffold of high porosity was used here, and demonstrated its 
biocompatibility, with high cellular viability in all four MSC types after four weeks of 
in vitro culture, and 2 months of in vivo implantation. In addition, it allowed the 
deposition of trabecular bone like ECM and calcium phosphate nodules in vitro, and 
ectopic bone formation within an in vivo environment. Finally, compared with the 
traditional monolayer culture, the osteogenic inductive potential of bioactive PCL-TCP 
scaffold was shown to be greatly effective, demonstrated by its capacity to upregulate 
osteogenic gene expression of MSC.  
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3.8 Conclusion 
In conclusion, the ontological and anatomical origins of MSC have a profound 
influence on their proliferation and differentiation capacities, and hence affect their 
performance as cellular sources for bone TE. hfMSC is the best cellular candidate 
compared to hUCMSC, haMSC and hATMSC because they express pluripotency 
markers, have lower immunogenicity and greater proliferative capacity. In addition, 
when cultured in osteogenic conditions, hfMSC exhibited the most robust osteogenic 
gene induction, extracellular mineralization and in vivo ectopic bone formation. The 
experimental data of this study support the use of hfMSC as a superior allogeneic 
cellular source over the other MSC types for BTE applications. As a result, hfMSC 
were selected as the cellular source for the following research work in this project.  
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Chapter 4 Bi-axial rotating bioreactor for in vitro 
maturation of TE bone grafts 
4.1 Introduction 
Besides the identification of hfMSC as the superior cellular candidate, the development 
of clinically transplantable tissue engineered bone grafts also required an advanced in 
vitro culture system for the cultivation and maturation of grafts. In order to achieve the 
best clinical outcome, this in vitro culture system should fulfill the following 
requirements: (1) enhance the cellular expansion to obtain the cellular constructs with 
clinically significant cell number; (2) promote the homogenous cell and extracellular 
matrix (ECM) distribution; (3) maintain the viability of grafts with large size; as well as 
(4) induce the proper osteogenic differentiation and mineralization [Holy, 2000; Martin, 
2004]. In vitro, without the presence of vascular network, traditional static culture can 
only support the 3D cellular constructs less than several hundred microns in thickness, 
which hinder their clinical applications [Ishaug, 1997; Martin, 1999]. This is because in 
static culture the mass transport is solely carried out by passive diffusion, which has a 
short effective distance of a few hundred microns, whereas the large 3D cellular 
constructs with high cellular density bring forward a demanding need for nutrient and 
oxygen. Therefore, bioreactors have been introduced into tissue engineering to mitigate 
the diffusion limitation of large 3D cellular constructs by increasing the mass transfer 
and promote better cellular differentiation by providing mechanical stimulation [Martin, 
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2004; Bilodeau, 2006; Chen, 2006]. Among various bioreactor designs, RWV 
bioreactors have demonstrated good potential for BTE applications, because of their 
characteristic of low-shear, three dimensionality, high mass transfer and thus provides a 
dynamic flow culture condition to promote tissue synthesis [Klement, 1993; Molnar, 
1997; Eiselt, 1998; Granet, 1998; Yu, 2004]. 
 
Previously, an improvement on RWV bioreactor design has been described, leading to 
the bi-axial rotational design, in which the culture vessel can rotate simultaneously in 
two perpendicular axes, unlike the uni-axial rotation of the conventional RWV 
bioreactor. This bi-axial bioreactor resulted in increases of fluid velocity with 
significant improvements of fluid transport through the scaffolds compared to 
conventional uni-axial rotating bioreactor and static culture on in silico simulation 
[Singh, 2005]. More recently, a perfusion system has been built in this bi-axial rotating 
bioreactor, which should further improve on fluid transport across scaffolds.  
 
In the second part of this Project, this bi-axial rotating bioreactor was investigated for 
their performance in the in vitro cultivation and maturation of TE bone grafts. hfMSC 
mediated PCL-TCP scaffold constructs were cultured in osteogenic medium under 
bioreactor culture or standard static culture, and assessed for their cellular viability, 
proliferation, differentiation/mineralization and in vivo ectopic bone forming properties.  
Compared to static culture, bioreactor cultured hfMSC-scaffolds reached cellular 
confluence earlier (Day 7 vs Day 28), with greater cellularity (2x, p<0.01), and 
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maintained high cellular viability in the core. In addition, bioreactor culture was 
associated with greater osteogenic induction, ALP expression (1.5x p<0.01), calcium 
deposition (5.5x, p<0.001) and bony nodule formation on SEM, and in-vivo ectopic 
bone formation in immunodeficient mice (3.2x, p<0.001) compared with 
static-cultured scaffolds. The use of bi-axial bioreactor here allowed the maintenance of 
cellular viability beyond the limits of conventional diffusion, with increased 
proliferation and osteogenic differentiation both in-vitro and in-vivo, suggesting its 
utility for BTE applications. 
 
4.2 Experimental design 
hfMSC were loaded into PCL-TCP scaffolds and pre-cultured in static for one week to 
enhanced the cellular attachment. Then, cellular scaffolds were divided randomly into 
two groups: (A) a bioreactor group where scaffolds were transferred to the bi-axial 
rotating bioreactor loaded with a total of 1000 ml of osteogenic inductive medium 
which fills the vessel and the reservoir with the medium change once a week for four 
weeks; and (B) the static culture group where scaffolds were transferred to 24-well 
plates with osteogenic inductive medium changed three times a week for four weeks 
(Figure 4-1).   
 
In the second part of this study, NOD/SCID mice subcutaneous implantation model was 
utilized to investigate the influence of bioreactor culture on the in vivo performance of 
                                       Chapter 4 Bioreactor Culture vs. Static Culture 
____________________________________________________________________________________________ 
- 175 - 
hfMSC cellular scaffolds. Cellular scaffolds were pre-differentiated in osteogenic 
medium under either bioreactor culture or static culture condition for 2 weeks before 
implantation. Three months after implantation, cellular scaffolds were retrieved for 
analysis (Figure 4-1). 
 
 
4.3 Cellular proliferation, distribution and viability 
The cellular proliferation, distribution and viability of hfMSC in the PCL-TCP 3D 
scaffolds were closely examined monitored under Phase Contrast Light Microscope 
(PCLM), double-stranded DNA (dsDNA) content quantification, and the FDA/PI 
staining up to 4 weeks.   
Pre-culture for 1 week 
“Static” vs. “Bioreactor” 
(4 wks) 
In vitro study 
Loading cells to scaffolds: 
“Static” vs. “Bioreactor” 
(2 wks) 
In vivo study 






Figure 4-1 Experimental design of Specific Aim #2 
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Figure 4-2 Cell adhesion and proliferation of hfMSC cultured in the PCL-TCP scaffolds. 
(A, E) Scaffolds which had been cultured for one week were transferred to either bioreactor or 
static culture conditions over 28 days. Bi-axial bioreactor cultured constructs achieved 
confluence of all the available space within the scaffolds by Day 7 (B-D), with the appearance of 
extracellular crystals from Day 14 of culture (red arrow, J), which increased in amount by Day 
28, limiting the passage of light through the scaffold (K, L) (the light transmission area in L was 
the pinhole area). In contrast, static cultured constructs reached confluence only after 28 days of 
culture, with evidence of mineralization (red arrow, P) appearing only at Day 28 (E-H &M-P). 
Scaffolds were viewed from the planar (top) and side profile under phase contrast light 
microscopy through the culture. 
Pinhole area
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Under bioreactor culture conditions, hfMSC proliferated rapidly, saturating all 
available spaces within the scaffolds, and reached confluence within 7 days, as seen in 
both planar and side view by light microscopy (Figure 4-2 A-D). Static cultured 
cellular scaffold constructs on the other hand, were not confluent by 7 days (Figure 4-2 
F-H), and gradually reached confluence within the scaffolds only after 28 days of 
culture (Figure 4-2 O, G). 
 
This observation was further confirmed by Picogreen assay through measuring total 
dsDNA content. dsDNA quantity increased rapidly, peaked at Day 7 and plateaued 
thereafter, in agreement with observation made via PCLM findings. On the other hand, 
in static culture, the dsDNA of cellular scaffold constructs increased slowly throughout 
28 days, and at the final time point day 28, the dsDNA of cellular scaffold constructs in 
static culture was significantly lower than bioreactor culture (p<0.001). (Figure 4-3) 
 
Figure 4-3 Quantification of dsDNA content in cellular scaffolds by Picogreen assay. It 
showed that bioreactor culture supported the significantly higher cellular proliferation rates 
(*** p<0.001), with cellular scaffolds achieving a confluence by Day 7, and achieving a 
higher final cell content within the scaffolds at all time points. 
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In addition, bioreactor cultured constructs demonstrated homogenous cellular 
distribution at the surface (planar view, Figure 4-4 A) as well as the internal core (core 










Planar view Core view A 
Figure 4-4 Cellular viability studies (FDA/PI staining): A) FDA/PI was used to stain for 
live and dead cells respectively, through confocal microscopy imaging of the planar (top) view, 
and after bisecting the scaffold into two in the middle, achieving a view of the scaffold’s centre 
(core view). B-I) Bi-axial bioreactor cultured constructs demonstrated confluence of the 
scaffold surface and interior, with homogenous cellular distribution at an earlier time point 
(B-C) than static cultured constructs (F-G) (D14 shown here). By Day 28, hfMSC in 
bioreactor-cultured constructs assumed osteoblast morphology, appearing ovoid in shape 
(D-E), while retaining high cellular viabilities in the core of the scaffolds (E). In contrast, 
hfMSC in static-cultured constructs remained spindle shaped (H), with poor cellular viabilities 
in the core of the scaffolds (I). (All images here are confocal z-stack images, constructed from 
44 horizontal image sections with 300 um in depth. Mag. 100x) 
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microscopy and FDA/PI staining (Figure 4-2 C, D and Figure 4-4 B, C). While 
bioreactor cultured constructs maintained good cellular viability at the core of the 
scaffold after 28 days of culture  (Figure 4-4 D, E), massive cellular death in core of 
the scaffold were observed in scaffolds under static culture conditions (Figure 4-4 I), 
despite good viabilities earlier in culture (Day 14, Figure 4-4 F, G).  
 
Interestingly, hfMSC were found to assume an osteoblastic morphology after 
bioreactor culture (day 28, Figure 4-4 D, E), appearing ovoid in shape as observed on 
FDA/PI staining, in contrast to static cultured constructs, where hfMSC maintained a 
typical spindle shaped morphology (Figure 4-4 H, I).  
 
4.4 Osteogenic differentiation and mineralization 
The light microscopy images revealed the more robust osteogenic differentiation and 
mineralization occurred in cellular scaffold constructs under bioreactor culture than 
static culture conditions. The deposition of extracellular calcium crystals appearing was 
observed in bioreactor treated scaffolds by Day 14 (Figure 4-2 J), which was only 
noticeable at Day 28 in static cultured constructs (Figure 4-2 P). After 28 days 
bioreactor culture, cellular scaffold constructs were highly mineralized so that they 
limited the passage of transmission light through the scaffold under the light 
microscopy, except the pinhole area (Figure 4-2 K, L).  
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Osteogenic differentiation and mineralization was further investigated by von Kossa 
staining, scanning electron microscopy (SEM), Energy Dispersive X-ray (EDX), ALP 
activities assay, and Calcium deposition assay.  
 
After 28 days bioreactor culture, the hfMSC mediated scaffold constructs were covered 
with a layer of mineralized ECM, obscuring the honey-comb structure of the PCL-TCP 
scaffolds (Figure 4-5, Bioreactor Day 28). This mineralized layer was stained 
intensively black by von Kossa staining. Whereas the static cultured cellular constructs 
were transparent with less dense mineral deposits and von Kossa staining at both day 14 
and 28 time points (Figure 4-5).  
 
 
Figure 4-5 von Kossa staining of cellular scaffolds. Results demonstrated that cellular 
scaffolds in bioreactor culture went through more robust osteogenic differentiation and 
mineralization than static culture, as shown in much darker of Von kossa staining at Day 14 
and 28. 
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Figure 4-6 Scanning electron microscopy (SEM) and EDX analysis of cellular scaffolds. 
(A) SEM showed that bioreactor cultured cellular scaffolds at Day 28 have high 
mineralization and larger amount of calcium crystals structure. (B) EDX analysis of the 
element components revealed the mineralized nodules found in SEM (in red circle) were 
calcium phosphate salts, consisting of P, Ca and O elements. 
B. EDX analysis 
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The microstructure of this mineralized layer were revealed under SEM imaging, where 
higher level of crystal-like ECM deposition was found in bioreactor cultured versus 
static cultured constructs (Figure 4-6 A). These deposits were identified as calcium 
phosphate salts, consisting mainly of P, Ca and O elements, through EDX element 
component analysis (Figure 4-6 B). 
 
Supporting this observation, bioreactor treated constructs expressed significantly 
higher level of ALP activity than the static culture constructs from day 7 through day 28 
(1.5x, p<0.001, Figure 4-7). Furthermore, cellular scaffold constructs in bioreactor 
culture deposited significantly higher calcium than static culture (4.9x at Day 14, 
p<0.001, and 5.7x at Day 28, p<0.001, Figure 4-8).   
 
 
Figure 4-7 ALP activity assay. Cellular scaffolds cultured in bi-axial bioreactor expressed 
higher level of ALP activity than those in static culture from day 7 (* p<0.05, ** p<0.01, *** 
p<0.001) 
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4.5 Subcutaneous implantation in a NOD/SCID mice model 
An in vivo xenotransplantation model was used to investigate the influence of 
bioreactor matured scaffolds on ectopic bone formation. After three months 
implantation, cellular scaffold implants were retrieved and analyzed by histology, 
immunohistochemistry and micro CT scanning to study the chimerism rate of human 
cells in murine tissue and ectopic bone formation.  
 
 
Figure 4-8 Calcium content assay. Analysis of calcium deposition in the scaffolds revealed 
significantly higher calcium deposition in bioreactor-cultured constructs than static-cultured 
constructs from Day 14 to 28. *** p<0.001. 
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Three months after subcutaneous implantation in immunodeficient mice, implants from 















Figure 4-9 Scaffold implant images and Chimerism analysis. (A-B) Implanted scaffolds 
from both groups integrated into the surrounding tissues with no evidence of tumor formation. 
(C-G) Immunostaining for human-specific Lamin A/C (green nuclei, counterstained with 
propidium iodide) showed a higher human: mouse chimerism rate in bioreactor-cultured 
versus static-cultured constructs (78.5±14.6% vs. 57.6±8.3%, p<0.05). (E,F are the enlarged 
images of blue rectangle areas in C,D; S indicates scaffold). Scale bar 500μm, * p<0.05. 
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host tissues, with no evidence of tumor formation (n=18) (Figure 4-9 A, B). 
Immunohistochemistry using human-specific Lamin A/C antibody showed that hfMSC 
survived inside the scaffolds for three months and bioreactor cultured constructs 
demonstrated higher human: mouse chimerism rates than static cultured constructs 
(78.5±14.6% vs. 57.6±8.3%, p=0.02) (Figure 4-9 C-G).  
 
 
In addition, after 3 months’ in vivo implantation, histological analysis showed that  
bioreactor cultured cellular scaffold constructs generated more uncalcified 
(demonstrated by Mason’s Trichrome staining, Figure 4-10 A, B), and calcified bone 





Figure 4-10 Histological analysis of cellular scaffold implants. Bioreactor cultured 
scaffold showed more uncalcified and calcified bone formation and mineralization by 
Mason’s Trichrome and von Kossa staining (counterstained with nuclear fast red) 
respectively, scale bar 100 μm.. 
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observations, micro CT analyses demonstrated more ectopic bone formation in 
bioreactor over static cultured constructs (3.2x, p<0.001) (Figure 4-11). 
 
B. Ectopic bone volume analysis
Figure 4-11 Micro CT analysis of cellular scaffold implants.  (A) 3D images of implants 
showed that there are much more ectopic bone formed in cellular scaffolds under bioreactor 
culture than static culture, and the empty scaffold implants (negative ctrl); (B)  ectopic 
bone volume analysis demonstrated 3.2 fold more ectopic bone formed in bioreactor 
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4.6 Discussion 
Bioreactors have been developed in order to address the need to circumvent the 
limitations of mass transfer in thick scaffold cultures, and in the case of BTE, to apply 
suitable mechano-transduction forces which in turn facilitate osteogenic differentiation 
through specific signaling pathways [Martin, 2004; Bilodeau, 2006]. In this study, it 
was demonstrated that bi-axial rotating bioreactor matured hfMSC/PCL-TCP scaffold 
constructs resulted in significantly higher cellular proliferation, homogenous cellular 
distribution and in-vitro and in-vivo osteogenic differentiation than those cultured in 
static condition. In addition, bi-axial rotating bioreactor cultured constructs retained 
high cellular viabilities in the core of the scaffold which was not achieved with static 
culture. 
 
Currently, several bioreactors such as spinner flasks, perfusion bioreactors and rotating 
wall vessel (RWV) bioreactors have been investigated for BTE applications, but have 
been beset by various limitations. The use of spinner flasks resulted in improved fluid 
flow through a simple design [Mygind, 2007; Song, 2008; Stiehler, 2008], although the 
turbulence generated can be detrimental for seeded cells and newly laid down ECM 
[Sikavitsas, 2002; Chen, 2006]. Perfusion bioreactors, which have been shown to 
enhance MSC proliferation and osteogenic differentiation in scaffold constructs 
[Sikavitsas, 2003; van, 2003; Gomes, 2006], have been limited by non-homogenous 
cellular distributions, with cells at the frontal zones being washed away by the 
oncoming perfusion flow with higher flow rates [Singh, 2007]. Rotating wall vessel 
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(RWV) bioreactors [Molnar, 1997; Granet, 1998; Yu, 2004], which generates low shear 
forces and three dimensional high mass transfer capacity, are prone to similar problems 
of non-homogenous cellular growth and ECM deposition [Goldstein, 2001; Sikavitsas, 
2002; Chen, 2006]. In addition, during free floating culture, collision between the 
scaffolds and the bioreactor walls can induce cellular damage and disrupt cellular 
attachment and matrix deposition on the scaffolds [Goldstein, 2001; Sikavitsas, 2002; 
Chen, 2006].  
 
Consequently, the bi-axial rotating bioreactor used here has been designed to address 
the deficiencies found in current bioreactor designs: firstly, a perfusion system was 
included to allow the exchange between the vessel and reservoir, allowing maximal 
mass transfer with consequential low shear stress, without the washout associated with  
conventional perfusion bioreactors; secondly, bi-axial rotation of the culture vessel 
improved upon uni-axial rotating designs, leading to more homogenous cellular and 
ECM distribution of the scaffold, as previously predicted from in-silico [Singh, 2005]; 
and lastly, cellular scaffold constructs were secured by pins instead of floating in free 
suspension, avoiding the risk of scaffold collisions with the vessel walls.   
 
By Day 28 of static culture, cellular necrosis were found within the core of scaffolds, 
which is 2,000 m (2 mm) away from the surface. This coincided with the achievement 
of cellular confluence within the scaffold in static culture, and hence the need for 
nutrients and oxygen to reach the core through diffusion alone. The cellular necrosis 
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observed here is largely predictable as the limits of mass transfer of nutrients is 
generally held to be around 200 m [Martin, 2004]. In contrast, bi-axial bioreactor 
cultured scaffolds, which achieved cellular confluence by day 7 of culture, resulted in 
high degrees of cellular viability at the core of the scaffolds from 7 through 28 days 
despite the high cellularity and mineralization, with consequential higher final cellular 
numbers and osteogenic differentiation and mineralization. This performance was 
better than the experience with spinner flasks, where Sutherland et al found a central 
necrotic core in 1 mm spheroid, which is 500 m from the surface [Sutherland, 1986].  
 
Culturing scaffolds in bioreactor resulted in higher cellularity which was obvious 
through both light microscopy and dsDNA content measurements, indicating the 
beneficial effects of improved mass transport. In addition, shear stresses found within 
the bi-axial bioreactor can provide key mechanical stimulation which has been 
implicated in the promotion of cellular proliferation of osteoprogenitor cell types 
[Ignatius, 2005; Bilodeau, 2006].  
 
In the bioreactor culture, shear forces would have been applied to both the surface and 
the interior of the scaffold during the first week of culture, in line with in silico fluid 
dynamic modeling simulations [Singh, 2005]. At the end of one week, however, 
cellular confluence of the scaffold would prevent any further convection from taking 
place within the scaffold itself. The maintenance of cellular viability at the scaffold core, 
which is 2,000 m from the surface, would depend on the improvement of mass 
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transfer of nutrients afforded by convection forces at the surface of the scaffold [Martin, 
2004].  
 
Shear stress generated by the bi-axial bioreactor can trigger mechanotransduction 
signal pathways, which in turn up-regulates production of cyclic adenosine 
monophosphate (cAMP) [Reich, 1990],  transforming growth factor beta1 (TGF-β1) 
[Sakai, 1998] and nitric oxide [Johnson, 1996], all of which have been implicated in 
bone tissue repair mechanisms. The improved osteogenic differentiation and 
mineralization of hfMSC cellular scaffolds in a dynamic bioreactor environment over a 
static culture system is in keeping with the general observation that shear forces 
stimulates osteogenic programming in MSC [Gomes, 2003; Sikavitsas, 2003; Park, 
2004; Holtorf, 2005; Datta, 2006; Kurpinski, 2006]. In addition, it has been observed 
that bi-axial bioreactor cultured hfMSC assumed an ovoid morphology similar to those 
of mature osteoblasts, suggesting a higher degree of differentiation being achieved 
compared to static cultured hfMSC.  
 
The improved in-vitro performance of bi-axial bioreactor cultured constructs over static 
cultured constructs was accompanied by higher human cell chimerism rates than static 
cultured constructs after implantation into NOD/SCID mice. Additionally, the higher 
ectopic bone formation in the bioreactor cultured group confirmed Mendes et al’s work, 
showing better in-vivo osteogenic performance with the use of pre-differentiated 
cellular constructs for transplantation [Mendes, 2002; Mendes, 2004].  
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4.7 Conclusion 
In conclusion, the use of this novel bi-axial rotating bioreactor allows a shorter in-vitro 
maturation culture time to be achieved, along with improved cellular and ECM 
distribution, and more efficient osteogenic induction and mineralization of bone tissue 
engineered grafts compared to standard static culture systems. More importantly, the 
use of the bi-axial rotating bioreactor resulted in improvements with the limits of mass 
transfer in thicker grafts, which will have important implication for their eventual 
clinical applications. 
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Chapter 5 In-vivo Assessment of Bone Tissue 
Engineered Grafts in a Rat Critical Sized 
Femoral Defect Model 
5.1 Introduction 
After the accomplishment of the first and second specific aims, hfMSC were selected 
as the superior cellular source, bi-axial rotating bioreactor was utilized as an advanced 
in vitro cultivation and maturation system for BTE applications. Together with 
PCL-TCP bioactive scaffolds, a highly osteogenic TE bone graft was developed in 
vitro with efficient in vivo ectopic bone capacities. To address the third specific aim, a 
suitable animal model with orthotopic bone defect is required to assess the functional 
capability of this TE bone grafts in bone defect healing.  
 
Experimental animal models provide instrumental preclinical evaluation of the 
functional efficacy and safety of new TE bone grafts [Vacanti, 1999; Goldstein, 2002]. 
Rat critical size femoral defect model was selected in the following study. Rat as 
animal model has the advantages of low cost, short life spans and rapid bone turnover 
rates. In addition, as the femur is a major loading bone, femoral defect can provide 
critical information about the bone healing process under the weight loading 
environment, which cannot be assessed in the craniofacial defect model and ectopic 
bone formation model. Although rats are quadrupedal animal, they maintain upright 
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postures during feeding and grooming, thus, they have a similar anatomic structure of 
femur and postural loading on the femur as in humans, and hence is a clinically relevant 
model [Jeffrey O, 2005]. Critical sized defects (CSD) were used, because they exceed 
the animal’s capability to heal the defects spontaneously and therefore are suitable for 
the evaluation of new bone grafts [Hollinger, 1990].  
 
In this part of study, a critical sized segmental defect with 7 mm in length was created 
on the right femur of each rat, and implanted with (i) TE bone grafts (TEBG), or (ii) 
PCL-TCP scaffolds alone (Control), or (iii) no treatment (Nil implants). After three 
months, nil implants group demonstrated limited new bone formation validating 7 mm 
as the critical sized defect. TEBG group achieved successful defect union with 2.1 fold 
more new bone formation and 10 fold increase in the stiffness of the damaged bones, 
compared to control group, which resulted into non-union defects. Furthermore, 
compared to control group, TEBG group had 2.2 fold increase of neo-vascularization 
around the defect region, suggesting a potential angiogenic effects of TE bone grafts. 
Therefore, the TE bone grafts developed in this project may function as an effective 
treatment for bone defect healing. 
 
5.2 Experimental design 
There were three experimental groups in this study: (i) TEBG group; (ii) control 
group; and (iii) untreated group (Figure 5-1). 7 mm segmental defects were created 
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on the right femurs of 30 rats and treated with the implantation of TE bone grafts 
(TEBG group, n=15), acellular scaffold (control group, n=10) or nil implants 
(untreated group, n=5). Acellular scaffold implants were used as the control group in 
this study, and untreated group without any implants were utilized for the validation 
of defects used in this study as CSD. TE bone grafts were generated by seeding 
hfMSC into PCL-TCP bioactive scaffolds, and followed by two-week of in vitro 
culture in a bi-axial rotating bioreactor prior to implantation (Figure 5-1). To prevent 
the potential immunorejection of human cells based TE bone grafts, Cyclosporin A 
(Novartis, Switzerland) was injected into all the SD rats on a dosage of 10mg per Kg 
body weight per day from one week before the surgery until the end of experiment.  
 
Out of 30 rats, 4 rats were subjected to euthanasia or deaths prior to 12 weeks after 
operation (1 from TEBG group, 1 from Control group, and 2 from Untreated group, 
drop-out rate: 13.3%). New bone formation was analyzed by X-ray examination 
monthly, micro CT scanning (week 0, 4 and 12), and Torsional testing (week 12). 
Figure 5-1 Experimental design of Specific Aim #3. 
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Neo-vascularization on the defect area was investigated by microfil enhanced micro CT 
analysis (week 4). Histological studies (H&E, von Kossa, Masson’s Trichrome) were 
performed to analyze the tissue morphology on the defect area (week 12). At last, the 
immunohistochemistry were carried out to investigate the chimerism of hfMSC in rat 
tissue (day 4 and week 2, 4). (Figure 5-1) 
 
A B C
Figure 5-2 In vitro maturing of TE bone grafts. (A) FDA/PI staining showed the complete 
confluence of cellular scaffolds while high degree of viability was maintained (scaffolds were 
cut longitudely into halves before staining with FDA/PI); (B) after two weeks culture, cellular 
scaffolds went through robust osteogenic differentiation and deposited large amount of calcium 
crystals (inserted picture was the high magnification image of red rectangle area); (C) the 
cellularity of TE bone graft increased rapidly from 0.50±0.13 million to 1.59±0.40 millions
within two weeks.  
A B 
C. Cellularity of TE bone grafts 
n=3 
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5.3 In vitro generation of TE grafts in bi-axial rotating bioreactor 
After bi-axial rotating bioreactor culture for 2 weeks, hfMSC occupied all the available 
space within the scaffolds and maintained a high degree of cellular viability indicated 
by FDA/PI live-dead staining as previously demonstrated in Chapter 3 and 4 (Figure 
5-2 A). Evidence of robust osteogenic differentiation, with large amount of calcium 
crystals was seen under light microscopy (Figure 5-2 B). It was demonstrated by 
Picogreen dsDNA assay that the cellularity of TE bone grafts have increased three fold 
within two weeks (from 0.50±0.13 million to 1.59±0.40 millions, Figure 5-2 C).  
 
5.4 New bone formation assessment 
In TEBG group, the critical sized bone defects achieved bony union after 3 months as 
seen through the X-ray examination (Figure 5-3) and micro CT assessment (Figure 
5-4), while in control group (acellular scaffold), the defects failed to heal. At the end of 
the first month, TEBG and control groups shared similar amount of new bone 
formation (Figure 5-4 & 5-5). But, after three months, TEBG group resulted in 2.1 fold 
more new bone formation in the defect area than control group as shown by micro CT 
analysis (p<0.05, Figure 5-4 & 5-5). In addition, femoral defects utilized in this model 
proved to be critical sized defects, indicated by the limited regeneration in untreated 
group (Nil implants) (Figure 5-4). 
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Figure 5-3 X-ray examination of new bone formation. TE bone grafts can heal the critical 
sized bone defect and achieved the union of defect after 3 months implantation (TEBG group), 
while control group (acellular scaffold) failed to heal as indicated by red arrow. 
 
Figure 5-4 Micro CT images of femoral defects. TEBG group resulted in successful defect 
union, while control group showed limited new bone formation, and untreated group showed 
no formation of new bone. (Threshold =200) 
Defect (0 mth) TEBG group (1 mth) TEBG group (3 mth)
Untreated group (3 mth) Control group (1 mth) Control group (3 mth)
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5.5 Mechanical testing 
Torsional testing was utilized to evaluate the mechanical properties of the damaged 
bone and the integration between implants and the defects. After 3 months, CSD 
implanted with TE bone grafts demonstrated improved mechanical properties, with a 
maximum torque before failure of 0.044±0.020 Nm and stiffness of 0.0039±0.0017 
Nm/degree; in contrast, control group with acellular scaffold implants, showed little 
stiffness while maximum torque cannot be measured as the defect did not achieve union 
(Figure 5-6). 
 
Figure 5-5 New bone formation volume analysis. After three months, TE bone grafts 
achieved significantly more new bone volume in defects than scaffolds alone, while this 
difference was not significant on 1 month (ns: not significant, *p<0.05). (Threshold =200) 
n=3 
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5.6 New vascularization 
Vascularization in the defect area, considered as one of the most critical processes 
during the bone defect healing, was investigated by micro CT analysis with perfusion of 
x-ray contrast agents (Microfil). At the one month time point, the TEBG group showed 
an increase of vascularization in the CSD with large number of capillaries branching 
Figure 5-6 Torsional testing of the damaged bone. TE bone grafts treated femurs (TEBG 
group) have significantly higher stiffness than acellular scaffolds treated ones (control group), 
and maximum torque in TEBG group was 0.044±0.020 Nm, while there was no observation 
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from larger vessels, and penetrating into the CSD; whereas, control group showed 
limited vascular infiltration into the defect area, especially the core region (Figure 5-7). 
Quantitative analysis demonstrated 2.2 fold more vascular volume (23.2±6.2 vs. 
10.6±4.4 mm3 per 550mm3 defect volume, p<0.05) in the TEBG group than control 




Figure 5-7 Micro CT analysis of vascularization in defect area. TE bone grafts induced 
neo-vascularization in the defect area, while the acellular scaffold resulted in limited vascular 
penetration into the defect area. (Threshold=190) 
TEBG group Control group 
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5.7 Histological analysis and immunohistochemistry 
Three months after transplantation, implants were retrieved for histological evaluation. 
In TEBG group, H&E staining showed a compact tissue formation around scaffolds, 
and the further analysis with Masson’s Trichrome and von Kossa staining demonstrated 
that this compact tissue was consisted of both immature and mature bone tissue. 
Immature bone tissue was stained with light blue color in Masson’s Trichrome staining, 
filling the available space within scaffolds. Calcified mature bone tissue interspersed 
among immature bone, as indicated by the black region in von Kossa staining (Figure 
5-9). In contrast, control group demonstrated a loose and little calcified tissue around 
the scaffolds (Figure 5-9).  
Figure 5-8 Vascular volume of defect area. Vascular volume analyzed from micro CT 
showed that TEBG group achieved significantly higher vascular volume than control group 
(* p<0.05).  
n=3 
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Chimerism of human cells in rat tissue was analyzed by immunohistochemistry method 
using human specific Lamin A/C antibody (red) with DAPI counterstaining (blue). It 
was found that the human cell in the TE grafts decrease dramatically within the first two 
weeks after implantation and cannot be detected by week 4. In addition, the cellular 
structure around the rods of scaffold grew rapidly with time, as indicated by the 
Figure 5-9 Histological analysis. H&E, Masson’s Trichrome and von Kossa staining showed 
that much more immature and mature bone were formed around the rods of the scaffolds in the 







Figure 5-10. Chimerism analysis of TE bone grafts after implantation. The immuno- 
histochemistry study using human specific Lamin A/C antibody (red) with DAPI 
counterstaining (blue) showed that after the implantation of TE grafts, the human cell in the 
TE grafts decrease dramatically within the first two weeks and cannot be detected since week 
4. In addition, the cellular structure around the rods of the scaffold became denser with time as 
indicated by increasing density of nuclei around the rods. (S: scaffold rods) 
S S 
S S 
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increasing density of nuclei around the rods from Day 4 to Week 8 (Figure 5-10). 
 
5.8 Discussion 
In this study, TE bone grafts, developed by the use of hfMSC, PCL-TCP bioactive 
scaffolds and bi-axial rotating bioreactor, demonstrated their effectiveness in the 
healing of critical sized bone defects in a rat model. Implantation of TE bone grafts lead 
to significantly more vascularization and new bone formation in the CSD and the 
successful bony union with significantly improved mechanical properties after three 
months, over the use of acellular scaffolds as a control. Histological evaluation showed 
that TEBG group resulted in denser tissues with larger amount of immature and mature 
bone formed around the scaffolds than in control group. However, hfMSC did not 
survive beyond 2 weeks of implantation in this xenogenic model.  
 
Bone, as a vascularized tissue, is highly reliant on the close spatial and temporal 
connection between vascular network and bone cells to maintain its normal metabolism, 
and because of the limited distance of effective diffusion, osteocytes are unable to 
survive if located more than 100 mm from nutrient vessels [Aronson, 1994; Yu, 2008]. 
Fracture healing is a highly complex process involving various factors. Among many 
known determinants, vascularization is a potential rate limiting factor and plays a 
critical role in promoting endochondral and intramembranous ossification, which 
determine the efficiency and consequence of new bone formation [Gerber, 2000; 
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Hausman, 2001; Yu, 2008]. Studies showed that the sufficient and rapid vascularization 
can enhance bone regeneration by speeding up the differentiation and/or maturation of 
infiltrating osteoblasts and osteoblast precursor cells during fracture healing [Murphy, 
2004; Kanczler, 2008; Yu, 2008; Yu, 2008]. In contrast, the failure to establish a 
sufficient vascular network lead to the cellular necrosis core in cellular bone grafts, 
limited new bone formation and delayed bone healing [Koefoed, 2005; Zhang, 2005]. 
In this study, rats from the TEBG group owned a significantly higher vasculature 
volume in the defect area than rats from control group, and this improved 
vascularization may explain the enhanced new bone formation and compact tissue 
formed around the rods of scaffolds inside the TE bone grafts (Figure 5-9). In control 
group, due to insufficient vasculature generation, new bone formation was restrained 
with only loose tissues formed inside the scaffolds (Figure 5-9).  
 
This angiogenic effect of TE bone grafts indicates that the cellular component in TE 
bone grafts, which is hfMSC, may have some inductive effect on the vascularization in 
the bone defect. This finding is consistent with recent reports on the angiogenic effect 
of MSC, and their emerging therapeutic applications in the treatment of heart failure 
and tissue ischaemia [Gnecchi, 2005; Ball, 2007; Ohnishi, 2007; Schuleri, 2007]. This 
angiogenic effect of MSC may be partially explained by their broad secretory spectrum 
of cytokines [Caplan, 2006; Parekkadan, 2007]. Phinney DG reported that using the 
technique of serial analysis of gene expression (SAGE), MSC were found to express 
mRNAs encoding a number of potent angiogenic factors as well as protein that regulate 
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endothelia cell motility, including Angio ‑ associated migratory cell protein, 
Angiopoietin 1&2, Endothelial cell growth factor 1, Placental growth factor, Vascular 
endothelial growth factor [Phinney, 2007]. Kinnaird et al. analyzed conditioned 
medium from cultured MSC and found that they express broad spectrum of arteriogenic 
cytokines including VEGF, basic fibroblast growth factor), PGF and Monocyte 
chemoattractant protein; moreover, this MSC conditioned medium can promote in vitro 
proliferation and migration of endothelial cells in a dose-dependent manner, and 
attenuated muscle atrophy in a murine hindlimb ischemia model [Kinnaird, 2004]. 
Asides from their paracrine effect on neo-vascularization, the direct MSC involvement 
and contribution to the formation of new blood vessels have been described[Annabi, 
2004; Silva, 2005; Ball, 2007], through trans-differentiating towards endothelial 
cells[Al-Khaldi, 2003; Oswald, 2004; Wu, 2005] and vascular smooth muscle 
lineages[Galmiche, 1993; Kinner, 2002]. However, in this study, the lost of hfMSC 2-4 
weeks after implantation indicates that the paracrine effect of hfMSC may play a major 
role in promoting vascularization.  
 
Vascularization, the critical determinant in bone regeneration, however is less studied 
in the context of tissue engineering due to the lack of a readily sensitive and 
quantifiable assay to measure vessel number, diameter and vascular network density 
within 3D constructs [Bolland, 2008]. Traditional approaches to measuring vessels, 
including the blood vessel casting followed by microscopy of section slices [Bentley, 
2002], and 2D qualitative studies using immunohistochemistry and in situ 
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hybridization [Lu, 2006], cannot provide a three dimensional assessment of vascular 
network [Guldberg, 2003]. In this study, a highly efficient technique combining 3D 
micro-CT imaging with a perfusable X-ray contrast agent (Microfil) was utilized to 
reconstruct the vascular network around the bone defect area and quantify the vascular 
volume at a high resolution of 15-30 µm [Bentley, 2002; Guldberg, 2003]. The 
utilization of this approach has been validated in a number of studies, including large 
vascular architecture evaluation in the urine brain [Heinzer, 2006], collateral vessel 
development in ischemic murine hindlimbs model [Duvall, 2004], myocardial micro 
circulation analysis [Malyar, 2004], tumor angiogenesis analysis [Kindlmann, 2005], 
vascularization associated with bone fracture healing [Lu, 2006], distraction 
osteogenesis [Moore, 2003] and segmental cortical bone graft transplantations [Zhang, 
2005; Rai, 2007; Bolland, 2008]. 
 
Aside their angiogenic effect to indirectly enhance the new bone formation, MSC, as 
the progenitors of osteoblast, osteocytes and bone lining cell, may also have the 
therapeutic potential to directly involved in the new bone formation through 
intramembranous ossification and endochondral ossification processes [Einhorn, 1998; 
Caplan, 2007]. This is confirmed by recent work by Tsuchida et al., showing that 
allogenic rat MSC can not only successfully heal the femoral defects, but also 
incorporated into the newly formed bone under the immunosuppression of FK506 
[Tsuchida, 2003]. Guillot et al. also reported that hfMSC participated in murine fracture 
healing through osteogenic differentiation and expressed human specific osteopontin 
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after intrauterine transplantation into osteogenesis imperfecta (OI) mice [Guillot, 2007]. 
Although there are quite a number of reports utilizing the human MSC based cellular 
scaffolds to successfully heal bone defects and demonstrate their advantages over the 
cell-free scaffolds, which is in consistence with this study, they did not monitor the 
survival situation of the human cells in such xenogenic environment, leaving the 
underlying mechanism unexplained [Bruder, 1998; Peterson, 2005; Meinel, 2006; 
Kirker-Head, 2007].  
 
In this study, the chimerism analysis was carried out using human specific antibody 
Lamin A/C to closely monitor the survival of hfMSC in vivo. Result showed that 
hfMSC can only survive for 2-4 weeks in this xenogenic environment. However, 
whether hfMSC participated in the new bone formation via direct cellular involvement 
remains an open question and requires further investigation using human specific 
antibodies against some bone markers, such as osteopontin. Similar result was reported 
by Jager M et al that human cord blood derived MSC demonstrated survive within the 
scaffolds for up to 4 weeks after xenotransplantation into athymic nude rats [Jager, 
2007]. Numerous work have reported that MSC possess unique immunologic 
properties: in vitro, they failed to elicit proliferation of allogeneic lymphocytes [Le 
Blanc, 2003; Rasmusson, 2003; Gotherstrom, 2007], and in vivo, transplantation of 
allogeneic mismatched MSC to adult animals has shown engraftment in murine and 
baboon experimental models [Bruder, 1998; Devine, 2003]. Xenogenic transplantation 
proves more challenging, especially given the huge species difference between the 
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human and rodents [Grinnemo, 2004]. Cyclosporin A was injected to SD rats 
throughout the entire study to prevent the potential immunorejection of xenogenic TE 
bone grafts, but the function of innate immune system might not be effectively 
suppressed [Lin, 1997; Isik, 2003]. In cellular transplantation paradigms, rapid cells 
death could be caused by the acute nonspecific immune inflammatory response after 
the surgery or by the cellular maladaption to the new environment, perhaps anoxia 
[Guerette, 1997; Guerette, 1997; Beauchamp, 1999]. Moreover, the gradual 
disappearance of hfMSC could be trigger by the capability of Natural Killer (NK) cells 
and macrophages to reject xenografts in the absence of T and B cell responses, as 
studies showed that NK cells can mediate direct cytotoxicity without the presence of 
xenoantibody and macrophages can be directly activated by xenoantigens from 
xenografts [Lin, 1997; Rolstad, 2001]. However, in order to understand the underlying 
mechanism for the disappearance of hfMSC, more studies are required to monitor 
immune responses including T cells, NK cells and macrophages infiltration to 
xenografts, especially in the first few days after transplantation.   
5.9 Conclusion 
The TE bone grafts developed in this project have demonstrated their potential for 
healing a critical sized (7 mm) defect in a rat model, leading to successful defect union, 
increased new bone regeneration, enhanced mechanical property and improved 
vascularization. However, further work is required to elucidate the mechanism of 
cellular demise after transplantation in this model. 
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Chapter 6 Conclusion and Recommendations 
6.1 Introduction 
Critical sized defects (CSD) remain a major challenge in orthopedic surgery, requiring 
implantation of effective bone grafts to achieve healing. However, current available 
bone grafts in the clinic cannot fulfill this increasing need, because of their drawbacks 
including the shortage of autografts, slow healing of allografts and incapability for 
remodeling of synthetic grafts. Bone tissue engineering (BTE) sets out to address the 
deficiency of effective bone grafts; but its further development has been beset by a 
couple of problems, including identifying suitable cellular sources and designing 
proper in vitro culture systems.  
 
6.2 Objective and Hypotheses 
The objective of this PhD thesis is to develop tissue engineered (TE) bone grafts as an 
effective treatment for CSD healing, with the hypotheses that: 
1. Human fetal bone marrow derived mesenchymal stem cell (hfMSC) are a highly 
proliferative and osteogenic cellular source for BTE application; 
2. The use of bi-axial rotating bioreactor for in vitro maturation of a TE bone graft 
will result in improved cellular proliferation, osteogenic differentiation and 
mineralization, and maintain cellular viability beyond the limits of conventional 
mass transfer.   
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3. Bioreactor matured hfMSC PCL-TCP scaffold constructs can successfully heal a 
critical sized defect in a rat femoral defect model. 
6.3 Findings 
6.3.1 hfMSC as the superior cellular candidate for BTE applications 
In the first part of this project, three types of MSC were isolated from human fetal bone 
marrow (hfMSC, n=5), human umbilical cord (hUCMSC, n=3) and human adult 
adipose tissue (hATMSC, n=3); and human adult bone marrow derived MSC (haMSC, 
n=3) were obtained from Tulane University Health Sciences Center (TUHSC) as a 
standard reference. These four types of MSC across different ontological and 
anatomical origins were fully characterized according to the criteria laid down by the 
International Society for Cellular Therapy [Dominici, 2006] (as previously described in 
Section 1.5.2). Then, they were systematically compared for BTE applications under 
different culture conditions in vitro (both monolayer and 3D scaffold culture) and by in 
vivo assessment of ectopic bone formation. In addition, comparison was conducted 
using multiple assays to corroborate the findings in gene, protein, cellular function and 
animal response level.  
 
Compared with other MSC, hfMSC have numerous advantages, which favor their 
applications for BTE. hfMSC express pluripotency markers such as Oct-4 and Nanog, 
which were absent in hATMSC and haMSC, and have lower immunogenicity indicated 
by the lower expression level of HLA-I compared to the other MSC types. Moreover, 
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hfMSC demonstrated greater proliferative capacity: in monolayer culture, hfMSC have 
the shortest population doubling time, and two fold higher clonogenicity than other 
MSC; while in 3D PCL-TCP scaffold culture, hfMSC proliferated the fastest and 
achieved cellular confluence within the scaffolds far earlier than for other MSC types. 
Under osteogenic induction, hfMSC exhibited the most robust osteogenesis in both 
monolayer and 3D scaffold culture, which was corroborated by multiple assays to 
examine the osteogenic induction (qPCR and ALP activity assay) and extracellular 
matrix deposition (von Kossa staining, calcium deposition assay, micro-CT 
quantification and SEM / EDX analysis). Finally, two months after subcutaneous 
implantation into NOD/SCID mice, hfMSC mediated scaffold constructs generated the 
largest amount of ectopic bone tissue than other MSC constructs, confirmed by micro 
CT analysis and histological method.  
 
6.3.2 Bi-axial rotating bioreactor as an advanced in vitro culture system 
In the second part of this project, a novel bi-axial rotating bioreactor with inbuilt 
perfusion system was exploited for generating TE bone grafts from hfMSC mediated 
PCL-TCP scaffold constructs. Compared with conventional static culture, this 
cutting-edged bi-axial rotating bioreactor demonstrated its great advantages: (1) It can 
promote significantly higher cellular proliferation in hfMSC scaffold constructs than 
static culture, with 2.5 fold more cellularity and achieving cellular confluence in 
scaffolds within a shorter period of time. (2) Bioreactor cultured constructs achieved 
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more homogenous distribution of cell and extracellular matrix (ECM), with complete 
saturation of cells and ECM, compared to static cultured constructs. (3) Bioreactor 
culture enhanced more robust osteogenic differentiation and mineralization than static 
culture, demonstrated by 1.5 fold higher ALP activity, 5.7 fold increase of calcium 
crystal deposition and the observation of ovoid shaped osteoblast differentiated from 
MSC. (4) Bioreactor was capable to maintain high degree of cellular viability in entire 
constructs throughout 28 days, including the inner cores of constructs (2,000 µm away 
from surface); while static culture resulted in large necrotic cores in constructs. (5) 
Three months after subcutaneous implantation in NOD/SCID mice, bioreactor cultured 
constructs possessed a significantly higher human cell chimerism rate in murine tissue 
than static cultured constructs as well as generated 3.2 fold more ectopic bone tissue .  
 
6.3.3 TE bone grafts to heal critical sized femoral defects in rat model  
Aside from demonstrating ectopic bone formation of those TE bone grafts (bioreactor 
matured hfMSC scaffolds) in NOD/SCID mice model, a rat femoral CSD model was 
utilized in the last part of this project for their functional assessment. This study 
demonstrated the potential use of these TE bone grafts as an effective treatment for 
CSD. One month after transplantation, TEBG group (rats implanted with TE bone 
grafts) had 2.2 fold higher increase of neo-vascularization around the defect area than 
those transplanted with acellular scaffolds in the control group, suggesting the potential 
angiogenic effect of TE bone grafts. Three months after implantation, TEBG group 
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achieved successful union of CSD, showing 2.1 fold significantly more new bone 
formation in the defect area than control group, as assessed by micro CT scanning and 
histological analysis; moreover, TEBG group restored the mechanical properties of 
damaged bones, with 10 fold increase of their stiffness, compared to control group. 
However, hfMSC chimerism decreased dramatically within 2 weeks and cannot be 
detected anymore from week 4, despite immunosuppression with Cyclosporin A.  
 
6.4 Limitations 
6.4.1 Limitations of Specific Aim # 1  
Safety is of paramount importance for any biomedical implantable products. 
Throughout this project, there was no tumor formation observed in these TE bone grafts, 
which have been implanted in the NOD/SCID mice subcutaneously or in the rat 
femoral defects. However, the potential tumorigenicity of these hfMSC based TE bone 
grafts should be further investigated. hfMSC may possess certain tumorigenicity effect , 
based on the following two findings about MSC: first, the prolonged in vitro culture of 
MSC could accumulate chromosomal abnormalities, leading to the cellular malignant 
transformation[Rubio, 2005; Miura, 2006; Tolar, 2007; Lazennec, 2008]; second, MSC 
have the immunomodulatory effect, with the possibility to suppress host immune 
system and promote tumor formation [Bartholomew, 2002; Djouad, 2003; Krampera, 
2003; Maitra, 2004; Beyth, 2005]. Due to the limited time and funding, this 
tumorigenicity effect of hfMSC was not systematically studied in this project. 
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Therefore, further investigations are required to ensure the safety of their utilization in 
the clinic. 
 
During the head-to-head comparison, the MSC used in this study were heterogenous, 
and consist of different subpopulations with variable cellular characteristics, as 
previously described in Section 1.5.2.1. The present study may offer more clinical 
relevant information, compared to a study using homogenous MSC through clonal 
cultures, because the utilization of clonal cultures in the clinic will be limited by the 
cost and technical difficulties involved. However, from a biological point of view, the 
clonal analysis will be beneficial, providing valuable information about the 
subpopulation composition of MSC and being able to identify super subpopulations 
from hfMSC with the highest proliferative and osteogenic capacities. Thus, further 
comparative analysis to study the different subpopulations within the same MSC and 
among various types of MSC would shed more light into the biological questions 
relating to stem cell heterogeneity.  
 
The 3D scaffolds used in this project were made of PCL-TCP composite material. 
β-TCP was added to PCL material to increase the bioactivity of scaffolds and promote 
cellular adhesion and osteogenic function, because β-TCP was known as a bioceramic 
material for its high osteoconductivity and osteoinductivity [LeGeros, 2002; Kokubo, 
2003]. However, during the FDM fabrication, PCL pellets and TCP granules are 
physically blended before being extruded out of a nozzle to lay down into scaffolds (as 
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previously described in Section 1.4.4.4); and large amount of TCP granules are 
encapsulated inside the fibers of scaffolds, with their functional groups being hidden 
from the surface. Thus, the bioactivity of scaffolds is greatly reduced. This problem was 
not addressed in this project and required further research work to modify current 
fabrication techniques in order to expose more TCP to the surface of scaffolds. This 
may in turn lead to improved osteogenic differentiation induction by the scaffold alone. 
 
6.4.2 Limitations of Specific Aim # 2 
In the second part of this project, bi-axial rotating bioreactor was compared to the 
conventional static culture and demonstrated its capability to promote cellular 
proliferation and osteogenic differentiation as well as maintain cellular viability. As 
previously described in Section 1.6.3, this bioreactor was designed based on the 
improvement of common bioreactors (spinner flasks, miniPERM and uni-axial rotating 
RWV bioreactors), and demonstrated improved fluid transport and homogenous fluid 
flow in computer simulations [Singh, 2005]. However, actual cell based 
experimentation is required to test this hypothesis in vitro and in vivo. Due to the 
limitation of time and funding, this project only conducted the comparative study 
between this bioreactor and conventional static culture. A direct comparison of this 
bioreactor with other commercially available bioreactors would yield important 
information on its performance, and test the prevailing assumption that this design 
would yield significant improvements for BTE applications. 
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6.4.3 Limitations of Specific Aim # 3 
In the last part of this project, a rat femoral CSD model was utilized to test the defect 
healing efficacy of TE bone grafts, with the results of improved neo-vascularization 
and new bone regeneration. However, hfMSC only survived for 2-4 weeks in vivo, 
leading to two open questions: (i) whether hfMSC have participated in the new bone 
formation through differentiation into osteoblasts or osteocytes? (ii) What is the reason 
for the loss of hfMSC shortly after transplantation? This may be due to acute cellular 
necrosis, or an acute inflammatory reaction to cellular transplantation, or the failure of 
cyclosporine immunosuppression to suppress cytotoxic mediated xenograft rejection. 
Understanding the mechanisms for rejection or necrosis may lead to clinically relevant 
strategies being developed. Finally, the mechanisms by which hfMSC improves on 
neo-vasculogenesis may shed light into how one can improve on vascularization of 
large tissue engineered grafts, of relevance not only to the area of BTE, but to other 
fields of tissue engineering. 
 
6.5 Implications of this work 
In this thesis, hfMSC has been identified as the most advantageous allogeneic cellular 
source for BTE applications through its superior proliferation and osteogenic 
differentiation capacity both in vitro and in vivo. This should lead to a relook at the 
cell types being currently explored in this field.  
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The use of a bi-axial rotating bioreactor designed to circumvent the problems relating 
to current bioreactor design has led to the generation of a highly osteogenic TE bone 
grafts through homogenous efficient cellular seeding, rapid cellular proliferation and 
osteogenic differentiaton of hfMSC. In particular, the ability to maintain cellular 
viability with ten fold increase in the efficiency of mass transfer is possibly the best 
result ever achieved for TB bone grafts, and should allow grafts of significant sizes to 
be generated which would be suitable for clinical transplantation. However, a direct 
comparison of the bi-axial rotating bioreactor with other more established bioreactors 
is required to test the premise that the improved design will lead to advantages for 
BTE applications.  
 
Finally, the use of biaxial rotating bioreactor matured hfMSC scaffolds here have 
successfully healed a rat femoral CSD with significantly better functional outcome 
than acellualr scaffolds. In addition, improved neovascularisation of the the TE bone 
grafts over accelular scaffolds was accompanied by larger amounts of woven and 
compact bone formed. This neo-vascularisation has important implications for the use 
of larger voluminous grafts. Such a graft should now be tested in a larger animal 
model. In addition, other ways to improve on vasculogenesis may need to be explored 
in tandem with the use of hfMSC as a cellular source. 
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6.6 Recommendations for future work 
In this project, TE bone grafts have been generated in vitro through the combinational 
use of hfMSC, PCL-TCP scaffolds and bi-axial rotating bioreactor and showed their 
bone formation capacity and defect healing efficacy in two animal models. In order to 
eventually bring these TE bone grafts from bench side to bedside in the near future, 
further investigations are required.   
6.6.1 Future work with hfMSC 
6.6.1.1 Chromosomal instability and in vitro hyperoxia culture 
The long term in vitro culture of human adult MSC and murine MSC can cause 
chromosomal instability and lead to the malignant transformation of MSC [Rubio, 
2005; Miura, 2006; Tolar, 2007; Lazennec, 2008]. This phenomenon could happen to 
hfMSC as well. Long term in vitro culture of hfMSC is required to continuously 
evaluate the integrity and stability of chromosome by karyotyping technique; and the 
cellular malignant transformation of hfMSC can be closely monitored by in vivo 
implantation into immunocompromised mice. The objective of this study to find out the 
safe in vitro expansion period, within which there are absolutely zero risk for cellular 
malignant transformation, serving as a beneficial guideline for future clinical 
applications of hfMSC.  
 
Furthermore, the in vitro culture condition for cellular expansion should be improved 
and optimized, especially the oxygen tension during in vitro culture. It is well known 
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that the oxygen level in the nature niche of MSC was lower than 7% [Grayson, 2006; 
Malda, 2007]; however, current culture condition uses as high as 20% oxygen for 
cellular expansion, which may cause and accumulate the oxidative damage to hfMSC, 
and eventually lead to the chromosomal instability and malignant transformation of 
hfMSC. Therefore, the optimal oxygen tension for in vitro culture of hfMSC should be 
found.  
 
6.6.1.2 Immunomodulatory effect of MSC 
On the other hand, the strong immunomodulatory effect of MSC is well reported both 
in vitro and in vivo, as previously describe in Section 1.5.2.2. They can inhibit T-cell 
alloreactivity and possess immunosuppressive effects, leaving their clinical 
applications under a high risk of tumorigenicity. More recently, this 
immunomodulatory effect has been reported in hfMSC, as well [Gotherstrom, 2003; 
Gotherstrom, 2004]. As a result, when using hfMSC in the clinical applications, their 
immunomodulatory effect should be noticed at all times. More research work should be 
performed to obtain more fundamental knowledge about their immunomodulatory 
effect, explore the underlying mechanism, and control this immunomodulatory effect in 
a desired way to eliminate their tumor-promoting potential.  
 
6.6.1.3 Clonal analysis of MSC 
In order to understand the variable characteristics of different cellular subpopulations in 
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MSC, clonal analysis is recommended for further investigation. The homogenous 
subpopulations in various MSC types can be separated using the clonal cultures. Then, 
individual subpopulations can be characterized and systematically compared for their 
proliferative capacities and osteogenic potentials in vitro and in vivo, as what has been 
done in this project.  
 
6.6.2 Future work with scaffold fabrication technology 
In order to increase the bioactivity of PCL-TCP scaffolds, the exposure of TCP to the 
surface of scaffolds should be enlarged. The possible approach is to introduce a layer of 
TCP coating to the surface of scaffold fibers.  
 
Chemical method can be exploited to link TCP to the surface of scaffolds; for instance, 
some chemical linkage groups can be introduced to the scaffolds surface and bound to 
TCP through chemical reaction. But the drawbacks of this method include the 
difficulties in homogenous TCP coating and the control of coating thickness, due to 3D 
structure of scaffolds. Moreover, chemical reaction will possibly raise contamination 




                                        Chapter 6 Conclusion and Recommendations 
____________________________________________________________________________________________ 
- 221 - 
 
On the other hand, physical approach can be pursued as well. For example, with certain 
heating treatments (such as microwave heating), scaffold surface can be melted slightly, 
and TCP granules can be coated to this half-melt surface. The utilization of physical 
methods can avoid the chemical contamination of scaffolds. The author’s pilot study 
showed a successful coating of TCP onto the struts of PCL scaffold with improved 
cellular adhesion (Figure 6-1, a collaborative work with Dr. Han Ming Yong from 
Figure 6-1 SEM images of TCP coating on PCL scaffold. (A) (B) microwave heat treated 
PCL scaffolds before TCP coating; (C) (D) PCL scaffolds after TCP coating; (E) EDX analysis 
of (D). (A collaborative work with Dr. Han Ming Yong from IMRE) 
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Institute of Materials Research and Engineering). However, the same problems 
remained in this study including the non-homogenous coating and difficulty to control 
coating thickness in 3D structure. What is more, this heating process of scaffold 
compromised the structure and mechanical properties of scaffolds. This TCP coating 
method should be further optimized in future.  
 
6.6.3 Future work with bi-axial rotating bioreactor 
6.6.3.1 Comparison of bi-axial rotating bioreactor to other types of bioreactors 
It is still unknown whether this bi-axial rotating bioreactor can perform better than 
other common bioreactors regarding cellular proliferation, osteogenic differentiation 
and mineralization. Further research work is required to systematically compare this 
bi-axial rotating bioreactor with these common bioreactors for their effect in inducing 
proliferation, osteogenic differentiation and mineralization, and the in vivo 
performance of cultured cellular scaffold constructs, as the comparative work 
conducted in present study. This may reveal more features about this novel bi-axial 
rotating bioreactor and its clinical potential applications. 
 
6.6.3.2 Explore the culture limitation of this bioreactor 
In this project, the biggest cellular constructs cultured in this bi-axial bioreactor are the 
TE bone grafts for rat defect healing, which are the cylinder shaped with a volume of 
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157 mm3. Further study can be done to explore the culture limitation of this bioreactor, 
and find out what is the maximal size of cellular constructs that can be cultured in this 
bi-axial bioreactor without occurring large cellular necrosis. The influence of scaffold’s 
shape and size on cellular proliferation, differentiation and viability maintenance can be 
investigated as well. This will provide the valuable information for the clinical 
utilization of this bi-axial rotating bioreactor.  
 
6.6.4 Future work with animal model 
6.6.4.1 Two remaining questions in present rat experiment 
In the present rat model experiment, hfMSC failed to survive more than 4 weeks, 
leaving a question open, which is whether human cells directly incorporated into the 
newly formed bone tissues. In order to address this question, one possible approach is 
to conduct immunohistochemistry analysis using human specific antibody against 
some well known bone markers, such as osteopontin. This method has proved its utility 
by Guillot el al., who reported the utilization of human specific osteopontin staining to 
detect human cells involving in murine bone tissue formation after intrauterine 
transplantation of hfMSC [Guillot, 2007]. 
 
Another unanswered question is “what is the possible cause for this rapid 
disappearance of hfMSC after transplantation”. The rapid cell death in the cellular 
transplantation paradigms can be explained by the acute inflammatory response to 
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xenografts or by the cellular maladaption to the xenogenic environment (for instance, 
anoxia) [Guerette, 1997; Guerette, 1997; Beauchamp, 1999]. This cellular 
disappearance can also be caused by the acquired immune response with insufficient 
immunosuppression. In order to clarify the underlying mechanism, research can be 
carried out to detect the existence of T cells, B cells, NK cells and macrophages around 
the defect area, using some specific antibodies, such as CD 8 and CD 68. 
 
6.6.4.2 Allogenic animal model instead of xenogenic model 
As the progenitors for osteoblasts, osteocytes and bone lining cells, MSC play an 
important role in the bone fracture healing via intramembranous ossification and 
endochondral ossification (please refer to Section 1.2.4.2). It will greatly benefit the 
future clinical applications to study and monitor the long term behaviors of MSC in 
host bone tissue following TE bone grafts transplantation. However, this long term 
study becomes very difficult to achieve in a xenogenic model, because of the xenogenic 
barrier; alternatively this could be performed in an allogenic model. For example, fetal 
MSC can be isolated from rat fetal bone marrow and utilized as the counterpart of 
human fetal MSC for the study.  
 
6.6.4.3 Large animal model with long term study 
The present rat femoral defect model would provide good evidence of the defect 
healing efficacy of those TE bone grafts generated in this project. The next step will be 
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to evaluate those TE bone grafts in a larger animal model, such as swine or sheep 
femoral defect model. Large animal models will provide much more instrumental 
experimental data than small animal work for the future clinical trials. Long term 
implantation design is also required in order to understand the in vivo degradation 
period of scaffolds, the survival time of MSC, the migration pattern of MSC and any 
long term side effect of those TE bone grafts. Another important issue during the bone 
defect healing is the long term bone remodeling after the successful union of defects, 
the last phase during the typical three-phase process of fracture healing (please refer to 
Section 1.2.4). This issue remains less investigated but worthy for the long term 
investigation in the future.  
 
6.6.5 Rapid vascularization after the implantation of TE bone grafts 
Vascularization still remains one of the major obstacles for BTE applications. The 
speed of vascularization after the grafts implantation has significant influence on the 
survival of TE bone grafts and their successful clinical outcome. After harvested from 
bioreactor and implanted into bone defects, TE bone grafts with high cellular density 
and mineralized ECM will be deprived of the dynamic culture condition; in contrast, in 
vivo, all the nutrient and gas exchange process will occur solely through passive 
diffusion, with a short effective distance of 100-200 µm [Carmeliet, 2000]. In order to 
continue to maintain the viability and functionality of the TE bone grafts after 
implantation, rapid vascularization surrounding and infiltrating the grafts become a 
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determinant factor for successful defect healing. After implantation of TE bone grafts, a 
spontaneous vascularization of the implant can be expected, however, this spontaneous 
process is often too slow to provide adequate nutrient transport to the cells in the 
interior of the TE bone grafts. Therefore, alternative strategies to enhance rapid 
vascularization are required to ensure the survival and excellent clinical outcome of 
large TE bone grafts. There are three strategies for exploitation in the future.  
 
6.6.5.1 Co-delivery of angiogenic growth factors 
The first strategy is to co-deliver the angiogenic growth factor, such as vascular 
endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF),  
platelet-derived growth factor (PDGF) and angiopoietin 1 (Ang1) in TE bone grafts. 
These are well known angiogenic growth factors, enhancing the vascularization in vivo. 
However, the difficulty of this method lies upon the control of the effective dosage of 
growth factors, because studies showed that overdose of these angiogenic factors may 
lead to vascular disorganized, leakage and hypotension [Zisch, 2003; Jain, 2005]. 
Moreover, maturation of blood vessels requires several angiogenic growth factors to 
work together other than one single growth factor, which increased the complexity of 
delivery process [Rouwkema, 2008]. Other obstacles include the short half-life and 
high cost of growth factors.  
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6.6.5.2 In vivo prevascularization 
The second strategy is the “in vivo prevascularization” or also referred to as “tissue 
prefabrication”, involving two surgical stages. In the initial stage, a TE bone graft can 
be implanted into a region with an artery (or vascular axis) suitable for microsurgical 
transfer, by either wrapped in an axially vascularized tissue, such as muscle, or by 
surgically introduce an artery into the graft. This stage will last for a few weeks for the 
formation of sufficient microvascular network in the graft and then followed by 
harvesting this TE bone graft with the microvascular network and supplying artery. At 
the final stages, this prevascularized TE bone graft will be implanted into the defect site 
and the vascular axis will be connected to the local vasculature using microsurgical 
vascular-anastomosis techniques, which results in instantaneous perfusion of the entire 
construct [Kneser, 2006; Kneser, 2006]. This strategy can achieve the immediate 
perfusion of TE bone grafts by surgical anastomosis. However, drawbacks are obvious, 
two surgical procedures will bring extra pain and cost, and the harvesting process will 
affect the normal tissue growth in the initial implant site [Rouwkema, 2008].  
 
6.6.5.3 In vitro prevascularization 
The last strategy is the “in vitro prevascularization”. Endothelia Cells (EC) or 
Endothelia Progenitor Cells (EPC) can be added into TE bone grafts and cultured in 
certain conditions to form prevascular network in vitro. After implantation, this 
prevascular network can then anastomose spontaneously to the ingrowing vasculature 
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of the host and supply the grafts with nutrients. Although this approach cannot provide 
perfusion to grafts as fast as the second strategy, it can greatly reduced the time for fully 
vascularization from weeks to days, because the host blood vessels do not need to grow 
into the entire construct, but only into the outer regions of the construct until the 
prevascular structures are reached [Rouwkema, 2008]. Tremblay et al. reported that the 
prevascularized skin grafts could anastomose to the host vascular system within four 
days, whereas non-prevascularized grafts took 14 days [Tremblay, 2005]. Levenberg et 
al. reported that in vitro prevascularization of a skeletal muscle graft significantly 
enhanced graft vascularization, perfusion and survival after implantation [Levenberg, 
2005]. There are already a few reports about the in vitro prevascularization with EC or 
EPCs can induce vascularization and enhance osteogenesis of TE bone grafts 
[Rouwkema, 2006; Yu, 2008; Yu, 2008].  
 
Furthermore, some preliminary study to co-culture the hfMSC and human umbilical 
Figure 6-2 Co-culture of hfMSC and hUVEC after 7 days’ monolayer culture. hUVEC 
demonstrated some special inductive effect on hfMSC to promote earlier osteogenic 
differentiation and mineralization, and the effect was associated with mixing ratios of two 
types of cells and the mineralization maximized with 1:5 mixing of hUVEC: MSC.  
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vein endothelial cells (hUVEC) was performed at the end of this project. Interestingly, 
result showed that, co-culture with hUVEC lead to significantly more osteogenic 
differentiation and mineralization of hfMSC after 7 days culture based on the intensity 
of von Kossa staining, and this inductive effect was associated with the mixing ratios of 
these two types of cells (Figure 6-2). However, after 14 days culture, there was no 
significant difference among these different study groups (data were not shown).  This 
phenomenon unveils that there are some special inductive effects of hUVEC on hfMSC, 
which can accelerate the osteogenic differentiation and mineralization. This is now the 
subject of study for another graduate student in the group. 
 
Therefore, the strategy of “in vitro prevascularization” seems to be a promising 
approach for the rapid vascularization, as it does not require extra surgical procedure 
and waiting time but can greatly shorten the time for fully vascularization. Further work 
is required to exploit the optimal co-culture condition in vitro, which can promote the 
prevascular network formation of EC or EPC and at the same time do not affect the 
osteogenic differentiation of hfMSC. Moreover, the optimal mixing ratio of EC (or 
ECP) and hfMSC has yet to be defined. Lastly, this special inductive effect of EC or 
EPC, unveiled in this study, can be further investigated, which may have certain 
potential use for the rapid maturation of TE bone grafts and shorten in vitro culture 
period.  
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6.7 Conclusion 
The current clinical treatment of large bone defects is harassed by the shortage of 
autografts and limited healing efficacy of allografts and synthetic grafts. This PhD 
project aimed to generate effective TE bone grafts to fulfill this increasing unmet 
clinical need. This objective has been achieved through the accomplishment of three 
well-defined specific aims step by step. Firstly, human fetal MSC (hfMSC) were 
isolated, characterized, compared to MSC from other origins and demonstrated as a 
superior cellular candidate for BTE applications, with low immunogenicity, high 
proliferation and robust osteogenic potential both in vitro and in vivo (Specific Aim #1, 
Chapter 3). Secondly, a novel bi-axial rotating bioreactor was exploited and 
demonstrated its efficacy in culturing and maturing hfMSC mediated PCL-TCP 
scaffold constructs into TE bone grafts by promoting cellular proliferation and 
osteogenic differentiation, as well as maintaining cellular viability (Specific Aim #2, 
Chapter 4). Finally, the TE bone grafts generated in this project were assessed in a rat 
critical sized femoral defect model and showed their efficacy to promote 
vascularization, achieve successful defect healing and improve mechanical properties 
of damaged bone (Specific Aim # 3, Chapter 5). In this way, this project generated 
hfMSC based TE bone grafts with great potential for future clinical applications.  
 
  References 
____________________________________________________________________________________________ 
- 231 - 
 
References 
Abbott, A. (2003). "Cell culture: biology's new dimension." Nature 424 (6951): 
870-2. 
Aggarwal, S. and M. F. Pittenger (2005). "Human mesenchymal stem cells modulate 
allogeneic immune cell responses." Blood 105 (4): 1815-22. 
Agrawal, C. M. and R. B. Ray (2001). "Biodegradable polymeric scaffolds for 
musculoskeletal tissue engineering." J Biomed Mater Res 55 (2): 141-50. 
Albrektsson, T. and C. Johansson (2001). "Osteoinduction, osteoconduction and 
osseointegration." Eur Spine J 10 Suppl 2 : S96-101. 
Al-Khaldi, A. and N. Eliopoulos, et al. (2003). "Postnatal bone marrow stromal cells 
elicit a potent VEGF-dependent neoangiogenic  response in vivo." Gene Ther 10 
(8): 621-9. 
Almeida-Porada, G. and S. D. El, et al. (2002). "Differentiative potential of human 
metanephric mesenchymal cells." Exp Hematol 30 (12): 1454-62. 
Andrew, J. G. and S. M. Andrew, et al. (1994). "Inflammatory cells in normal human 
fracture healing." Acta Orthop Scand 65 (4): 462-6. 
Annabi, B. and E. Naud, et al. (2004). "Vascular progenitors derived from murine 
bone marrow stromal cells are regulated  by fibroblast growth factor and are avidly 
recruited by vascularizing tumors." J Cell Biochem 91 (6): 1146-58. 
Aronson, J. (1994). "Temporal and spatial increases in blood flow during distraction 
osteogenesis." Clin Orthop Relat Res(301): 124-31. 
Atmani, H. and D. Chappard, et al. (2003). "Proliferation and differentiation of 
osteoblasts and adipocytes in rat bone marrow stromal cell cultures: effects of 
dexamethasone and calcitriol." J Cell Biochem 89 (2): 364-72. 
Aubin, J. E. (1998). "Bone stem cells." J Cell Biochem Suppl 30-31 : 73-82. 
Aubin, J. E. (2001). "Regulation of osteoblast formation and function." Rev Endocr 
Metab Disord 2 (1): 81-94. 
Baddoo, M. and K. Hill, et al. (2003). "Characterization of mesenchymal stem cells 
isolated from murine bone marrow by negative selection." J Cell Biochem 89 (6): 
1235-49. 
Baksh, D. and R. Yao, et al. (2007). "Comparison of proliferative and multilineage 
differentiation potential of human mesenchymal stem cells derived from umbilical 
cord and bone marrow." Stem Cells 25 (6): 1384-92. 
  References 
____________________________________________________________________________________________ 
- 232 - 
Ball, S. G. and C. A. Shuttleworth, et al. (2007). "Mesenchymal stem cells and 
neovascularization: role of platelet-derived growth factor receptors." J Cell Mol 
Med 11 (5): 1012-30. 
Banas, A. and T. Teratani, et al. (2007). "Adipose tissue-derived mesenchymal stem 
cells as a source of human hepatocytes." Hepatology 46 (1): 219-28. 
Bancroft, G. N. and V. I. Sikavitsas, et al. (2003). "Design of a flow perfusion 
bioreactor system for bone tissue-engineering applications." Tissue Eng 9 (3): 
549-54. 
Bancroft, G. N. and V. I. Sikavitsas, et al. (2002). "Fluid flow increases mineralized 
matrix deposition in 3D perfusion culture of marrow stromal osteoblasts in a 
dose-dependent manner." Proc Natl Acad Sci U S A 99 (20): 12600-5. 
Banfi, A. and A. Muraglia, et al. (2000). "Proliferation kinetics and differentiation 
potential of ex vivo expanded human bone marrow stromal cells: Implications for 
their use in cell therapy." Exp Hematol 28 (6): 707-15. 
Banwart, J. C. and M. A. Asher, et al. (1995). "Iliac crest bone graft harvest donor site 
morbidity. A statistical evaluation." Spine 20 (9): 1055-60. 
Barry, F. P. and R. E. Boynton, et al. (1999). "The monoclonal antibody SH-2, raised 
against human mesenchymal stem cells, recognizes an epitope on endoglin 
(CD105)." Biochem Biophys Res Commun 265 (1): 134-9. 
Barry, F. and R. Boynton, et al. (2001). "The SH-3 and SH-4 antibodies recognize 
distinct epitopes on CD73 from human mesenchymal stem cells." Biochem Biophys 
Res Commun 289 (2): 519-24. 
Bartholomew, A. and C. Sturgeon, et al. (2002). "Mesenchymal stem cells suppress 
lymphocyte proliferation in vitro and prolong skin graft survival in vivo." Exp 
Hematol 30 (1): 42-8. 
Beauchamp, J. R. and J. E. Morgan, et al. (1999). "Dynamics of myoblast 
transplantation reveal a discrete minority of precursors with stem cell-like 
properties as the myogenic source." J Cell Biol 144 (6): 1113-22. 
Bellows, C. G. and Y. H. Wang, et al. (1994). "1,25-dihydroxyvitamin D3 stimulates 
adipocyte differentiation in cultures of fetal rat calvaria cells: comparison with the 
effects of dexamethasone." Endocrinology 134 (5): 2221-9. 
Bensaid, W. and K. Oudina, et al. (2005). "De novo reconstruction of functional bone 
by tissue engineering in the metatarsal sheep model." Tissue Eng 11 (5-6): 814-24. 
Bentley, M. D. and M. C. Ortiz, et al. (2002). "The use of microcomputed 
tomography to study microvasculature in small rodents." Am J Physiol Regul Integr 
Comp Physiol 282 (5): R1267-79. 
Beyth, S. and Z. Borovsky, et al. (2005). "Human mesenchymal stem cells alter 
antigen-presenting cell maturation and induce  T-cell unresponsiveness." Blood 
  References 
____________________________________________________________________________________________ 
- 233 - 
105 (5): 2214-9. 
Bieback, K. and S. Kern, et al. (2004). "Critical parameters for the isolation of 
mesenchymal stem cells from umbilical cord blood." Stem Cells 22 (4): 625-34. 
Bielby, R. and E. Jones, et al. (2007). "The role of mesenchymal stem cells in 
maintenance and repair of bone." Injury 38 Suppl 1 : S26-32. 
Billotte, W. G. and M. C. Hofmann (1999). "Establishment of a shear stress protocol 
to study the mechanosensitivity of human primary osteogenic cells in vitro." 
Biomed Sci Instrum 35 : 327-32. 
Bilodeau, K. and D. Mantovani (2006). "Bioreactors for tissue engineering: focus on 
mechanical constraints. A comparative review." Tissue Eng 12 (8): 2367-83. 
Blaker, J. J. and J. E. Gough, et al. (2003). "In vitro evaluation of novel bioactive 
composites based on Bioglass-filled polylactide foams for bone tissue engineering 
scaffolds." J Biomed Mater Res A 67 (4): 1401-11. 
Bolander, M. E. (1992). "Regulation of fracture repair by growth factors." Proc Soc 
Exp Biol Med 200 (2): 165-70. 
Bolander, M. E. (1992). "Regulation of fracture repair by growth factors." Proc Soc 
Exp Biol Med 200 (2): 165-70. 
Bolland, B. J. and J. M. Kanczler, et al. (2008). "Development of in vivo muCT 
evaluation of neovascularisation in tissue engineered bone constructs." Bone. 
Bongso, A. (2005). Stem cells : from bench to bedside, New Jersey : World Scientific. 
Boyan, B. D. and T. W. Hummert, et al. (1996). "Role of material surfaces in 
regulating bone and cartilage cell response." Biomaterials 17 (2): 137-46. 
Bruder, S. P. and B. S. Fox (1999). "Tissue engineering of bone. Cell based 
strategies." Clin Orthop Relat Res(367 Suppl): S68-83. 
Bruder, S. P. and N. Jaiswal, et al. (1997). "Growth kinetics, self-renewal, and the 
osteogenic potential of purified human mesenchymal stem cells during extensive 
subcultivation and following cryopreservation." J Cell Biochem 64 (2): 278-94. 
Bruder, S. P. and N. Jaiswal, et al. (1997). "Growth kinetics, self-renewal, and the 
osteogenic potential of purified human mesenchymal stem cells during extensive 
subcultivation and following cryopreservation." J Cell Biochem 64 (2): 278-94. 
Bruder, S. P. and K. H. Kraus, et al. (1998). "The effect of implants loaded with 
autologous mesenchymal stem cells on the healing of canine segmental bone 
defects." J Bone Joint Surg Am 80 (7): 985-96. 
Bruder, S. P. and A. A. Kurth, et al. (1998). "Bone regeneration by implantation of 
purified, culture-expanded human mesenchymal stem cells." J Orthop Res 16 (2): 
155-62. 
  References 
____________________________________________________________________________________________ 
- 234 - 
Bruder, S. P. and A. A. Kurth, et al. (1998). "Bone regeneration by implantation of 
purified, culture-expanded human mesenchymal stem cells." J Orthop Res 16 (2): 
155-62. 
Bruinink, A. and D. Siragusano, et al. (2001). "The stiffness of bone marrow cell-knit 
composites is increased during mechanical load." Biomaterials 22 (23): 3169-78. 
Buckwalter, J. A. and M. J. Glimcher, et al. (1996). "Bone biology. I: Structure, blood 
supply, cells, matrix, and mineralization." Instr Course Lect 45 : 371-86. 
Buckwalter, J. A. and M. J. Glimcher, et al. (1996). "Bone biology. II: Formation, 
form, modeling, remodeling, and regulation of cell function." Instr Course Lect 45 : 
387-99. 
Burg, K. J. and S. Porter, et al. (2000). "Biomaterial developments for bone tissue 
engineering." Biomaterials 21 (23): 2347-59. 
Butler, D. L. and S. A. Goldstein, et al. (2000). "Functional tissue engineering: the 
role of biomechanics." J Biomech Eng 122 (6): 570-5. 
Campagnoli, C. and I. A. Roberts, et al. (2001). "Identification of mesenchymal 
stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow." 
Blood 98 (8): 2396-402. 
Campagnoli, C. and I. A. Roberts, et al. (2001). "Identification of mesenchymal 
stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow." 
Blood 98 (8): 2396-402. 
Cancedda, R. and M. Mastrogiacomo, et al. (2003). "Bone marrow stromal cells and 
their use in regenerating bone." Novartis Found Symp 249 : 133-43; discussion 
143-7, 170-4, 239-41. 
Caplan, A. I. (1991). "Mesenchymal stem cells." J Orthop Res 9 (5): 641-50. 
Caplan, A. I. (2005). "Review: mesenchymal stem cells: cell-based reconstructive 
therapy in orthopedics." Tissue Eng 11 (7-8): 1198-211. 
Caplan, A. I. (2007). "Adult mesenchymal stem cells for tissue engineering versus 
regenerative medicine." J Cell Physiol 213 (2): 341-7. 
Caplan, A. I. and J. E. Dennis (2006). "Mesenchymal stem cells as trophic mediators." 
J Cell Biochem 98 (5): 1076-84. 
Carmeliet, P. and R. K. Jain (2000). "Angiogenesis in cancer and other diseases." 
Nature 407 (6801): 249-57. 
Carrier, R. L. and M. Papadaki, et al. (1999). "Cardiac tissue engineering: cell seeding, 
cultivation parameters, and tissue construct characterization." Biotechnol Bioeng 64 
(5): 580-9. 
Chan, J. and N. M. O' Donoghue K; de, Fuente J; Roberts, I A; Kumar, S; Morgan, J 
E; Fisk (2005). "Human fetal mesenchymal stem cells as vehicles for gene 
  References 
____________________________________________________________________________________________ 
- 235 - 
delivery." Stem Cells 23 (1): 93-102. 
Chan, J. and N. M. O' Donoghue K; Gavina, M; Torrente, Y; Kennea, N; Mehmet, H; 
Stewart, H; Watt, D J; Morgan, J E; Fisk (2006). "Galectin-1 induces skeletal 
muscle differentiation in human fetal mesenchymal stem cells and increases muscle 
regeneration." Stem Cells 24 (8): 1879-91. 
Chan, J. and S. N. Waddington, et al. (2007). "Widespread distribution and muscle 
differentiation of human fetal mesenchymal stem cells after intrauterine 
transplantation in dystrophic mdx mouse." Stem Cells 25 (4): 875-84. 
Chen, H. C. and Y. C. Hu (2006). "Bioreactors for tissue engineering." Biotechnol 
Lett 28 (18): 1415-23. 
Ciapetti, G. and L. Ambrosio, et al. (2003). "Osteoblast growth and function in porous 
poly epsilon -caprolactone matrices for bone repair: a preliminary study." 
Biomaterials 24 (21): 3815-24. 
Clarkson, E. D. (2001). "Fetal tissue transplantation for patients with Parkinson's 
disease: a database of published clinical results." Drugs Aging 18 (10): 773-85. 
Colter, D. C. and R. Class, et al. (2000). "Rapid expansion of recycling stem cells in 
cultures of plastic-adherent cells from human bone marrow." Proc Natl Acad Sci U 
S A 97 (7): 3213-8. 
Colter, D. C. and I. Sekiya, et al. (2001). "Identification of a subpopulation of rapidly 
self-renewing and multipotential adult stem cells in colonies of human marrow 
stromal cells." Proc Natl Acad Sci U S A 98 (14): 7841-5. 
Connolly, J. F. and R. Guse, et al. (1989). "Autologous marrow injection for delayed 
unions of the tibia: a preliminary report." J Orthop Trauma 3 (4): 276-82. 
Connolly, J. F. and R. Guse, et al. (1991). "Autologous marrow injection as a 
substitute for operative grafting of tibial nonunions." Clin Orthop Relat Res(266): 
259-70. 
Coombes, A. G. and S. C. Rizzi, et al. (2004). "Precipitation casting of 
polycaprolactone for applications in tissue engineering and drug delivery." 
Biomaterials 25 (2): 315-25. 
Cruess, R. L. and J. Dumont (1975). "Fracture healing." Can J Surg 18 (5): 403-13. 
Cukierman, E. and R. Pankov, et al. (2001). "Taking cell-matrix adhesions to the third 
dimension." Science 294 (5547): 1708-12. 
Datta, N. and Q. P. Pham, et al. (2006). "In vitro generated extracellular matrix and 
fluid shear stress synergistically enhance 3D osteoblastic differentiation." Proc Natl 
Acad Sci U S A 103 (8): 2488-93. 
Davies, J. E. (1996). "In vitro modeling of the bone/implant interface." Anat Rec 245 
(2): 426-45. 
  References 
____________________________________________________________________________________________ 
- 236 - 
Davies, J. E. (1998). "Mechanisms of endosseous integration." Int J Prosthodont 11 
(5): 391-401. 
De, B. C. and A. F. Dell, et al. (2001). "Multipotent mesenchymal stem cells from 
adult human synovial membrane." Arthritis Rheum 44 (8): 1928-42. 
De, C. P. and G. J. Bartsch, et al. (2007). "Isolation of amniotic stem cell lines with 
potential for therapy." Nat Biotechnol 25 (1): 100-6. 
De, K. I. and K. C. Hicok, et al. (2006). "Effect of vitamin D pretreatment of human 
mesenchymal stem cells on ectopic bone formation." J Oral Implantol 32 (3): 103-9. 
Devine, S. M. and C. Cobbs, et al. (2003). "Mesenchymal stem cells distribute to a 
wide range of tissues following systemic infusion into nonhuman primates." Blood 
101 (8): 2999-3001. 
Di, N. M. and C. Carlo-Stella, et al. (2002). "Human bone marrow stromal cells 
suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic 
stimuli." Blood 99 (10): 3838-43. 
Digirolamo, C. M. and D. Stokes, et al. (1999). "Propagation and senescence of 
human marrow stromal cells in culture: a simple colony-forming assay identifies 
samples with the greatest potential to propagate and differentiate." Br J Haematol 
107 (2): 275-81. 
Digirolamo, C. M. and D. Stokes, et al. (1999). "Propagation and senescence of 
human marrow stromal cells in culture: a simple colony-forming assay identifies 
samples with the greatest potential to propagate and differentiate." Br J Haematol 
107 (2): 275-81. 
Dimitriou, R. and E. Tsiridis, et al. (2005). "Current concepts of molecular aspects of 
bone healing." Injury 36 (12): 1392-404. 
D'Ippolito G; Schiller, P C; Ricordi, C; Roos, B A; Howard, G. A. (1999). 
"Age-related osteogenic potential of mesenchymal stromal stem cells from human 
vertebral bone marrow." J Bone Miner Res 14 (7): 1115-22. 
Djouad, F. and P. Plence, et al. (2003). "Immunosuppressive effect of mesenchymal 
stem cells favors tumor growth in allogeneic animals." Blood 102 (10): 3837-44. 
Dominici, M. and B. K. Le, et al. (2006). "Minimal criteria for defining multipotent 
mesenchymal stromal cells. The International Society for Cellular Therapy position 
statement." Cytotherapy 8 (4): 315-7. 
Downey, P. A. and M. I. Siegel (2006). "Bone biology and the clinical implications 
for osteoporosis." Phys Ther 86 (1): 77-91. 
Dudas, J. R. and K. G. Marra, et al. (2006). "The osteogenic potential of 
adipose-derived stem cells for the repair of rabbit calvarial defects." Ann Plast Surg 
56 (5): 543-8. 
  References 
____________________________________________________________________________________________ 
- 237 - 
Duvall, C. L. and T. W. Robert, et al. (2004). "Quantitative microcomputed 
tomography analysis of collateral vessel development after ischemic injury." Am J 
Physiol Heart Circ Physiol 287 (1): H302-10. 
Duvall, C. L. and W. R. Taylor, et al. (2004). "Quantitative microcomputed 
tomography analysis of collateral vessel development after ischemic injury." Am J 
Physiol Heart Circ Physiol 287 (1): H302-10. 
Eghbali-Fatourechi, G. Z. and J. Lamsam, et al. (2005). "Circulating 
osteoblast-lineage cells in humans." N Engl J Med 352 (19): 1959-66. 
Einhorn, T. A. (1998). "The cell and molecular biology of fracture healing." Clin 
Orthop Relat Res(355 Suppl): S7-21. 
Eiselt, P. and B. S. Kim, et al. (1998). "Development of technologies aiding 
large-tissue engineering." Biotechnol Prog 14 (1): 134-40. 
Britannica, E. (2007). The New Encyclopaedia Britannica, 2007 Edition, 
Encyclopedia Britannica, Incorporated. 
Endres, M. and D. W. Hutmacher, et al. (2003). "Osteogenic induction of human bone 
marrow-derived mesenchymal progenitor cells in novel synthetic polymer-hydrogel 
matrices." Tissue Eng 9 (4): 689-702. 
Farrington-Rock, C. and N. J. Crofts, et al. (2004). "Chondrogenic and adipogenic 
potential of microvascular pericytes." Circulation 110 (15): 2226-32. 
Fowler, B. L. and B. E. Dall, et al. (1995). "Complications associated with harvesting 
autogenous iliac bone graft." Am J Orthop 24 (12): 895-903. 
Frank, O. and M. Heim, et al. (2002). "Real-time quantitative RT-PCR analysis of 
human bone marrow stromal cells during osteogenic differentiation in vitro." J Cell 
Biochem 85 (4): 737-46. 
Freed, L. E. and R. Langer, et al. (1997). "Tissue engineering of cartilage in space." 
Proc Natl Acad Sci U S A 94 (25): 13885-90. 
Friedenstein, A. J. and U. F. Deriglasova, et al. (1974). "Precursors for fibroblasts in 
different populations of hematopoietic cells as detected by the in vitro colony assay 
method." Exp Hematol 2 (2): 83-92. 
Friedenstein, A. J. and J. F. Gorskaja, et al. (1976). "Fibroblast precursors in normal 
and irradiated mouse hematopoietic organs." Exp Hematol 4 (5): 267-74. 
Friedenstein, A. J. and K. V. Petrakova, et al. (1968). "Heterotopic of bone 
marrow.Analysis of precursor cells for osteogenic and hematopoietic tissues." 
Transplantation 6 (2): 230-47. 
Friedenstein, A. J. and S. I. Piatetzky, et al. (1966). "Osteogenesis in transplants of 
bone marrow cells." J Embryol Exp Morphol 16 (3): 381-90. 
Galmiche, M. C. and V. E. Koteliansky, et al. (1993). "Stromal cells from human 
  References 
____________________________________________________________________________________________ 
- 238 - 
long-term marrow cultures are mesenchymal cells that differentiate following a 
vascular smooth muscle differentiation pathway." Blood 82 (1): 66-76. 
Gang, E. J. and J. A. Jeong, et al. (2006). "In vitro endothelial potential of human UC 
blood-derived mesenchymal stem cells." Cytotherapy 8 (3): 215-27. 
Gerber, H. P. and N. Ferrara (2000). "Angiogenesis and bone growth." Trends 
Cardiovasc Med 10 (5): 223-8. 
Gerstenfeld, L. C. and D. M. Cullinane, et al. (2003). "Fracture healing as a post-natal 
developmental process: molecular, spatial, and temporal aspects of its regulation." J 
Cell Biochem 88 (5): 873-84. 
Giannoudis, P. V. and T. A. Einhorn, et al. (2007). "Fracture healing: a harmony of 
optimal biology and optimal fixation?" Injury 38 Suppl 4 : S1-2. 
Giuliani, N. and R. Bataille, et al. (2001). "Myeloma cells induce imbalance in the 
osteoprotegerin/osteoprotegerin ligand system in the human bone marrow 
environment." Blood 98 (13): 3527-33. 
Gnecchi, M. and H. He, et al. (2005). "Paracrine action accounts for marked 
protection of ischemic heart by Akt-modified mesenchymal stem cells." Nat Med 
11 (4): 367-8. 
Goldstein, A. S. and T. M. Juarez, et al. (2001). "Effect of convection on osteoblastic 
cell growth and function in biodegradable polymer foam scaffolds." Biomaterials 22 
(11): 1279-88. 
Goldstein, S. A. (2002). "Tissue engineering: functional assessment and clinical 
outcome." Ann N Y Acad Sci 961 : 183-92. 
Gomes, M. E. and C. M. Bossano, et al. (2006). "In vitro localization of bone growth 
factors in constructs of biodegradable scaffolds seeded with marrow stromal cells 
and cultured in a flow perfusion bioreactor." Tissue Eng 12 (1): 177-88. 
Gomes, M. E. and V. I. Sikavitsas, et al. (2003). "Effect of flow perfusion on the 
osteogenic differentiation of bone marrow stromal cells cultured on starch-based 
three-dimensional scaffolds." J Biomed Mater Res A 67 (1): 87-95. 
Goodship, A. E. and J. L. Cunningham, et al. (1998). "Strain rate and timing of 
stimulation in mechanical modulation of fracture healing." Clin Orthop Relat 
Res(355 Suppl): S105-15. 
Gori, F. and L. C. Hofbauer, et al. (2000). "The expression of osteoprotegerin and 
RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage 
cells is developmentally regulated." Endocrinology 141 (12): 4768-76. 
Gotherstrom, C. (2007). "Immunomodulation by multipotent mesenchymal stromal 
cells." Transplantation 84 (1 Suppl): S35-7. 
Gotherstrom, C. (2007). "Immunomodulation by multipotent mesenchymal stromal 
  References 
____________________________________________________________________________________________ 
- 239 - 
cells." Transplantation 84 (1 Suppl): S35-7. 
Gotherstrom, C. and O. Ringden, et al. (2004). "Immunologic properties of human 
fetal mesenchymal stem cells." Am J Obstet Gynecol 190 (1): 239-45. 
Gotherstrom, C. and O. Ringden, et al. (2003). "Immunomodulatory effects of human 
foetal liver-derived mesenchymal stem cells." Bone Marrow Transplant 32 (3): 
265-72. 
Gotherstrom, C. and O. Ringden, et al. (2003). "Immunomodulatory effects of human 
foetal liver-derived mesenchymal stem cells." Bone Marrow Transplant 32 (3): 
265-72. 
Gotherstrom, C. and O. Ringden, et al. (2003). "Immunomodulatory effects of human 
foetal liver-derived mesenchymal stem cells." Bone Marrow Transplant 32 (3): 
265-72. 
Goulet, J. A. and L. E. Senunas, et al. (1997). "Autogenous iliac crest bone graft. 
Complications and functional assessment." Clin Orthop Relat Res(339): 76-81. 
Granet, C. and N. Laroche, et al. (1998). "Rotating-wall vessels, promising 
bioreactors for osteoblastic cell culture: comparison with other 3D conditions." Med 
Biol Eng Comput 36 (4): 513-9. 
Granet, C. and N. Laroche, et al. (1998). "Rotating-wall vessels, promising 
bioreactors for osteoblastic cell culture: comparison with other 3D conditions." Med 
Biol Eng Comput 36 (4): 513-9. 
Grayson, W. L. and F. Zhao, et al. (2006). "Effects of hypoxia on human 
mesenchymal stem cell expansion and plasticity in 3D constructs." J Cell Physiol 
207 (2): 331-9. 
Grinnemo, K. H. and A. Mansson, et al. (2004). "Xenoreactivity and engraftment of 
human mesenchymal stem cells transplanted into  infarcted rat myocardium." J 
Thorac Cardiovasc Surg 127 (5): 1293-300. 
Gronthos, S. and D. M. Franklin, et al. (2001). "Surface protein characterization of 
human adipose tissue-derived stromal cells." J Cell Physiol 189 (1): 54-63. 
Gronthos, S. and S. E. Graves, et al. (1994). "The STRO-1+ fraction of adult human 
bone marrow contains the osteogenic precursors." Blood 84 (12): 4164-73. 
Guerette, B. and P. A. Moisset, et al. (1997). "Inflammatory damage following 
first-generation replication-defective adenovirus controlled by anti-LFA-1." J 
Leukoc Biol 61 (4): 533-8. 
Guerette, B. and D. Skuk, et al. (1997). "Prevention by anti-LFA-1 of acute myoblast 
death following transplantation." J Immunol 159 (5): 2522-31. 
Guillot, P. V. and O. Abass, et al. (2007). "Intrauterine transplantation of human fetal 
mesenchymal stem cells from first trimester blood repairs bone and reduces 
  References 
____________________________________________________________________________________________ 
- 240 - 
fractures in osteogenesis imperfecta mice." Blood. 
Guillot, P. V. and O. Abass, et al. (2008). "Intrauterine transplantation of human fetal 
mesenchymal stem cells from first-trimester blood repairs bone and reduces 
fractures in osteogenesis imperfecta mice." Blood 111 (3): 1717-25. 
Guillot, P. V. and B. C. De, et al. (2008). "Comparative osteogenic transcription 
profiling of various fetal and adult mesenchymal stem cell sources." Differentiation. 
Guillot, P. V. and C. Gotherstrom, et al. (2007). "Human first-trimester fetal MSC 
express pluripotency markers and grow faster and  have longer telomeres than 
adult MSC." Stem Cells 25 (3): 646-54. 
Guldberg, R. E. and R. T. Ballock, et al. (2003). "Analyzing bone, blood vessels, and 
biomaterials with microcomputed tomography." IEEE Eng Med Biol Mag 22 (5): 
77-83. 
Hausman, M. R. and M. B. Schaffler, et al. (2001). "Prevention of fracture healing in 
rats by an inhibitor of angiogenesis." Bone 29 (6): 560-4. 
Haynesworth, S. E. and M. A. Baber, et al. (1992). "Cell surface antigens on human 
marrow-derived mesenchymal cells are detected by monoclonal antibodies." Bone 
13 (1): 69-80. 
Heinzer, S. and T. Krucker, et al. (2006). "Hierarchical microimaging for multiscale 
analysis of large vascular networks." Neuroimage 32 (2): 626-36. 
Hillsley, M. V. and J. A. Frangos (1994). "Bone tissue engineering: the role of 
interstitial fluid flow." Biotechnol Bioeng 43 (7): 573-81. 
Hohlfeld, J. and B. R. de, et al. (2005). "Tissue engineered fetal skin constructs for 
paediatric burns." Lancet 366 (9488): 840-2. 
Hollinger, J. O. and J. Brekke, et al. (1996). "Role of bone substitutes." Clin Orthop 
Relat Res(324): 55-65. 
Hollinger, J. O. and J. C. Kleinschmidt (1990). "The critical size defect as an 
experimental model to test bone repair materials." J Craniofac Surg 1 (1): 60-8. 
Hollister, S. J. (2005). "Porous scaffold design for tissue engineering." Nat Mater 4 
(7): 518-24. 
Holtorf, H. L. and J. A. Jansen, et al. (2005). "Flow perfusion culture induces the 
osteoblastic differentiation of marrow stroma cell-scaffold constructs in the absence 
of dexamethasone." J Biomed Mater Res A 72 (3): 326-34. 
Holtorf, H. L. and J. A. Jansen, et al. (2005). "Flow perfusion culture induces the 
osteoblastic differentiation of marrow stroma cell-scaffold constructs in the absence 
of dexamethasone." J Biomed Mater Res A 72 (3): 326-34. 
Holtorf, H. L. and J. A. Jansen, et al. (2006). "Modulation of cell differentiation in 
bone tissue engineering constructs cultured in a bioreactor." Adv Exp Med Biol 
  References 
____________________________________________________________________________________________ 
- 241 - 
585 : 225-41. 
Holtorf, H. L. and T. L. Sheffield, et al. (2005). "Flow perfusion culture of marrow 
stromal cells seeded on porous biphasic calcium phosphate ceramics." Ann Biomed 
Eng 33 (9): 1238-48. 
Holy, C. E. and M. S. Shoichet, et al. (2000). "Engineering three-dimensional bone 
tissue in vitro using biodegradable scaffolds: investigating initial cell-seeding 
density and culture period." J Biomed Mater Res 51 (3): 376-82. 
Holy, C. E. and M. S. Shoichet, et al. (2000). "Engineering three-dimensional bone 
tissue in vitro using biodegradable scaffolds: investigating initial cell-seeding 
density and culture period." J Biomed Mater Res 51 (3): 376-82. 
Deng, H. and Y. Liu, et al. (2005). Current Topics in Bone Biology, World Scientific 
Publishing Company. 
Horowitz, M. C. and Y. Xi, et al. (2001). "Control of osteoclastogenesis and bone 
resorption by members of the TNF family of receptors and ligands." Cytokine 
Growth Factor Rev 12 (1): 9-18. 
Horwitz, E. M. and P. L. Gordon, et al. (2002). "Isolated allogeneic bone 
marrow-derived mesenchymal cells engraft and stimulate growth in children with 
osteogenesis imperfecta: Implications for cell therapy of bone." Proc Natl Acad Sci 
U S A 99 (13): 8932-7. 
Horwitz, E. M. and B. K. Le, et al. (2005). "Clarification of the nomenclature for 
MSC: The International Society for Cellular Therapy position statement." 
Cytotherapy 7 (5): 393-5. 
Hu, Y. and L. Liao, et al. (2003). "Isolation and identification of mesenchymal stem 
cells from human fetal pancreas." J Lab Clin Med 141 (5): 342-9. 
Hutmacher, D. W. (2000). "Scaffolds in tissue engineering bone and cartilage." 
Biomaterials 21 (24): 2529-43. 
Hutmacher, D. W. (2000). "Scaffolds in tissue engineering bone and cartilage." 
Biomaterials 21 (24): 2529-43. 
Hutmacher, D. W. and T. Schantz, et al. (2001). "Mechanical properties and cell 
cultural response of polycaprolactone scaffolds designed and fabricated via fused 
deposition modeling." J Biomed Mater Res 55 (2): 203-16. 
Hutmacher, D. W. and T. Schantz, et al. (2001). "Mechanical properties and cell 
cultural response of polycaprolactone scaffolds designed and fabricated via fused 
deposition modeling." J Biomed Mater Res 55 (2): 203-16. 
Hutmacher, D. W. and H. Singh (2008). "Computational fluid dynamics for improved 
bioreactor design and 3D culture." Trends Biotechnol. 
Hutmacher, D. W. and M. Sittinger, et al. (2004). "Scaffold-based tissue engineering: 
  References 
____________________________________________________________________________________________ 
- 242 - 
rationale for computer-aided design and solid  free-form fabrication systems." 
Trends Biotechnol 22 (7): 354-62. 
Ifkovits, J. L. and J. A. Burdick (2007). "Review: photopolymerizable and degradable 
biomaterials for tissue engineering applications." Tissue Eng 13 (10): 2369-85. 
Ignatius, A. and H. Blessing, et al. (2005). "Tissue engineering of bone: effects of 
mechanical strain on osteoblastic cells in type I collagen matrices." Biomaterials 26 
(3): 311-8. 
Im, G. I. and Y. W. Shin, et al. (2005). "Do adipose tissue-derived mesenchymal stem 
cells have the same osteogenic and chondrogenic potential as bone marrow-derived 
cells?" Osteoarthritis Cartilage 13 (10): 845-53. 
Inoue, K. and H. Ohgushi, et al. (1997). "The effect of aging on bone formation in 
porous hydroxyapatite: biochemical and histological analysis." J Bone Miner Res 
12 (6): 989-94. 
in't Anker P ; Noort, W A; Scherjon, S A; Kleijburg-van, Keur C; Kruisselbrink, A B; 
van, Bezooijen R; Beekhuizen, W; Willemze, R; Kanhai, H H; Fibbe, W. E. (2003). 
"Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and 
spleen exhibit a similar immunophenotype but a heterogeneous multilineage 
differentiation potential." Haematologica 88 (8): 845-52. 
in't Anker, P; Scherjon, S A; Kleijburg-van, Keur C; Noort, W A; Claas, F H; 
Willemze, R; Fibbe, W E; Kanhai, H. H. (2003). "Amniotic fluid as a novel source 
of mesenchymal stem cells for therapeutic transplantation." Blood 102 (4): 1548-9. 
Ishaug, S. L. and G. M. Crane, et al. (1997). "Bone formation by three-dimensional 
stromal osteoblast culture in biodegradable polymer scaffolds." J Biomed Mater Res 
36 (1): 17-28. 
Isik, S. and E. Er, et al. (2003). "Prolongation of skin xenograft survival with 
modified cultured fibroblasts." Plast Reconstr Surg 111 (1): 275-82; discussion 
283-5. 
Jager, M. and O. Degistirici, et al. (2007). "Bone healing and migration of cord 
blood-derived stem cells into a critical size  femoral defect after 
xenotransplantation." J Bone Miner Res 22 (8): 1224-33. 
Jain, R. K. and P. Au, et al. (2005). "Engineering vascularized tissue." Nat Biotechnol 
23 (7): 821-3. 
Javazon, E. H. and K. J. Beggs, et al. (2004). "Mesenchymal stem cells: paradoxes of 
passaging." Exp Hematol 32 (5): 414-25. 
Javazon, E. H. and D. C. Colter, et al. (2001). "Rat marrow stromal cells are more 
sensitive to plating density and expand more rapidly from single-cell-derived 
colonies than human marrow stromal cells." Stem Cells 19 (3): 219-25. 
Lieberman, J. R. and G. E. Friedlaender (2005). Bone Regeneration and Repair: 
  References 
____________________________________________________________________________________________ 
- 243 - 
Biology and Clinical Applications, Humana Press. 
Jeffrey O, H. and T. A. Einhorn, et al. (2005). Bone Tissue Engineering, Boca Raton : 
CRC Press. 
Chan, J. K. Y. (2006). Human Fetal Mesenchymal Stem Cells for Intrauterine Cellular 
/ Gene Therapy using Muscular Dystrophy as a Model. London W12 0NN, United 
Kingdom, Imperial College London, Hammersmith Campus. Doctor of 
Philosophy. 
Bilezikian, J. P. (2002). Principles of Bone Biology, Academic Press. 
Johnson, D. L. and T. N. McAllister, et al. (1996). "Fluid flow stimulates rapid and 
continuous release of nitric oxide in osteoblasts." Am J Physiol 271 (1 Pt 1): 
E205-8. 
Jones, E. and D. McGonagle (2008). "Human bone marrow mesenchymal stem cells 
in vivo." Rheumatology (Oxford) 47 (2): 126-31. 
Kahn, A. and R. Gibbons, et al. (1995). "Age-related bone loss. A hypothesis and 
initial assessment in mice." Clin Orthop Relat Res(313): 69-75. 
Kanczler, J. M. and R. O. Oreffo (2008). "Osteogenesis and angiogenesis: the 
potential for engineering bone." Eur Cell Mater 15 : 100-14. 
Karageorgiou, V. and D. Kaplan (2005). "Porosity of 3D biomaterial scaffolds and 
osteogenesis." Biomaterials 26 (27): 5474-91. 
Kaspar, D. and W. Seidl, et al. (2002). "Proliferation of human-derived osteoblast-like 
cells depends on the cycle number  and frequency of uniaxial strain." J Biomech 
35 (7): 873-80. 
Kaspar, D. and W. Seidl, et al. (2000). "Dynamic cell stretching increases human 
osteoblast proliferation and CICP synthesis but decreases osteocalcin synthesis and 
alkaline phosphatase activity." J Biomech 33 (1): 45-51. 
Keilhoff, G. and A. Goihl, et al. (2006). "Transdifferentiation of mesenchymal stem 
cells into Schwann cell-like myelinating cells." Eur J Cell Biol 85 (1): 11-24. 
Kennea, N. L. and N. M. Fisk, et al. (2003). "Neural cell differentiation of fetal 
mesenchymal stem cells." Early Human Development 73 : 121-122 (Abstr.). 
Kermani, A. J. and F. Fathi, et al. (2008). "Characterization and Genetic Manipulation 
of Human Umbilical Cord Vein Mesenchymal Stem Cells: Potential Application in 
Cell-Based Gene Therapy." Rejuvenation Res. 
Kim, B. S. and C. C. Lee, et al. (2008). "Growth, differentiation, and biochemical 
signatures of rhesus monkey mesenchymal stem cells." Stem Cells Dev 17 (1): 
185-98. 
Kim, B. S. and A. J. Putnam, et al. (1998). "Optimizing seeding and culture methods 
to engineer smooth muscle tissue on biodegradable polymer matrices." Biotechnol 
  References 
____________________________________________________________________________________________ 
- 244 - 
Bioeng 57 (1): 46-54. 
Kim, H. J. and U. J. Kim, et al. (2007). "Bone regeneration on macroporous 
aqueous-derived silk 3-D scaffolds." Macromol Biosci 7 (5): 643-55. 
Kimelman, N. and G. Pelled, et al. (2007). "Review: gene- and stem cell-based 
therapeutics for bone regeneration and repair." Tissue Eng 13 (6): 1135-50. 
Kindlmann, G. L. and D. M. Weinstein, et al. (2005). "Practical vessel imaging by 
computed tomography in live transgenic mouse models for human tumors." Mol 
Imaging 4 (4): 417-24. 
Kinnaird, T. and E. Stabile, et al. (2004). "Marrow-derived stromal cells express 
genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and 
in vivo arteriogenesis through paracrine mechanisms." Circ Res 94 (5): 678-85. 
Kinner, B. and J. M. Zaleskas, et al. (2002). "Regulation of smooth muscle actin 
expression and contraction in adult human mesenchymal stem cells." Exp Cell Res 
278 (1): 72-83. 
Kirker-Head, C. and V. Karageorgiou, et al. (2007). "BMP-silk composite matrices 
heal critically sized femoral defects." Bone 41 (2): 247-55. 
Klement, B. J. and B. S. Spooner (1993). "Utilization of microgravity bioreactors for 
differentiation of mammalian skeletal tissue." J Cell Biochem 51 (3): 252-6. 
Klyushnenkova, E. and J. D. Mosca, et al. (2005). "T cell responses to allogeneic 
human mesenchymal stem cells: immunogenicity, tolerance, and suppression." J 
Biomed Sci 12 (1): 47-57. 
Kneser, U. and E. Polykandriotis, et al. (2006). "Engineering of vascularized 
transplantable bone tissues: induction of axial vascularization in an osteoconductive 
matrix using an arteriovenous loop." Tissue Eng 12 (7): 1721-31. 
Kneser, U. and D. J. Schaefer, et al. (2006). "Tissue engineering of bone: the 
reconstructive surgeon's point of view." J Cell Mol Med 10 (1): 7-19. 
Kobune, M. and Y. Kawano, et al. (2003). "Telomerized human multipotent 
mesenchymal cells can differentiate into hematopoietic and cobblestone 
area-supporting cells." Exp Hematol 31 (8): 715-22. 
Koc, O. N. and J. Day, et al. (2002). "Allogeneic mesenchymal stem cell infusion for 
treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome 
(MPS-IH)." Bone Marrow Transplant 30 (4): 215-22. 
Koc, O. N. and S. L. Gerson, et al. (2000). "Rapid hematopoietic recovery after 
coinfusion of autologous-blood stem cells and culture-expanded marrow 
mesenchymal stem cells in advanced breast cancer patients receiving high-dose 
chemotherapy." J Clin Oncol 18 (2): 307-16. 
Koefoed, M. and H. Ito, et al. (2005). "Biological effects of rAAV-caAlk2 coating on 
  References 
____________________________________________________________________________________________ 
- 245 - 
structural allograft healing." Mol Ther 12 (2): 212-8. 
Kokubo, T. and H. M. Kim, et al. (2003). "Novel bioactive materials with different 
mechanical properties." Biomaterials 24 (13): 2161-75. 
Kokubu, T. and D. J. Hak, et al. (2003). "Development of an atrophic nonunion model 
and comparison to a closed healing fracture in rat femur." J Orthop Res 21 (3): 
503-10. 
Krampera, M. and S. Glennie, et al. (2003). "Bone marrow mesenchymal stem cells 
inhibit the response of naive and memory antigen-specific T cells to their cognate 
peptide." Blood 101 (9): 3722-9. 
Kruyt, M. C. and W. J. Dhert, et al. (2004). "Bone tissue engineering in a critical size 
defect compared to ectopic implantations in the goat." J Orthop Res 22 (3): 544-51. 
Kurpinski, K. and J. Chu, et al. (2006). "Anisotropic mechanosensing by 
mesenchymal stem cells." Proc Natl Acad Sci U S A 103 (44): 16095-100. 
Lange, C. and F. Togel, et al. (2005). "Administered mesenchymal stem cells enhance 
recovery from ischemia/reperfusion-induced acute renal failure in rats." Kidney Int 
68 (4): 1613-7. 
Langer, R. and J. P. Vacanti (1993). "Tissue engineering." Science 260 (5110): 920-6. 
Lanyon, L. E. (1984). "Functional strain as a determinant for bone remodeling." 
Calcif Tissue Int 36 Suppl 1 : S56-61. 
Lanyon, L. E. and C. T. Rubin (1984). "Static vs dynamic loads as an influence on 
bone remodelling." J Biomech 17 (12): 897-905. 
Laurencin, C. T. and A. M. Ambrosio, et al. (1999). "Tissue engineering: orthopedic 
applications." Annu Rev Biomed Eng 1 : 19-46. 
Lazarus, H. M. and S. E. Haynesworth, et al. (1995). "Ex vivo expansion and 
subsequent infusion of human bone marrow-derived stromal progenitor cells 
(mesenchymal progenitor cells): implications for therapeutic use." Bone Marrow 
Transplant 16 (4): 557-64. 
Lazennec, G. and C. Jorgensen (2008). "Concise review: adult multipotent stromal 
cells and cancer: risk or benefit?" Stem Cells 26 (6): 1387-94. 
Le Blanc, K. (2003). "Immunomodulatory effects of fetal and adult mesenchymal 
stem cells." Cytotherapy 5 (6): 485-9. 
Le Blanc, K. and C. Gotherstrom, et al. (2005). "Fetal mesenchymal stem-cell 
engraftment in bone after in utero transplantation in a patient with severe 
osteogenesis imperfecta." Transplantation 79 (11): 1607-14. 
Le Blanc, K. and M. Pittenger (2005). "Mesenchymal stem cells: progress toward 
promise." Cytotherapy 7 (1): 36-45. 
  References 
____________________________________________________________________________________________ 
- 246 - 
Le Blanc, K. and I. Rasmusson, et al. (2004). "Treatment of severe acute 
graft-versus-host disease with third party haploidentical mesenchymal stem cells." 
Lancet 363 (9419): 1439-41. 
Le Blanc, K. and C. Tammik, et al. (2003). "HLA expression and immunologic 
properties of differentiated and undifferentiated mesenchymal stem cells." Exp 
Hematol 31 (10): 890-6. 
Le Blanc, K. and L. Tammik, et al. (2003). "Mesenchymal stem cells inhibit and 
stimulate mixed lymphocyte cultures and mitogenic responses independently of the 
major histocompatibility complex." Scand J Immunol 57 (1): 11-20. 
Le, A. X. and T. Miclau, et al. (2001). "Molecular aspects of healing in stabilized and 
non-stabilized fractures." J Orthop Res 19 (1): 78-84. 
Le, B. K. (2003). "Immunomodulatory effects of fetal and adult mesenchymal stem 
cells." Cytotherapy 5 (6): 485-9. 
Lee, O. K. and T. K. Kuo, et al. (2004). "Isolation of multipotent mesenchymal stem 
cells from umbilical cord blood." Blood 103 (5): 1669-75. 
LeGeros, R. Z. (2002). "Properties of osteoconductive biomaterials: calcium 
phosphates." Clin Orthop Relat Res(395): 81-98. 
Leong, K. F. and C. M. Cheah, et al. (2003). "Solid freeform fabrication of 
three-dimensional scaffolds for engineering replacement tissues and organs." 
Biomaterials 24 (13): 2363-78. 
Levenberg, S. and J. Rouwkema, et al. (2005). "Engineering vascularized skeletal 
muscle tissue." Nat Biotechnol 23 (7): 879-84. 
Li, Y. and J. Chen, et al. (2005). "Gliosis and brain remodeling after treatment of 
stroke in rats with marrow stromal cells." Glia 49 (3): 407-17. 
Li, Y. and T. Ma, et al. (2001). "Effects of filtration seeding on cell density, spatial 
distribution, and proliferation in nonwoven fibrous matrices." Biotechnol Prog 17 
(5): 935-44. 
Li, Y. and T. Ma, et al. (2001). "Effects of filtration seeding on cell density, spatial 
distribution, and proliferation in nonwoven fibrous matrices." Biotechnol Prog 17 
(5): 935-44. 
Lin, Y. and M. Vandeputte, et al. (1997). "Natural killer cell- and 
macrophage-mediated rejection of concordant xenografts in the absence of T and B 
cell responses." J Immunol 158 (12): 5658-67. 
Liu, T. M. and M. Martina, et al. (2007). "Identification of common pathways 
mediating differentiation of bone marrow- and adipose tissue-derived human 
mesenchymal stem cells into three mesenchymal lineages." Stem Cells 25 (3): 
750-60. 
  References 
____________________________________________________________________________________________ 
- 247 - 
Liu, X. and P. X. Ma (2004). "Polymeric scaffolds for bone tissue engineering." Ann 
Biomed Eng 32 (3): 477-86. 
Logeart-Avramoglou, D. and F. Anagnostou, et al. (2005). "Engineering bone: 
challenges and obstacles." J Cell Mol Med 9 (1): 72-84. 
Loh, Y. H. and Q. Wu, et al. (2006). "The Oct4 and Nanog transcription network 
regulates pluripotency in mouse embryonic stem cells." Nat Genet 38 (4): 431-40. 
Lu, C. and R. Marcucio, et al. (2006). "Assessing angiogenesis during fracture 
healing." Iowa Orthop J 26 : 17-26. 
Lu, C. and R. Marcucio, et al. (2006). "Assessing angiogenesis during fracture 
healing." Iowa Orthop J 26 : 17-26. 
MacKenzie, T. C. and C. Campagnoli, et al. (2001). "Circulating human fetal stromal 
cells engraft and differentiate in multiple tissues following transplantation into 
pre-immune fetal lambs." Blood 98 : 798 (Abstr.). 
Maitra, B. and E. Szekely, et al. (2004). "Human mesenchymal stem cells support 
unrelated donor hematopoietic stem cells and suppress T-cell activation." Bone 
Marrow Transplant 33 (6): 597-604. 
Malard, O. and F. Espitalier, et al. (2007). "Biomaterials for tissue reconstruction and 
bone substitution of the ear, nose and throat, face and neck." Expert Rev Med 
Devices 4 (5): 729-39. 
Malda, J. and T. J. Klein, et al. (2007). "The roles of hypoxia in the in vitro 
engineering of tissues." Tissue Eng 13 (9): 2153-62. 
Malladi, P. and Y. Xu, et al. (2006). "Functions of vitamin D, retinoic acid, and 
dexamethasone in mouse adipose-derived mesenchymal cells." Tissue Eng 12 (7): 
2031-40. 
Malyar, N. M. and M. Gossl, et al. (2004). "Relationship between arterial diameter 
and perfused tissue volume in myocardial microcirculation: a micro-CT-based 
analysis." Am J Physiol Heart Circ Physiol 286 (6): H2386-92. 
Maquet, V. and A. R. Boccaccini, et al. (2004). "Porous 
poly(alpha-hydroxyacid)/Bioglass composite scaffolds for bone tissue engineering. 
I: Preparation and in vitro characterisation." Biomaterials 25 (18): 4185-94. 
Marolt, D. and A. Augst, et al. (2006). "Bone and cartilage tissue constructs grown 
using human bone marrow stromal cells, silk scaffolds and rotating bioreactors." 
Biomaterials 27 (36): 6138-49. 
Marsh, D. R. and G. Li (1999). "The biology of fracture healing: optimising 
outcome." Br Med Bull 55 (4): 856-69. 
Martin, I. and B. Obradovic, et al. (1999). "Method for quantitative analysis of 
glycosaminoglycan distribution in cultured natural and engineered cartilage." Ann 
  References 
____________________________________________________________________________________________ 
- 248 - 
Biomed Eng 27 (5): 656-62. 
Martin, I. and D. Wendt, et al. (2004). "The role of bioreactors in tissue engineering." 
Trends Biotechnol 22 (2): 80-6. 
Martin, Y. and P. Vermette (2005). "Bioreactors for tissue mass culture: design, 
characterization, and recent advances." Biomaterials 26 (35): 7481-503. 
Mauney, J. R. and C. Jaquiery, et al. (2005). "In vitro and in vivo evaluation of 
differentially demineralized cancellous bone scaffolds combined with human bone 
marrow stromal cells for tissue engineering." Biomaterials 26 (16): 3173-85. 
Mauney, J. R. and V. Volloch, et al. (2005). "Role of adult mesenchymal stem cells in 
bone tissue engineering applications: current status and future prospects." Tissue 
Eng 11 (5-6): 787-802. 
McKibbin, B. (1978). "The biology of fracture healing in long bones." J Bone Joint 
Surg Br 60-B (2): 150-62. 
Meinel, L. and O. Betz, et al. (2006). "Silk based biomaterials to heal critical sized 
femur defects." Bone 39 (4): 922-31. 
Meinel, L. and O. Betz, et al. (2006). "Silk based biomaterials to heal critical sized 
femur defects." Bone 39 (4): 922-31. 
Meinel, L. and V. Karageorgiou, et al. (2004). "Bone tissue engineering using human 
mesenchymal stem cells: effects of scaffold material and medium flow." Ann 
Biomed Eng 32 (1): 112-22. 
Mendes, S. C. and M. Sleijster, et al. (2002). "A cultured living bone equivalent 
enhances bone formation when compared to a cell seeding approach." J Mater Sci 
Mater Med 13 (6): 575-81. 
Mendes, S. C. and J. M. Tibbe, et al. (2002). "Bone tissue-engineered implants using 
human bone marrow stromal cells: effect of culture conditions and donor age." 
Tissue Eng 8 (6): 911-20. 
Mendes, S. C. and J. M. Tibbe, et al. (2004). "Relation between in vitro and in vivo 
osteogenic potential of cultured human bone marrow stromal cells." J Mater Sci 
Mater Med 15 (10): 1123-8. 
Mikos, A. G. and G. Sarakinos, et al. (1993). "Prevascularization of porous 
biodegradable polymers." Biotechnol Bioeng 42 (6): 716-23. 
Miura, M. and Y. Miura, et al. (2006). "Accumulated chromosomal instability in 
murine bone marrow mesenchymal stem cells  leads to malignant transformation." 
Stem Cells 24 (4): 1095-103. 
Molnar, G. and N. A. Schroedl, et al. (1997). "Skeletal muscle satellite cells cultured 
in simulated microgravity." In vitro Cell Dev Biol Anim 33 (5): 386-91. 
Montjovent, M. O. and N. Burri, et al. (2004). "Fetal bone cells for tissue 
  References 
____________________________________________________________________________________________ 
- 249 - 
engineering." Bone 35 (6): 1323-33. 
Moore, D. C. and C. W. Leblanc, et al. (2003). "Physiologic weight-bearing increases 
new vessel formation during distraction osteogenesis: a micro-tomographic imaging 
study." J Orthop Res 21 (3): 489-96. 
Mueller, S. M. and J. Glowacki (2001). "Age-related decline in the osteogenic 
potential of human bone marrow cells cultured in three-dimensional collagen 
sponges." J Cell Biochem 82 (4): 583-90. 
Mueller, S. M. and J. Glowacki (2001). "Age-related decline in the osteogenic 
potential of human bone marrow cells cultured in three-dimensional collagen 
sponges." J Cell Biochem 82 (4): 583-90. 
Mukundakrishnan, K. and P. S. Ayyaswamy, et al. (2004). "Modeling of phosphate 
ion transfer to the surface of osteoblasts under normal gravity and simulated 
microgravity conditions." Ann N Y Acad Sci 1027 : 85-98. 
Muraglia, A. and R. Cancedda, et al. (2000). "Clonal mesenchymal progenitors from 
human bone marrow differentiate in vitro according to a hierarchical model." J Cell 
Sci 113 ( Pt 7) : 1161-6. 
Muraglia, A. and R. Cancedda, et al. (2000). "Clonal mesenchymal progenitors from 
human bone marrow differentiate in vitro according to a hierarchical model." J Cell 
Sci 113 ( Pt 7) : 1161-6. 
Murphy, J. M. and D. J. Fink, et al. (2003). "Stem cell therapy in a caprine model of 
osteoarthritis." Arthritis Rheum 48 (12): 3464-74. 
Murphy, W. L. and C. A. Simmons, et al. (2004). "Bone regeneration via a mineral 
substrate and induced angiogenesis." J Dent Res 83 (3): 204-10. 
Muschler, G. F. and C. Nakamoto, et al. (2004). "Engineering principles of clinical 
cell-based tissue engineering." J Bone Joint Surg Am 86-A (7): 1541-58. 
Mygind, T. and M. Stiehler, et al. (2007). "Mesenchymal stem cell ingrowth and 
differentiation on coralline hydroxyapatite scaffolds." Biomaterials 28 (6): 1036-47. 
Nakahara, H. and J. E. Dennis, et al. (1991). "In vitro differentiation of bone and 
hypertrophic cartilage from periosteal-derived cells." Exp Cell Res 195 (2): 
492-503. 
Neidlinger-Wilke, C. and H. J. Wilke, et al. (1994). "Cyclic stretching of human 
osteoblasts affects proliferation and metabolism: a new experimental method and its 
application." J Orthop Res 12 (1): 70-8. 
Niemeyer, P. and U. Krause, et al. (2006). "Mesenchymal stem cell-based 
HLA-independent cell therapy for tissue engineering of bone and cartilage." Curr 
Stem Cell Res Ther 1 (1): 21-7. 
Ohnishi, S. and H. Ohgushi, et al. (2007). "Mesenchymal stem cells for the treatment 
  References 
____________________________________________________________________________________________ 
- 250 - 
of heart failure." Int J Hematol 86 (1): 17-21. 
Okumura, M. and H. Ohgushi, et al. (1997). "Osteoblastic phenotype expression on 
the surface of hydroxyapatite ceramics." J Biomed Mater Res 37 (1): 122-9. 
Ong, S. Y. and H. Dai, et al. (2006). "Hepatic differentiation potential of 
commercially available human mesenchymal stem cells." Tissue Eng 12 (12): 
3477-85. 
Ontiveros, C. and R. Irwin, et al. (2004). "Hypoxia suppresses runx2 independent of 
modeled microgravity." J Cell Physiol 200 (2): 169-76. 
Ontiveros, C. and L. R. McCabe (2003). "Simulated microgravity suppresses 
osteoblast phenotype, Runx2 levels and AP-1 transactivation." J Cell Biochem 88 
(3): 427-37. 
Oswald, J. and S. Boxberger, et al. (2004). "Mesenchymal stem cells can be 
differentiated into endothelial cells in vitro." Stem Cells 22 (3): 377-84. 
Oswald, J. and S. Boxberger, et al. (2004). "Mesenchymal stem cells can be 
differentiated into endothelial cells in vitro." Stem Cells 22 (3): 377-84. 
Panepucci, R. A. and J. L. Siufi, et al. (2004). "Comparison of gene expression of 
umbilical cord vein and bone marrow-derived mesenchymal stem cells." Stem Cells 
22 (7): 1263-78. 
Parekkadan, B. and P. D. van, et al. (2007). "Mesenchymal stem cell-derived 
molecules reverse fulminant hepatic failure." PLoS ONE 2 (9): e941. 
Parikh, S. N. (2002). "Bone graft substitutes: past, present, future." J Postgrad Med 48 
(2): 142-8. 
Park, J. S. and J. S. Chu, et al. (2004). "Differential effects of equiaxial and uniaxial 
strain on mesenchymal stem cells." Biotechnol Bioeng 88 (3): 359-68. 
Pereira, R. F. and H. M. O, et al. (1998). "Marrow stromal cells as a source of 
progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype 
of osteogenesis imperfecta." Proc Natl Acad Sci U S A 95 (3): 1142-7. 
Peterson, B. and J. Zhang, et al. (2005). "Healing of critically sized femoral defects, 
using genetically modified mesenchymal stem cells from human adipose tissue." 
Tissue Eng 11 (1-2): 120-9. 
Phinney, D. G. (2007). "Biochemical heterogeneity of mesenchymal stem cell 
populations: clues to their therapeutic efficacy." Cell Cycle 6 (23): 2884-9. 
Phinney, D. G. and G. Kopen, et al. (1999). "Donor variation in the growth properties 
and osteogenic potential of human marrow stromal cells." J Cell Biochem 75 (3): 
424-36. 
Piersma, A. H. and K. G. Brockbank, et al. (1985). "Characterization of fibroblastic 
stromal cells from murine bone marrow." Exp Hematol 13 (4): 237-43. 
  References 
____________________________________________________________________________________________ 
- 251 - 
Pioletti, D. P. and M. O. Montjovent, et al. (2006). "Bone tissue engineering using 
foetal cell therapy." Swiss Med Wkly 136 (35-36): 557-60. 
Pittenger, M. F. and A. M. Mackay, et al. (1999). "Multilineage potential of adult 
human mesenchymal stem cells." Science 284 (5411): 143-7. 
Pochampally, R. R. and J. R. Smith, et al. (2004). "Serum deprivation of human 
marrow stromal cells (hMSCs) selects for a subpopulation of early progenitor cells 
with enhanced expression of OCT-4 and other embryonic genes." Blood 103 (5): 
1647-52. 
Polkinghorne, J. (1989). "Review of the guidance on the research use of fetuses and 
fetal material." London: HMSO CM 762. . 
Porada, C. D. and E. D. Zanjani, et al. (2006). "Adult mesenchymal stem cells: a 
pluripotent population with multiple applications." Curr Stem Cell Res Ther 1 (3): 
365-9. 
Pountos, I. and D. Corscadden, et al. (2007). "Mesenchymal stem cell tissue 
engineering: techniques for isolation, expansion and application." Injury 38 Suppl 
4 : S23-33. 
Qi, H. and D. J. Aguiar, et al. (2003). "Identification of genes responsible for 
osteoblast differentiation from human mesodermal progenitor cells." Proc Natl 
Acad Sci U S A 100 (6): 3305-10. 
Qiu, Q. Q. and P. Ducheyne, et al. (1999). "Fabrication, characterization and 
evaluation of bioceramic hollow microspheres used as microcarriers for 3-D bone 
tissue formation in rotating bioreactors." Biomaterials 20 (11): 989-1001. 
Quarto, R. and M. Mastrogiacomo, et al. (2001). "Repair of large bone defects with 
the use of autologous bone marrow stromal cells." N Engl J Med 344 (5): 385-6. 
Martin, R. B. and D. B. Burr, et al. (1998). Skeletal Tissue Mechanics, Springer. 
Rai, B. and M. E. Oest, et al. (2007). "Combination of platelet-rich plasma with 
polycaprolactone-tricalcium phosphate scaffolds for segmental bone defect repair." 
J Biomed Mater Res A 81 (4): 888-99. 
Rai, B. and S. H. Teoh, et al. (2005). "An in vitro evaluation of PCL-TCP composites 
as delivery systems for platelet-rich plasma." J Control Release 107 (2): 330-42. 
Rai, B. and S. H. Teoh, et al. (2004). "The effect of rhBMP-2 on canine osteoblasts 
seeded onto 3D bioactive polycaprolactone scaffolds." Biomaterials 25 (24): 
5499-506. 
Rai, B. and S. H. Teoh, et al. (2004). "The effect of rhBMP-2 on canine osteoblasts 
seeded onto 3D bioactive polycaprolactone scaffolds." Biomaterials 25 (24): 
5499-506. 
Holmes, R. E. and S. M. Lemperle, et al. (2000). Protected Bone Regeneration, 
  References 
____________________________________________________________________________________________ 
- 252 - 
Medtronic Sofamor Danek. 2000. 
Rasmusson, I. and O. Ringden, et al. (2003). "Mesenchymal stem cells inhibit the 
formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or 
natural killer cells." Transplantation 76 (8): 1208-13. 
Reich, K. M. and C. V. Gay, et al. (1990). "Fluid shear stress as a mediator of 
osteoblast cyclic adenosine monophosphate production." J Cell Physiol 143 (1): 
100-4. 
Reich, K. M. and T. N. McAllister, et al. (1997). "Activation of G proteins mediates 
flow-induced prostaglandin E2 production in osteoblasts." Endocrinology 138 (3): 
1014-8. 
Ringden, O. and M. Uzunel, et al. (2006). "Mesenchymal stem cells for treatment of 
therapy-resistant graft-versus-host disease." Transplantation 81 (10): 1390-7. 
Lanza, R. and R. Langer, et al. (2007). Principles of Tissue Engineering, Third 
Edition, Academic Press. 
Rodriguez, J. P. and L. Montecinos, et al. (2000). "Mesenchymal stem cells from 
osteoporotic patients produce a type I collagen-deficient extracellular matrix 
favoring adipogenic differentiation." J Cell Biochem 79 (4): 557-65. 
Rolstad, B. (2001). "The athymic nude rat: an animal experimental model to reveal 
novel aspects of innate immune responses?" Immunol Rev 184 : 136-44. 
Rombouts, W. J. and R. E. Ploemacher (2003). "Primary murine MSC show highly 
efficient homing to the bone marrow but lose homing ability following culture." 
Leukemia 17 (1): 160-70. 
Rosser, A. E. and S. B. Dunnett (2003). "Neural transplantation in patients with 
Huntington's disease." CNS Drugs 17 (12): 853-67. 
Rouwkema, J. and B. J. de, et al. (2006). "Endothelial cells assemble into a 
3-dimensional prevascular network in a bone tissue engineering construct." Tissue 
Eng 12 (9): 2685-93. 
Rouwkema, J. and N. C. Rivron, et al. (2008). "Vascularization in tissue engineering." 
Trends Biotechnol. 
Rubio, D. and J. Garcia-Castro, et al. (2005). "Spontaneous human adult stem cell 
transformation." Cancer Res 65 (8): 3035-9. 
Rucci, N. and S. Migliaccio, et al. (2002). "Characterization of the osteoblast-like cell 
phenotype under microgravity conditions in the NASA-approved Rotating Wall 
Vessel bioreactor (RWV)." J Cell Biochem 85 (1): 167-79. 
Rzhaninova, A. A. and S. N. Gornostaeva, et al. (2005). "Isolation and phenotypical 
characterization of mesenchymal stem cells from human fetal thymus." Bull Exp 
Biol Med 139 (1): 134-40. 
  References 
____________________________________________________________________________________________ 
- 253 - 
Sachlos, E. and J. T. Czernuszka (2003). "Making tissue engineering scaffolds work. 
Review: the application of solid freeform fabrication technology to the production 
of tissue engineering scaffolds." Eur Cell Mater 5 : 29-39; discussion 39-40. 
Sakaguchi, Y. and I. Sekiya, et al. (2004). "Suspended cells from trabecular bone by 
collagenase digestion become virtually identical to mesenchymal stem cells 
obtained from marrow aspirates." Blood 104 (9): 2728-35. 
Sakai, K. and M. Mohtai, et al. (1998). "Fluid shear stress increases transforming 
growth factor beta 1 expression in human osteoblast-like cells: modulation by 
cation channel blockades." Calcif Tissue Int 63 (6): 515-20. 
Salgado, A. J. and O. P. Coutinho, et al. (2004). "Bone tissue engineering: state of the 
art and future trends." Macromol Biosci 4 (8): 743-65. 
Salgado, A. J. and O. P. Coutinho, et al. (2004). "Bone tissue engineering: state of the 
art and future trends." Macromol Biosci 4 (8): 743-65. 
Sarugaser, R. and D. Lickorish, et al. (2005). "Human umbilical cord perivascular 
(HUCPV) cells: a source of mesenchymal progenitors." Stem Cells 23 (2): 220-9. 
Schantz, J. T. and D. W. Hutmacher, et al. (2002). "Induction of ectopic bone 
formation by using human periosteal cells in combination with a novel scaffold 
technology." Cell Transplant 11 (2): 125-38. 
Schimming, R. and R. Schmelzeisen (2004). "Tissue-engineered bone for maxillary 
sinus augmentation." J Oral Maxillofac Surg 62 (6): 724-9. 
Schmitz, J. P. and J. O. Hollinger (1986). "The critical size defect as an experimental 
model for craniomandibulofacial nonunions." Clin Orthop Relat Res(205): 299-308. 
Schuleri, K. H. and A. J. Boyle, et al. (2007). "Mesenchymal stem cells for cardiac 
regenerative therapy." Handb Exp Pharmacol(180): 195-218. 
Service, R. F. (2000). "Tissue engineers build new bone." Science 289 (5484): 
1498-500. 
Sgodda, M. and H. Aurich, et al. (2007). "Hepatocyte differentiation of mesenchymal 
stem cells from rat peritoneal adipose  tissue in vitro and in vivo." Exp Cell Res 
313 (13): 2875-86. 
Shake, J. G. and P. J. Gruber, et al. (2002). "Mesenchymal stem cell implantation in a 
swine myocardial infarct model: engraftment and functional effects." Ann Thorac 
Surg 73 (6): 1919-25; discussion 1926. 
Shao, X. and J. C. Goh, et al. (2006). "Repair of large articular osteochondral defects 
using hybrid scaffolds and bone marrow-derived mesenchymal stem cells in a rabbit 
model." Tissue Eng 12 (6): 1539-51. 
Sikavitsas, V. I. and G. N. Bancroft, et al. (2003). "Mineralized matrix deposition by 
marrow stromal osteoblasts in 3D perfusion culture increases with increasing fluid 
  References 
____________________________________________________________________________________________ 
- 254 - 
shear forces." Proc Natl Acad Sci U S A 100 (25): 14683-8. 
Sikavitsas, V. I. and G. N. Bancroft, et al. (2005). "Flow perfusion enhances the 
calcified matrix deposition of marrow stromal cells in biodegradable nonwoven 
fiber mesh scaffolds." Ann Biomed Eng 33 (1): 63-70. 
Sikavitsas, V. I. and G. N. Bancroft, et al. (2002). "Formation of three-dimensional 
cell/polymer constructs for bone tissue engineering in a spinner flask and a rotating 
wall vessel bioreactor." J Biomed Mater Res 62 (1): 136-48. 
Sikavitsas, V. I. and G. N. Bancroft, et al. (2002). "Formation of three-dimensional 
cell/polymer constructs for bone tissue engineering in a spinner flask and a rotating 
wall vessel bioreactor." J Biomed Mater Res 62 (1): 136-48. 
Sikavitsas, V. I. and D. J. van, et al. (2003). "Influence of the in vitro culture period 
on the in vivo performance of cell/titanium bone tissue-engineered constructs using 
a rat cranial critical size defect model." J Biomed Mater Res A 67 (3): 944-51. 
Sikavitsas, V. I. and D. J. van, et al. (2003). "Influence of the in vitro culture period 
on the in vivo performance of cell/titanium bone tissue-engineered constructs using 
a rat cranial critical size defect model." J Biomed Mater Res A 67 (3): 944-51. 
Silva, G. V. and S. Litovsky, et al. (2005). "Mesenchymal stem cells differentiate into 
an endothelial phenotype, enhance vascular density, and improve heart function in a 
canine chronic ischemia model." Circulation 111 (2): 150-6. 
Simmons, P. J. and B. Torok-Storb (1991). "Identification of stromal cell precursors 
in human bone marrow by a novel monoclonal antibody, STRO-1." Blood 78 (1): 
55-62. 
Simmons, P. J. and B. Torok-Storb (1991). "Identification of stromal cell precursors 
in human bone marrow by a novel monoclonal antibody, STRO-1." Blood 78 (1): 
55-62. 
Singh, H. and E. S. Ang, et al. (2007). "Flow modeling in a novel non-perfusion 
conical bioreactor." Biotechnol Bioeng 97 (5): 1291-9. 
Singh, H. and S. H. Teoh, et al. (2005). "Flow modelling within a scaffold under the 
influence of uni-axial and bi-axial bioreactor rotation." J Biotechnol 119 (2): 
181-96. 
Song, K. and T. Liu, et al. (2007). "Three-dimensional fabrication of engineered bone 
with human bio-derived bone scaffolds in a rotating wall vessel bioreactor." J 
Biomed Mater Res A. 
Song, K. and T. Liu, et al. (2008). "Three-dimensional fabrication of engineered bone 
with human bio-derived bone scaffolds in a rotating wall vessel bioreactor." J 
Biomed Mater Res A 86 (2): 323-32. 
Stanford, C. M. and J. W. Stevens, et al. (1995). "Cellular deformation reversibly 
depresses RT-PCR detectable levels of bone-related mRNA." J Biomech 28 (12): 
  References 
____________________________________________________________________________________________ 
- 255 - 
1419-27. 
Stevens, B. and Y. Yang, et al. (2008). "A review of materials, fabrication methods, 
and strategies used to enhance bone regeneration in engineered bone tissues." J 
Biomed Mater Res B Appl Biomater 85 (2): 573-82. 
Stiehler, M. and C. Bunger, et al. (2008). "Effect of dynamic 3-D culture on 
proliferation, distribution, and osteogenic differentiation of human mesenchymal 
stem cells." J Biomed Mater Res A. 
Sutherland, R. M. and B. Sordat, et al. (1986). "Oxygenation and differentiation in 
multicellular spheroids of human colon carcinoma." Cancer Res 46 (10): 5320-9. 
Suzuki, Y. and K. J. Kim, et al. (2001). "Stromal cell activity in bone marrow from 
the tibia and iliac crest of patients with rheumatoid arthritis." J Bone Miner Metab 
19 (1): 56-60. 
Tallheden, T. and J. E. Dennis, et al. (2003). "Phenotypic plasticity of human articular 
chondrocytes." J Bone Joint Surg Am 85-A Suppl 2 : 93-100. 
Tolar, J. and A. J. Nauta, et al. (2007). "Sarcoma derived from cultured mesenchymal 
stem cells." Stem Cells 25 (2): 371-9. 
Torigoe, I. and S. Sotome, et al. (2007). "Novel cell seeding system into a porous 
scaffold using a modified low-pressure method to enhance cell seeding efficiency 
and bone formation." Cell Transplant 16 (7): 729-39. 
Touraine, J. L. and M. G. Roncarolo, et al. (1993). "Fetal liver transplantation: 
biology and clinical results." Bone Marrow Transplant 11 Suppl 1 : 119-22. 
Tremblay, P. L. and V. Hudon, et al. (2005). "Inosculation of tissue-engineered 
capillaries with the host's vasculature in a reconstructed skin transplanted on mice." 
Am J Transplant 5 (5): 1002-10. 
Tsang, V. L. and S. N. Bhatia (2004). "Three-dimensional tissue fabrication." Adv 
Drug Deliv Rev 56 (11): 1635-47. 
Tse, W. T. and J. D. Pendleton, et al. (2003). "Suppression of allogeneic T-cell 
proliferation by human marrow stromal cells: implications in transplantation." 
Transplantation 75 (3): 389-97. 
Tsuchida, H. and J. Hashimoto, et al. (2003). "Engineered allogeneic mesenchymal 
stem cells repair femoral segmental defect in rats." J Orthop Res 21 (1): 44-53. 
Unsworth, B. R. and P. I. Lelkes (1998). "Growing tissues in microgravity." Nat Med 
4 (8): 901-7. 
Vacanti, C. A. and L. J. Bonassar (1999). "An overview of tissue engineered bone." 
Clin Orthop Relat Res(367 Suppl): S375-81. 
Vacanti, J. P. and M. A. Morse, et al. (1988). "Selective cell transplantation using 
bioabsorbable artificial polymers as matrices." J Pediatr Surg 23 (1 Pt 2): 3-9. 
  References 
____________________________________________________________________________________________ 
- 256 - 
van, D. J. and G. N. Bancroft, et al. (2003). "Flow perfusion culture of marrow 
stromal osteoblasts in titanium fiber mesh." J Biomed Mater Res A 64 (2): 235-41. 
Vunjak-Novakovic, G. and B. Obradovic, et al. (1998). "Dynamic cell seeding of 
polymer scaffolds for cartilage tissue engineering." Biotechnol Prog 14 (2): 
193-202. 
Wang, M. (2003). "Developing bioactive composite materials for tissue replacement." 
Biomaterials 24 (13): 2133-51. 
Weinand, C. and R. Gupta, et al. (2007). "Comparison of hydrogels in the in vivo 
formation of tissue-engineered bone using mesenchymal stem cells and 
beta-tricalcium phosphate." Tissue Eng 13 (4): 757-65. 
Weissman, I. L. (2000). "Translating stem and progenitor cell biology to the clinic: 
barriers and opportunities." Science 287 (5457): 1442-6. 
Wendt, D. and A. Marsano, et al. (2003). "Oscillating perfusion of cell suspensions 
through three-dimensional scaffolds enhances cell seeding efficiency and 
uniformity." Biotechnol Bioeng 84 (2): 205-14. 
Williams, D. F. (2008). "On the mechanisms of biocompatibility." Biomaterials 29 
(20): 2941-53. 
Woodbury, D. and E. J. Schwarz, et al. (2000). "Adult rat and human bone marrow 
stromal cells differentiate into neurons." J Neurosci Res 61 (4): 364-70. 
Wu, X. and L. Huang, et al. (2005). "Mesenchymal stem cells participating in ex vivo 
endothelium repair and its effect on vascular smooth muscle cells growth." Int J 
Cardiol 105 (3): 274-82. 
Yang, S. and K. F. Leong, et al. (2001). "The design of scaffolds for use in tissue 
engineering. Part I. Traditional factors." Tissue Eng 7 (6): 679-89. 
Yang, S. and K. F. Leong, et al. (2002). "The design of scaffolds for use in tissue 
engineering. Part II. Rapid prototyping techniques." Tissue Eng 8 (1): 1-11. 
Yeong, W. Y. and C. K. Chua, et al. (2004). "Rapid prototyping in tissue engineering: 
challenges and potential." Trends Biotechnol 22 (12): 643-52. 
Yeong, W. Y. and C. K. Chua, et al. (2004). "Rapid prototyping in tissue engineering: 
challenges and potential." Trends Biotechnol 22 (12): 643-52. 
Yu, H. and P. J. Vandevord, et al. (2008). "Promotion of osteogenesis in 
tissue-engineered bone by pre-seeding endothelial progenitor cells-derived 
endothelial cells." J Orthop Res 26 (8): 1147-52. 
Yu, H. and P. J. Vandevord, et al. (2008). "Improved tissue-engineered bone 
regeneration by endothelial cell mediated vascularization." Biomaterials. 
Yu, X. and E. A. Botchwey, et al. (2004). "Bioreactor-based bone tissue engineering: 
the influence of dynamic flow on osteoblast phenotypic expression and matrix 
  References 
____________________________________________________________________________________________ 
- 257 - 
mineralization." Proc Natl Acad Sci U S A 101 (31): 11203-8. 
Zein, I. and D. W. Hutmacher, et al. (2002). "Fused deposition modeling of novel 
scaffold architectures for tissue engineering applications." Biomaterials 23 (4): 
1169-85. 
Zein, I. and D. W. Hutmacher, et al. (2002). "Fused deposition modeling of novel 
scaffold architectures for tissue engineering applications." Biomaterials 23 (4): 
1169-85. 
Zhang, X. and C. Xie, et al. (2005). "Periosteal progenitor cell fate in segmental 
cortical bone graft transplantations: implications for functional tissue engineering." 
J Bone Miner Res 20 (12): 2124-37. 
Zhao, F. and T. Ma (2005). "Perfusion bioreactor system for human mesenchymal 
stem cell tissue engineering: dynamic cell seeding and construct development." 
Biotechnol Bioeng 91 (4): 482-93. 
Zhao, L. R. and W. M. Duan, et al. (2002). "Human bone marrow stem cells exhibit 
neural phenotypes and ameliorate neurological deficits after grafting into the 
ischemic brain of rats." Exp Neurol 174 (1): 11-20. 
Zhao, Z. and L. Liao, et al. (2005). "Establishment and properties of fetal 
dermis-derived mesenchymal stem cell lines: plasticity in vitro and hematopoietic 
protection in vivo." Bone Marrow Transplant 36 (4): 355-65. 
Zhou, Y. S. and Y. S. Liu, et al. (2006). "Is 1, 25-dihydroxyvitamin D3 an ideal 
substitute for dexamethasone for inducing osteogenic differentiation of human 
adipose tissue-derived stromal cells in vitro?" Chin Med J (Engl) 119 (15): 1278-86. 
Zhuang, H. and Y. Lin, et al. (2007). "Effects of 1,25-dihydroxyvitamin D3 on 
proliferation and differentiation of porcine preadipocyte in vitro." Chem Biol 
Interact 170 (2): 114-23. 
Zisch, A. H. and M. P. Lutolf, et al. (2003). "Biopolymeric delivery matrices for 
angiogenic growth factors." Cardiovasc Pathol 12 (6): 295-310. 
Zuk, P. A. and M. Zhu, et al. (2001). "Multilineage cells from human adipose tissue: 
implications for cell-based therapies." Tissue Eng 7 (2): 211-28. 
 
  Appendices 
____________________________________________________________________________________________ 
- 258 - 
Appendices 
Appendix I: DSRB approval 
 
 
  Appendices 
____________________________________________________________________________________________ 
- 259 - 




  Appendices 
____________________________________________________________________________________________ 
- 260 - 
Appendix III: Publications 
ZY Zhang, SH Teoh, MS Chong, JT Schantz, NM Fisk, MA Choolani and J Chan. 
Superior Osteogenic Capacity for Bone Tissue Engineering of Fetal Compared To 
Perinatal and Adult Mesenchymal Stem Cells. Stem Cells 2008 ePub (In press).  
 
ZY Zhang, SH Teoh, WS Chong, TT Foo, YC Chng, MA Choolani and J Chan. A 
biaxial rotating bioreactor for the culture of fetal mesenchymal stem cells for bone 
tissue engineering. Biomaterial (Accepted for publication) 
 
 
